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Abstract 
The studies described in this thesis explore the molecular mechanisms by 
which nutrition modulates Adult Hippocamapal Neurogenesis (AHN) using a 
human hippocampal progenitor cell line (HPC). AHN has been shown to be 
important for cognition and mood regulation. Interestingly, diet in the form of the 
Omega-3 fatty acids Eicosapentaenoic acid (EPA) and Docosahexaenoic acid 
(DHA) is known to have beneficial effects on cognition and mood; these effects 
are hypothesised to be mediated via modulating AHN. My studies show that in 
an in vitro model of stress, EPA (10µM) and DHA (10µM) prevent the 
detrimental effects of Cortisol on proliferation and neurogenesis by increasing 
the percentage of dividing cells and neurogenesis while decreasing apoptosis 
mainly by promoting survival. Resveratrol (1µM), a stilbenoid present in the skin 
of red fruit, prevents the Cortisol induced changes by increasing the percentage 
of dividing cells and neurogenesis but has no effect on apoptosis. Intermittent 
fasting (IF), shown to promote AHN, increases the expression of Klotho, the 
longevity gene. Klotho over expression increases neurogenesis. Whereas 
Klotho knock down decreases neurogenesis by diminishing survival. To further 
investigate the molecular pathways downstream of Resveratrol as mimetic of IF 
and Klotho expression, I focused on PPARγ (Peroxisome proliferator-activated 
receptor) a nuclear receptor transcription factor which is known to activate 
Klotho transcription and is activated by Resveratrol. My results show that 
Resveratrol partly requires PPARγ to activate Klotho and that Klotho is partly 
required during proliferation for Resveratrol to exert its effect. Whereas, 
Resveratrol partly requires both Klotho and PPARγ to increase neurogenesis 
and PPARγ requires Klotho to increase the proportion of mature neurons. 
These experiments provide evidence that PPARγ and Klotho are two of the 
neurogenic effectors of Resveratrol. 
This thesis provides for the first time evidence in a human in vitro model of 
neurogenesis and stress that EPA, DHA and Resveratrol can modulate 
neurogenesis and prevent its decrease induced by stress. This study also 
provides the first identification of Klotho and PPARγ as downstream effectors of 
Resveratrol on neurogenesis. 
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1.1 Neurogenesis in the adult brain 
“Once development was ended, the fonts of growth and regeneration of the 
axons and dendrites dried up irrevocably. In the adult centres, the nerve paths 
are something fixed, and immutable: everything may die, nothing may be 
regenerated” (Cajal, 1928).  
The well known statement from Santiago Ramon y Cajal in 1928 had been 
taken for granted until Altman and Das (Altman and Das, 1965) provided the 
first evidence of postnatal hippocampal neurogenesis in rats using 
autoradiographic and histological methods. However, adult neurogenesis in the 
mammalian brain was not generally accepted until the early nineties when 
studies using Bromodeoxyuridine (BrdU) and retroviral vectors as markers for 
dividing cells confirmed the generation of new neurons in certain regions of the 
adult mammalian brain (Corotto et al., 1993; Luskin, 1993; Seki and Arai, 1993). 
Adult neurogenic niches have been consistently found in two restricted areas: 
the subventricular zone (SVZ) of the lateral ventricles (Doetsch and Alvarez-
Buylla, 1996) and in the subgranular zone (SGZ) of the dentate gyrus (DG) 
(Kempermann and Gage, 2000). In these regions neural stem cells (NSCs) and 
the more specified neural progenitor cells (NPCs) have been shown to give rise 
to new neurons in various species (Altman and Das, 1965; Kaplan and Hinds, 
1977; Bayer et al., 1982; Kaplan and Bell, 1984; Luskin, 1993; Doetsch and 
Alvarez-Buylla, 1996; Sanai et al., 2011) including humans (Eriksson et al., 
1998).  
Neurogenesis in the adult brain is divided into specific steps: proliferation and 
survival of NPCs and NSCs, as well as survival, differentiation, maturation and 
integration of early and mature neurons. Adult NSCs and adult NPCs are self-
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replicating, multipotent cells that can differentiate into multiple types of neural 
cells, including neurons, astrocytes and oligodendrocytes (Gage, 2000; Taupin 
and Gage, 2002). See Figure 1-1. NSCs have the potential to divide indefinitely 
and give rise to NPCs. NPCs have a limited capacity to self-replicate and 
differentiate into target cells after a restricted number of divisions (Taupin and 
Gage, 2002; Lucassen et al., 2009).  
 
Figure 1-1 Neurogenesis is the birth of new neurons 
Neural stem cells are defined as cells that have the ability to self-renew and to give rise 
to the three major cell types of the mammalian CNS: neurons, astrocytes, and 
Oligodendrocytes. Credit: J. Simons, Illustrator at The Salk Institute for Biological 
Studies.  
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Two types of NSCs have been identified in the SVZ and the SGZ that are 
distinguishable by their morphology, proliferating behaviour and marker 
expression (Zhao et al., 2008; Mu et al., 2010): In the SVZ type B cells are 
GFAP and CD133 positive radial glia-like progenitor cells. These slowly dividing 
cells generate the more rapidly dividing type C cells; transit-amplifying 
progenitor cells with very short or no processes that are positive for the marker 
Dlx2, Mash1 and EGFR. The majority of those will turn into type A cells: Dcx 
and PSA-NCAM expressing neuroblasts that migrate via the rostral migratory 
stream into the olfactory bulb where they differentiate into GABAergic and 
dopaminergic interneurons. In the SGZ the radial cells or type 1 cells are 
positive for the marker GFAP, SOX2 and Nestin. This population of quiescent 
NSCs might give rise to type 2 cells; actively self-replicating nonradial 
progenitor cells that are SOX2 and Nestin positive but GFAP negative and 
might generate Dcx positive neuroblasts that eventually differentiate into 
glutamatergic dentate granule cells (Figure 1-2). 
 
Figure 1-2 Overview of the maturation of NPC to mature neurons and the 
markers they express. 
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Many of the newly generated neurons die within two weeks, however the 
surviving ones become fully integrated and functional (Kempermann et al., 
2003). In Figure 1-3 it is shown how newborn neurons in the hippocampus 
migrate only a short distance into the granule cell layer. Within three weeks they 
send axons to the CA3 region and the hilus to form functional synapses with 
interneurons from the hilus and neurons from the CA3 (Chan et al., 2008). The 
new neurons start to receive synaptic inputs from the cortex and fire action 
potentials themselves (van Praag et al., 2002). NPCs from the SVZ in turn 
migrate a greater distance via the rostral migratory stream (RMS) into the 
olfactory bulb to become interneurons (Doetsch and Alvarez-Buylla, 1996).  
It is still not perfectly understood why neurogenesis is restricted to the 
hippocampus and the SVZ considering that NPCs have been isolated from 
many CNS regions. However, several transplantation experiments (Suhonen et 
al., 1996; Shihabuddin et al., 2000; Seidenfaden et al., 2006) have shown that 
the fate of transplanted NSCs is determined by the microenvironment of the 
graft side. For example, NPC from the spinal cord can normally not give rise to 
neurons. However, once transplanted in the DG or SVZ, spinal cord NPCs can 
generate neurons (Shihabuddin et al., 2000). This demonstrates the importance 
of the microenvironment of the neurogenic niches. Where and how 
neurogenesis occurs is tightly orchestrated by a multitude of cell intrinsic and 
extrinsic factors. Intrinsic factors include CREB (Giachino et al., 2005) and 
NeuroD1 (Gao et al., 2009), whereas extrinsic factors include BDNF (Bath et 
al., 2008) and GABA (Gascon et al., 2006) or Glutamate (Platel et al., 2010). 
For a detailed review see (Mu et al., 2010).  
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It has long been understood that AHN is associated with learning and memory 
as well as mood and can be influenced internally via molecular and epigenetic 
factors as well as external factors such as environment, stress, learning, 
exercise, aging and diet (Figure 1-4). For a review see (An et al., 2008). A 
decline in neurogenesis in the SGZ during ageing is associated with 
increasingly impaired cognitive functions, which can be ameliorated by external 
events with systemic impact, such as voluntary running (van Praag et al., 2005).  
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Figure 1-3 Schematic representation of the sagittal view of a rodent brain  
highlighting the two neurogenic zones of the adult mammalian brain: The 
subventricular zone (SVZ) of the lateral ventricles and the subgranular zone of the 
dentate gyrus (DG) in the hippocampus. Neurons generated in the SVZ migrate 
through the rostral migratory stream (RMS) and are incorporated into the olfactory bulb. 
The hippocampal region contained in the black square is enlarged showing (1) neural 
progenitor cells in the in the subgranular zone of the dentate gyrus proliferating, (2) 
migrating as neuroblasts into the granule cell layer and (3) maturing into new granule 
neurons. They integrate into the hippocampal circuitry by receiving inputs from the 
entorhinal cortex, and extend projections into the CA3. (Stangl and Thuret, 2009) 
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Figure 1-4 Overview of physiological and environmental modulation of Adult 
Hippocampal Neurogenesis 
and its impact on Learning & Memory abilities and Mood. The doyted squares contain 
the enlarged hippocampus. The red dots symbolize newborn neurons in the dentate 
gyrus. (Stangl and Thuret, 2009) 
 
1.2 Functionality of adult hippocampal neurogenesis 
This thesis is set out to explore the impact of external factors such as diet on 
AHN. The hippocampus plays an important role in learning, memory and mood, 
which will be explored in detail in sections 1.2.1 and 1.2.2. As described in 
Figure 1-4 hippocampal neurogenesis can be modulated by multiple 
environmental stimuli and is considered to be necessary for optimisation and 
adaption of hippocampal function to environmental changes by experience 
Reviewed in (Glasper et al., 2012). Briefly, under optimal environmental 
conditions neurogenesis and exploratory behaviour are increased to enable the 
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development of greater cognitive function and spatial navigation skills. In turn, 
under prolonged adverse and potentially life threatening conditions, 
hippocampal neurogenesis is decreased which amongst other effects leads to 
inhibited exploratory behaviour and increased anxiety to maximise the likelihood 
of survival by staying out of danger (Glasper et al., 2012). These consequences 
might explain the important implications AHN has on improved learning and 
memory or developing anxiety and depression like behaviour.  
The focus of this thesis is the modulation of AHN by certain dietary components 
described in section 1.3 and the possible effect on learning, memory (Section 
1.2.1) and depressive symptoms (Section 1.2.2). 
1.2.1 Learning and Memory 
A multitude of studies has been conducted to explore the relation between 
neurogenesis in the dentate gyrus and cognitive ability. They aimed to find an 
answer on whether and how neurogenesis in the dentate gyrus is involved in 
acquiring, storing, short or long-term retention and retrieval of spatial memory or 
object/place recognition, reviewed in (Aimone et al., 2010a; Koehl and Abrous, 
2011). Due to several confounding factors, such as variations in mouse strains, 
ablation technique and experimental settings, these studies produced 
inconsistent results. However, correlative evidence, ablation studies and 
computational modelling support the putative function of AHN in various forms 
of hippocampal dependent learning and memory (An et al., 2008; Aimone et al., 
2009; Aimone et al., 2010a). New neurons in the dentate gyrus are said to be 
involved in memory processing during spatial learning, associative memory and 
pattern separation (Reviewed in (Stangl and Thuret, 2009). The level of 
hippocampal neurogenesis and the performance in hippocampal-dependent 
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learning tasks has been shown to positively correlate in various mouse models 
(Kempermann and Gage, 2002; Thuret et al., 2009). Further, it has been shown 
that changes in neurogenesis induced by the environment correlate with 
performance in hippocampal-dependent learning tasks (Reviewed in (Stangl 
and Thuret, 2009). Interestingly, not only the generation and integration of new 
cells plays an important role during learning and the formation of memory but 
apoptosis as well. Blocking apoptosis prevents the survival of dentate granule 
cells and proliferation of NPC, leading to an impaired performance in spatial 
learning and memory. This suggests that learning is a dynamic process during 
which dentate granule cells are selectively added and removed from the 
neuronal network (Dupret et al., 2007). 
Many genetic and environmental factors that affect AHN cause corresponding 
changes in cognitive performance. Voluntary running (van Praag et al., 1999; 
Spanier et al., 2009; Aimone et al., 2010a, b; Deng et al., 2010; Yu et al., 2010; 
Marlatt et al., 2012) and enriched environment (Kempermann et al., 1997b, a; 
Kuhn et al., 1997; Bruel-Jungerman et al., 2005; Tashiro et al., 2007; Rippe et 
al., 2010; Chiu et al., 2012; German et al., 2012; Liu et al., 2012) lead to an 
increased AHN and an improved performance in spatial and long term memory 
tasks. In contrast, AHN decreases with age and elderly animals display 
impaired learning and memory abilities (Klempin and Kempermann, 2007; 
Villeda et al., 2011). Interestingly, age-dependent blood borne factors from old 
mice negatively affect adult neurogenesis and associated behaviour such as 
spatial learning, and fear conditioning as shown in a heterochronic parabiosis 
experiment joining young and old mice (Villeda et al., 2011).  
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When investigating the role of adult born neurons we have to question whether 
their contribution to memory processing in the DG is unique and distinct 
compared to that from neurons born during development. Kee et al. showed for 
the first time that adult born neurons were preferentially recruited by spatial 
learning tasks using immediate early genes (IEG) to image the activity of adult-
born neurons (Kee et al., 2007). However, the same team showed that 
developmentally born and adult born granule cells are integrated into 
hippocampal memory networks at similar rates. Their data further suggest a 
functional equivalence between DG cells generated at different developmental 
stages (Stone et al., 2011). Before the role of granule neurons generated at 
different developmental stages can be definitely regarded as equivalent these 
results need confirmation and further investigation. 
1.2.2 Depression 
Worldwide, major depressive disorder (MDD) is estimated to become the 
second leading cause of disease burden by the year 2030 after HIV (Mathers 
and Loncar, 2006). Depression is defined mainly by diagnostic criteria 
formulated by the Diagnostic and Statistic Manual IV (DSM-IV) published by the 
American Psychiatric Association (2000). Symptoms include low self esteem, 
lack of interest, sleep disturbance, eating disturbance, poor concentration and 
suicidal thoughts. The heterogeneity of the disease suggests that multiple 
different neural mechanisms and distinct brain regions may underlie its 
aetiology (Manji et al., 2001;Nestler et al., 2002;Warner-Schmidt and Duman, 
2006). In human imaging and post mortem studies the prefrontal and cingulate 
cortex, hippocampus, striatum, amygdala and thalamus have been identified as 
brain areas that are associated with depression (Drevets, 2001; Liotti and 
Mayberg, 2001; Manji et al., 2001; Nestler et al., 2002). The highly 
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intercommunicative connections these brain regions form are implicated in 
depression (Manji et al., 2001; Nestler et al., 2002). To shed further light on the 
processes during depression and improve treatment, the cellular mechanisms 
within these regions need to be identified.  
One of the theories trying to explain the mechanism of depression is the 
neurogenesis hypothesis. It claims that the decrease in newborn dentate 
granule cells in the dentate gyrus is associated with the pathophysiology of 
depression (Becker and Wojtowicz, 2007; Vollmayr et al., 2007). This 
hypothesis is further supported by the fact that antidepressant treatments 
enhanced neurogenesis (Gould et al., 1997). However, while decreasing 
neurogenesis alone is not sufficient to initiate a depression-like phenotype, 
neurogenesis in the hippocampus is required for antidepressants to elicit some 
of their positive behavioural effects. Reviewed in (Samuels and Hen, 2011). 
Neurogenesis can be reduced by stress, a causal factor in the pathogenesis of 
major depression. Upon exposure to a stressor the hypothalamic-pituitary-
adrenal axis (HPA) releases high levels of endogenous glucocorticoid 
hormones, like the corticosterone Cortisol. This reaction, controlled by the 
hippocampus, provides the body with energy, increases focus and attention and 
helps to respond to immediate potentially life-threatening situations (Pariante, 
2009). However, chronically elevated levels of glucocorticoids can lead to 
disturbances in reproductive functions, metabolic functions, brain 
electrophysiological properties, and depressive symptoms, reviewed in 
(Pariante, 2009). Chronic exposure to stressful conditions is a commonly used 
model for depression in laboratory animal and has been shown to reduce AHN. 
(For a review see (Warner-Schmidt and Duman, 2006)). Furthermore, AHN is 
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reduced in animal models of depression (Dranovsky and Hen, 2006). Indeed, 
acute and chronic treatment with corticosterone decreases cell proliferation 
(Gould et al., 1992; Murray et al., 2008; Cao et al., 2009; Colman et al., 2009; 
David et al., 2009; Spencer et al., 2009; Vafeiadou et al., 2009; Kennedy et al., 
2010; Thurston et al., 2010) whereas adrenalectomy increases AHN. 
Additionally, glucocorticoids inhibit the proliferation, differentiation and survival 
of new cells within the hippocampus (Wong and Herbert, 2004). In this thesis an 
in vitro model of stress using Cortisol (Section 2.1.5.1) (Anacker et al., 2011) is 
employed to test the potential preventive properties of dietary components 
(Section 1.3) against stressed-induced decreased neurogenesis. 
Pharmacological treatment for depression with common antidepressant drugs, 
such as selective serotonin reuptake inhibitors (SSRIs) changes metabolic 
activity in the prefrontal cortex and the hippocampus (Mayberg et al., 2000; 
Kennedy et al., 2001; Seminowicz et al., 2004). Antidepressant treatment takes 
several weeks to show an effect in human; that delay suggests that structural 
changes in neural circuitry, such as adult neurogenesis, are involved in eliciting 
its positive effect (Duman et al., 1999; Duman and Monteggia, 2006; Warner-
Schmidt and Duman, 2006; Sahay and Hen, 2008). Chronic administration of 
antidepressants, such as SSRIs and monoamine oxidase inhibitors, increases 
AHN and accelerates the maturation of young neurons in the DG (Malberg et 
al., 2000; Manev et al., 2001; Santarelli et al., 2003; Wang et al., 2008). 
Neurogenesis can also be increased by acute electroconvulsive therapy (ECT) 
(Malberg et al., 2000; Scott et al., 2000; Manev et al., 2001; Wang et al., 2008). 
Additionally, the effect of stress on AHN can be reversed by various 
antidepressants (Dranovsky and Hen, 2006; Surget et al., 2008). Importantly, 
these enhancing effects are restricted to the hippocampus and do not affect cell 
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proliferation in the SVZ, an area with no emotional behavioural relevance 
(Encinas et al., 2006). Finally, in several animal models of depression, 
disruption of AHN blocks the behavioural efficacy of antidepressants (i.e. 
Santarelli et al., 2003).  
Not only environmental factors such as running, exercise and environmental 
enrichment (van Praag et al., 1999; Bjornebekk et al., 2005; van Praag et al., 
2005; Chiu et al., 2012; Marlatt et al., 2012) have been associated with an 
antidepressant effect possibly via enhancing AHN, but various components of 
our daily diet have now been correlated to impact on neurogenesis and also  to 
improve cognition and depressive behaviour.  
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1.3 Dietary influences on AHN 
Understanding the molecular mechanisms by which diet influences adult 
hippocampal neurogenesis could help in preventing and treating cognitive and 
mood decline and moreover lead to new therapeutic targets. 
The four different levels on which dietary modulation of AHN can take place 
shown in Figure 1-5 are: Calorie intake, meal frequency, meal texture and meal 
content. These four parameters modulate AHN as well as cognitive 
performance and mood as shown in animal models and intervention or 
epidemiological studies in humans (Reviewed in (Stangl and Thuret, 2009). 
Caloric intake and meal frequency in the form of dietary restriction (DR) and 
intermittent fasting (IF) will be explained in section 1.3.3 and 1.3.4. Regarding 
meal content, nutrients such as Omega-3 fatty acids (Omega-3s) (Section 
1.3.1) and flavonoids (Section 1.3.2) have been shown to impact on AHN, 
cognition and depression. 
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Figure 1-5 Overview of the impact of diet on adult hippocampal neurogenesis.  
The red dots symbolize newborn neurons in the dentate gyrus of the hippocampus. 
(Stangl and Thuret, 2009) 
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1.3.1 Omega-3 and omega-6 fatty acids 
One of the dietary ingredients that are highly discussed at present in 
association with depression and learning and memory abilities are Omega-3 
fatty acids (Omega-3s). 
The Omega-3s, α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and 
docosahexaenoic acid (DHA) are nutritionally important and essential for 
maintaining a normal neurological function. Omega-3s cannot be synthesized 
by mammals and need to be supplied by diet. Common sources of Omega-3s 
include fish oils and plant oils such as flaxseed oil, algal oil and hemp seed oil.  
 
Essential fatty acids (short-chain fatty acids) 
α-Linolenic Acid (ALA)  
(18:3 n-3)   
Linoleic acid (LA)  
(18:2 n-6)  
Conditionally essential fatty acids (long-chain fatty acids) 
Eicosapentaenoic Acid (EPA)  
(20:5 n-3)   
Docosahexaenoic Acid (DHA)  
(22:6 n-3)  
 
Arachidonic Acid (AA)  
(20:4 n-6) 
 
Table 1-1 Omega-3, Omega-6 fatty acids 
Overview of essential and conditionally essential Omega-3 and Omega-6 fatty acids. 
Nomenclature: 18:3 n-3: 18 is the number of C atoms, 3 is the number of C-C double 
bonds, n-3 denotes the position of first double bond at the third C atom counting from 
the omega end (red numbers); indicating an Omega-3 fatty acid. The blue numbers are 
the counting used by chemists and start at the carbonyl end. 
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In Table 1-1 the important essential and conditionally essential fatty acids are 
listed. True essential fatty acids are the Omega-3 fatty acids α-Linolenic acid 
(ALA) and the Omega-6 fatty acid Linoleic acid (LA) (Burr and Burr, 1930). The 
conditionally essential Omega-3s EPA and DHA are long-chain fatty acids that 
are not contained in plants; however they can be formed out of the short-chain 
fatty acid ALA in mammals, although very little ALA is converted to DHA in the 
adult human compared to during development (Innis, 2007). This ability is 
limited by the capacity of the enzyme Δ6 desaturase over which the Omega-6 
and the Omega-3 pathway compete (Portolesi et al., 2007). The pathway for the 
biosynthesis of EPA and DHA is explained in Figure 1-6. Omega-3s are widely 
accepted to have beneficial effects on the brain and associated behaviour, 
whereas Omega-6s, such as Arachidonic acid (AA), increase the production of 
proinflammatory cytokines (Maes and Smith, 1998). Moreover, in depressed 
patients a higher Omega-6 to Omega-3 ratio correlated with higher TNF-alpha, 
IL-6, and IL-6 soluble receptor levels, suggesting that diets with high Omega-6 
to Omega-3 ratios may enhance the risk for both depression and inflammatory 
diseases (Kiecolt-Glaser et al., 2007). The recommended ratio of Omega-6 to 
Omega-3 is 4:1 (Hibbeln et al., 2006), however, the actual ratio in the average 
diet of the western world is 30:1 (Chang et al., 2005). Omega-6s and Omega-3s 
are not inter-convertible in the human body. This imbalance might be a target 
for possible dietary intervention to improve learning and memory and 
depressive symptoms. 
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Figure 1-6 Pathway for Omega-3 and Omega-6 fatty acid biosynthesis 
For the first three steps of their biosynthesis long-chain Omega-3 and Omega-6 fatty 
acids share the same enzymes: Δ6 desaturase, Δ5 desaturase. For the conversion of 
EPA to DHA Δ6 desaturase is used again. EPA: Eicosapentaenoic Acid, DHA: 
Docosahexaenoic Acid. Adopted from (Nakamura and Nara, 2004)  
The dry weight of the mammalian brain consists to 50% of lipids, mainly 
phospholipids, of which DHA and AA are the main polyunsaturated fatty acids 
(PUFA) (Svennerholm, 1968; Sastry, 1985). DHA is predominately found in the 
phosphatidylethanolamine (PE) and the phosphatidylserine (PS) fraction which 
together with phosphatidylcholine (PC) constitute the major building block of 
neuronal membranes (Rapoport, 2001). The majority of DHA gets accumulated 
into the brain perinatally during development up to the second year after birth in 
humans (Martinez, 1992). Omega-3s play crucial roles in the development 
(Makrides et al., 2010) and function of the central nervous system (Crupi et al., 
2011). They are critical for healthy brain development and function because of 
their roles in membrane structure and cytokine regulation (Innis, 2007; Gupta et 
al., 2012). However, phospholipid concentrations decline in the hippocampus 
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during aging (Delion et al., 1997) and neurodegenerative diseases such as 
Alzheimer’s disease (AD) (Soderberg et al., 1991). Further, a deficiency of 
hippocampal Omega-3s is associated with a decrease in learning and memory 
abilities in rodents and a decline in memory in AD patients (Tully et al., 2003; 
Chung et al., 2008). However, the symptoms of an Omega-3 deficit can be 
reversed with a supplemented diet. In an animal model of adult immune 
stressed mice a diet enriched with PUFA decreased hippocampal microglia 
activation and increased neurogenesis in the hippocampus leading to normal 
long-term potentiation (LTP) (Crupi et al., 2011). One possible mechanism of 
how PUFA exert their positive action is their impact on the protein localisation in 
lipid rafts. DHA concentrations influence the properties and organisation of 
proteins in the cell membrane, affecting membrane fluidity (Langelier et al., 
2010). Overall, increased DHA levels have been shown to promote neurite 
outgrowth, neuronal differentiation and synaptogenesis during development 
(Calderon and Kim, 2004; Cao et al., 2009; Adijiang and Niwa, 2010). 
1.3.1.1 Omega-3s and learning and memory 
Low intake of Omega-3s is associated with several forms of cognitive decline in 
the elderly (Freemantle et al., 2006) whereas a diet rich in Omega-3s is 
associated with a prevention of cognitive decline (van Gelder et al., 2007). 
Interestingly, rodents deficient for Omega-3s have shown impaired performance 
in spatial memory tasks that could be rescued with dietary intake of Omega-3s 
(Fedorova and Salem, Jr., 2006). In DHA deficient rats, the Omega-3 levels in 
the hippocampus could be rescued with a DHA supplemented diet and 
subsequently the performance in learning and memory tasks improved (Chung 
et al., 2008). Furthermore, Omega-3 supplementation during brain 
development, as well as during adulthood increased DHA levels of the 
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hippocampus and improved learning and memory abilities (Chung et al., 2008). 
It has been suggested that Omega-3s sustain learning and memory 
performance by reinforcing synaptic plasticity. Several in vivo experiments or in 
vitro set ups using rodent brain slices showed that a diet sufficient in Omega-3s 
can maintain or rescue LTP and enhance dendritic spine formation. DHA affects 
synaptic transmission in mammalian brain and increases the levels of 
phosphatides and of specific presynaptic or postsynaptic proteins in the brain 
cells of rodents receiving DHA (Cansev et al., 2008). Further DHA enhanced 
induced neurite growth, synaptogenesis, synapsin, and glutamate receptor 
expression, and glutamatergic synaptic function (Cao et al., 2009). Together 
this may support the role of DHA in important cellular aspects related to 
hippocampus-related cognitive function. Figure 1-7 shows an overview of the 
implications of Omega-3s during development (1.) and maintenance (2.) of 
learning and memory as reviewed in (Hui-Min, 2010).  
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Figure 1-7 Overview of the effects of Omega-3s on the development (1.) and 
maintenance (2.) of learning memory performance. 
(1.) Overview of effects on the development of learning and memory. The developing 
brain can carry out limited DHA biosynthesis from ALA and incorporate it into 
phosphatidylethanolamine (PE). Omega-3 signalling is involved in brain development. 
(2.) Overview of effects on maintenance of learning memory. The mature brain can 
take up DHA and incorporate it into the PE fractions of neuronal membranes, where 
Omega-3 signalling strengthens synaptic plasticity, increase neuron protection and 
reverse age-related changes. Interactions between the effects of DHA and oestrogen 
are possible. Adapted from (Hui-Min, 2010). 
 
1.3.1.2 Omega-3s and Depression 
Moreover Omega-3s have been shown to be beneficial in depression. Clinical 
research has shown that Omega-3 concentrations are lower in patients with 
depression (Logan, 2004), and Omega-3 supplementation has even emerged 
as a treatment for depression (Frangou et al., 2006; Jazayeri et al., 2008). In 
epidemiologic studies a diet high in Omega-3s is associated with a decreased 
risk of major depression, perinatal depression and bipolar disorder (Noaghiul 
and Hibbeln, 2003; Hibbeln, 2009). Trials supplementing PUFAs or comparing 
the amount of fish consumption generally show an improvement in depressive 
symptoms (Hibbeln, 1998; Tiemeier et al., 2003; Adams et al., 2008; Jazayeri et 
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al., 2008); although the trials up to date are difficult to compare as neither the 
dose range (1-9 g/d) nor the ratio of EPA to DHA or their separate 
administration are consistent. Reviewed in (Perica and Delas, 2011). All 
together, we lack data from adequately powered control trials in human to be 
able to tell whether Omega-3 supplements are sufficient as a monotherapy in 
the treatment of major depressive disorder (MDD). Further reduced Omega-3 
levels in the brain of depressed patients are not only owing to an insufficient 
supply but also due to interaction between diet and metabolism (Otten et al., 
1997; Keelan et al., 2000). Some studies report a significant decrease of 
Omega-3s in depressed patients whereas Omega-6s levels hardly change 
(Maes et al., 1996; Maes et al., 1999; De Vriese et al., 2003; Tiemeier et al., 
2003; Frasure-Smith et al., 2004) or are even increased (Maes and Smith, 
1998). The Omega-6 fatty acid arachidonic acid increases the production of 
proinflammatory cytokines, operating as precursors of the proinflammatory 
eicosanoids of the prostaglandin 2-series (Maes and Smith, 1998). 
Furthermore, in patients with MDD higher Omega-6: Omega-3 ratio correlated 
with higher levels of the proinflammatory markers TNF-alpha, IL-6, and IL-6 
soluble receptor. This suggests that diets with high Omega-6 to Omega-3 ratios 
may enhance the risk for both depression and inflammatory diseases (Kiecolt-
Glaser et al., 2007). Interestingly, a diet high in Omega-6s and saturated fats 
even impacts on future generations through the exposure of the embryo in utero 
to the content of the maternal diet. This exposure affects the risk for obesity, 
neurocognitive function via immune response dysregulation and 
proinflammatory responses in the hippocampus leading to elevated levels of 
anxiety and spatial learning deficits (Bilbo and Tsang, 2010; Massiera et al., 
2010). For a review of the effects of Omega-6s see (Simopoulos, 2011). 
Page 46 of 318 
The mechanisms underlying these positive as well as negative behavioural 
effects are currently unknown. However it is likely that the positive effects on 
learning, memory (Hooijmans et al., 2009;Petursdottir et al., 2008) and mood 
(Appleton et al., 2006) are mediated by increased AHN as shown in animals fed 
with a diet rich in the Omega-3 fatty acid Docosahexaenoic acid (Kawakita et 
al., 2006). Similar positive results for cognition were achieved using a diet 
enriched in polyphenols and PUFA in an AD mouse model (Fernández-
Fernández et al., 2012). 
1.3.2 Polyphenols  
Polyphenols are secondary metabolites of plants and are generally involved in 
defence against ultraviolet radiation or pathogens, such as bacteria and fungi. 
These molecules are derived from phenylalanine and contain an aromatic 
phenol ring with a reactive hydroxyl group. Some dietary sources for 
polyphenols are citrus, tea, ginko, grape, cocoa and blueberries. They consist of 
several subclasses including phenolic acids, flavonoids, stilbenes and lignans 
(Figure 1-8). The biggest group are the flavonoids which are subdivided in 
flavonols, flavones, isoflavones, flavanones, anthocyanidins, and flavanoles.  
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Figure 1-8 Overview of the chemical structure of polyphenols. Adapted from 
(Manach et al., 2004) 
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Figure 1-9 Overview of the chemical structure of flavonoids. Adapted from 
(Manach et al., 2004). 
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Polyphenols are said to have neuroprotective effects through interaction with 
neuronal signalling pathways, inhibition of neuroinflammation and impact on the 
vascular system, reviewed in (Spencer, 2010a). For example, studies in 
humans have shown that polyphenols-rich dark chocolate decreases blood 
pressure (Taubert et al., 2003). Further studies have reported that flavanol-rich 
cocoa improves vasodilatation (Heiss et al., 2003; Taubert et al., 2003). Also 
wine, grape juice and black tea have been shown to have a vasodilatatory effect 
(Kukekov et al., 1999; Hirata et al., 2004; Janszky et al., 2005). Flavanols in 
cocoa have been shown to improve cerebrovascular blood flow (Fisher et al., 
2006; Francis et al., 2006) and increased blood flow in the brain is known to 
facilitate AHN (Ruitenberg et al., 2005; Tiehuis et al., 2008). Additionally, fMRI 
studies have shown that cerebral blood flow is decreased in patients with 
dementia (Nagahama et al., 2003; Ruitenberg et al., 2005) whereas it is 
increased shortly after flavanol consumption (Fisher et al., 2006; Wang et al., 
2008).  Furthermore, it has been demonstrated that flavonoids inhibit 
neuroinflammatory effects. Interestingly, neuroinflammation plays an important 
role in Alzheimer’s and Parkinson’s disease (McGeer and McGeer, 2003; Hirsch 
et al., 2005) as well as brain injuries such as stroke (Zheng et al., 2003). 
Flavonoid-rich blueberry extract decreased nitric oxide, IL-1β and TNFα 
production (Lau et al., 2007). The flavonol quercetin (Chen et al., 2005), the 
flavone wogonin (Lee et al., 2003) and the flavanone naringenin (Vafeiadou et 
al., 2009) also reduced nitric oxide and TNFα levels, factors that are largely 
involved in microglial and astrocytic mediated neuroinflammatory effects.  
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Flavonoids further impact on synaptic plasticity and cognitive function. In animal 
models synaptic plasticity and cognition were improved using the flavanols 
fisetin (Maher et al., 2006) and (-)epicatechin (van Praag et al., 2007). The 
ancient decoction Xiaobuxin-Tang has been used as treatment for depressive 
disorders for centuries and is packed with flavonoids. It increases, supposedly 
via BDNF, AHN in chronically stressed rats (Adams et al., 2008). In another 
animal study, a blueberry-rich diet improved spatial working memory via CREB 
and BDNF activation (Williams et al., 2008). Most interestingly the flavonols 
rutin and quercetin showed an antidepressant effect in a rat model (Dimpfel, 
2009) as well as cocoa polyphenolic extract (Bisson et al., 2008).  
The effects of flavonoids have been extensively studied and discussed in 
several reviews (Spencer, 2010a, b), but will not be discussed in depths here as 
the focus of this thesis is on the stilbenoid and non-flavonoid Resveratrol. 
1.3.2.1 The stilbenoid Resveratrol 
 
Figure 1-10 Resveratrol (RSVL) 3,5,4'-trihydroxy-trans-stilbenoid 
 
Within the subclass of stilbenes, 3,5,4′-hydroxystilbenoid, or Resveratrol is very 
well known. The non-flavonoid Resveratrol is a specific polyphenol abundant in 
the skin of red grapes and red wines and in lower concentrations in peanuts, 
pistachios, some berries and cocoa. The most dominant source of RSVL is wine 
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covering 98.4% of the average intake (Zamora-Ros et al., 2008). RSVL is 
produced by plants as a phytoalexin to protect them from fungal and bacterial 
invasion. The trans-isomeric form of Resveratrol (Figure 1-10) is by far more 
commonly found in plants and has been more extensively studied then the cis-
isomeric form. It has been suggested to have specific biological properties, 
including antioxidant, chemopreventive, anti-thrombogenic, anti-inflammatory, 
cardioprotective, neuroprotective, antiaging and cancer preventive activities 
(Chachay et al., 2011).  
Ghanim et al. showed in two human trails that RSVL (40mg) reduces plasma 
biomarkers associated with inflammation, can reduce the oxidative and 
inflammatory response caused by a diet high in fat and carbohydrates and has 
the potential to reduce the risk of diseases associated with these mechanisms 
such as diabetes (Ghanim et al., 2010; Ghanim et al., 2011). RSVL improves 
insulin sensitivity and reduces oxidative stress in diabetic patients (Brasnyo et 
al., 2011). Another human study found that RSVL increases cerebral blood flow 
(Kennedy et al., 2010). RSVL has been mostly investigated in several in vivo 
and in vitro models. The anti-proliferative, pro-apoptotic effects of RSVL on 
cancer have been reviewed in (Aggarwal et al., 2004). Most of the animal 
experiments have been conducted in rat or mouse and the dose range used 
was from 10mg-200mg/kg body weight. Trauma or ischemic lesion was induced 
using chemicals or Middle cerebral artery occlusion (MCAO) where an acute 
dose of RSVL could reduce the lesion area and alleviate associated symptoms 
(Wang et al., 2004; Appleton et al., 2006; Baur et al., 2006; Airan et al., 2007; 
Klempin and Kempermann, 2007; Sonmez et al., 2007; Tsai et al., 2007; Adams 
et al., 2008; Kumar and Sharma, 2010; Singleton et al., 2010; Li et al., 2012). 
Further, RSVL has been shown to enhance learning and memory (Oomen et 
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al., 2009; Ranney and Petro, 2009). Recently is has been shown to reverse 
cognitive behavioural deficits in aged rats. Moreover, working memory 
correlated with RSVL levels in the hippocampus (Joseph et al., 2008). 
RSVL has also been shown to enhance hippocampal neurogenesis (Harada et 
al., 2011; Moriya et al., 2011). A growing body of in vivo evidence indicates that 
Resveratrol has protective effects in rodent models of stress (Baur and Sinclair, 
2006). RSVL interacts with a great number of kinases, receptors and enzymes 
and pathways which could be responsible for exerting its biological effects. Sirt1 
(sirtuin1 or silent mating type information regulation 2 homolog) 1), 5' adenosine 
monophosphate-activated protein kinase (AMPK), cyclooxygenases and the 
peroxisome proliferator-activated receptor (PPAR) PPARγ have been 
mentioned times. See also Table 1-2. 
In a very compelling rodent study it has been shown that RSVL and the 
phosphodiesterase type 4 (PDE4)-inhibitor, rolipram -that enhances the effects 
of the antidepressant sertraline (Anacker et al., 2011)- have similar effects. 
Rolipram and RSVL treatment, both lead to the same gene expression pattern, 
improved mitochondrial function, increased physical endurance and basal 
metabolism and protection against diet-induced obesity and glucose 
intolerance. They both activate 5' adenosine monophosphate-activated protein 
kinase (AMPK), Acetyl-CoA carboxylase (ACC) and increase Nicotine adenine 
dinucleotide (NAD+) and Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α) levels, suggesting that they increase Sirt1 activity 
indirectly via the upstream target PDE4 (Park et al., 2012). Sirt1 is an enzyme 
that deacetylates proteins that contribute to cellular regulation (reaction to 
stressors, longevity) (Sinclair and Guarente, 2006) and increases lifespan 
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calorie restricted mice (Haigis and Guarente, 2006) and Saccharomyces 
cerevisiae (Howitz et al., 2003). See Figure 1-11 for an overview on how RSVL 
and CR might act on Sirtuins and longevity 
 
 
Figure 1-11 Proposed model of how RSVL mimics CR 
Resveratrol inhibits PDE activity and induces cAMP signaling and, ultimately, the 
activation of the CamKKb-AMPK pathway. CR increases cAMP levels by increasing 
glucagon and catecholamine levels, which activate cAMP production. AMPK increases 
mitochondrial biogenesis and function by increasing PGC-1a expression, NAD+ levels, 
and Sirt1 activity (Park et al., 2012). 
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Resveratrol also has been shown to activate the transcription factor PPARγ 
(Peroxisome proliferator-activated receptor) and to protect brain tissue against 
ischemia (Inoue et al., 2003). In rodents, Resveratrol was shown to significantly 
ameliorate fatty livers and life spans of obese, diabetic mice (Baur et al., 2006). 
RSVL improves some symptoms of age related diseases but does not enhance 
longevity in healthy rodents (Labbe et al., 2011; Miller et al., 2011). In lower 
organism such as Saccharomyces cerevisiae (yeast), Caenorhabditis elegans 
(worms), Drosophila melanogaster (fruit flies), RSVL mimics caloric restriction 
and activates sirtuins and extends lifespan (Wood et al., 2004)  
1.3.2.2 Resveratrol as mimetic of caloric restriction 
Additionally, it has been shown that Resveratrol delays age-related deterioration 
and mimics transcriptional aspects of caloric restriction and intermittent fasting 
(Pearson et al., 2008). Caloric restriction is generally defined as a decrease of 
10%-40% of caloric intake compared to ad libitum feeding without malnutrition. 
Intermittent fasting is also known as alternate day fasting and can be described 
as alternating eating ad libitum and fasting every other day. Dietary restriction 
and RSVL have been said to affect lifespan and age related metabolic disorders 
such as cardiovascular disease, diabetes, obesity and even cancer (Dolinsky 
and Dyck, 2011; Mercken et al.). Furthermore they have been shown to impact 
on brain health (Arunachalam et al., 2010; Brownstein et al., 2010; Qiu et al., 
2010). Their similar impact on health suggests that they have common 
molecular targets and pathways. Table 1-2 shows some of the molecular 
targets that are affected by both caloric restriction and Resveratrol treatment.  
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molecular signal Intermittent fasting calorie restriction Resveratrol treatment 
increased adiponectin 
 (Shinmura et al., 2007; Kondo et al., 2009; 
Dolinsky et al., 2010) (Rivera et al., 2009; Rius et al., 2010) 
increased AMPK 
 
(Shinmura et al., 2007; Kondo et al., 2009; 
Dolinsky et al., 2010; Edwards et al., 2010) 
(Baur et al., 2006; Goh et al., 2007; Adams et 




(Giani et al., 2008; Sung et al., 2011) 
(Hashimoto et al., 2001; Thirunavukkarasu et 
al., 2007; Tatlidede et al., 2009) 
increased endothelial nitric 
oxide synthase 
 
(Mattagajasingh et al., 2007; Kondo et al., 
2009; Dolinsky et al., 2010; Rippe et al., 2010) 
(Leikert et al., 2002; Wallerath et al., 2002; 
Miatello et al., 2005; Nicholson et al., 2008; 
Penumathsa et al., 2008; Arunachalam et al., 
2010; Toklu et al., 2010) 
increased Mn superoxide 
dismutase 
 
(Chandrasekar et al., 2001; Rippe et al., 2010) 
(Thirunavukkarasu et al., 2007; Csiszar et al., 
2009; Danz et al., 2009; Spanier et al., 2009; 
Tanno et al., 2010) 
reduced IL-6  (Nicklas et al., 2004; Seymour et al., 2006) (Wang et al., 2001; Inanaga et al., 2009) 
reduced NF-κB (Castello et al., 2010) (Chandrasekar et al., 2001; Csiszar et al., 2009) (Rius et al., 2010) 
reduced TNF-α  (Nicklas et al., 2004; Seymour et al., 2006) (Rivera et al., 2009) 
increased PGC-1α 
 (Corton and Brown-Borg, 2005; Anderson et 
al., 2008) 
(Baur et al., 2006; Lagouge et al., 2006; 
Anderson et al., 2008) 
increased SIRT1 
 (Cohen et al., 2004; Shinmura et al., 2008; 
Rippe et al., 2010) (Danz et al., 2009; Kao et al., 2010) 
PPARγ activation   (Inoue et al., 2003) 
Table 1-2 Common molecular targets of calorie restriction and Resveratrol 
Adapted from (Dolinsky and Dyck, 2011) 
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1.3.3 Dietary restriction 
The mechanisms underlying dietary restriction (DR) on lifespan are still 
unknown, although several pathways have been hypothesised to be involved 
including: inflammatory processes, oxidative stress, mitochondrial function, 
apoptosis and body fat composition. Positive effects on longevity have been 
reported in short lived species such as Saccharomyces cerevisiae (yeast), 
Caenorhabditis elegans (worms), Drosophila melanogaster (fruit flies), mice, 
and rats, reviewed in (Colman and Anderson, 2011). However long-term studies 
in human or non-human primates are needed to elucidate and define the impact 
of dietary restriction and one long-term study is currently ongoing in human 
(Calerie http://calerie.dcri.duke.edu/index.html). While preliminary data 
regarding lifespan from an ongoing non-human primate study are still 
inconclusive (Colman and Anderson, 2011), many of the general beneficial 
effects that have been observed in rodents are similar: reduced abdominal 
adiposity (Colman et al., 2009), improved insulin sensitivity and lipid/lipoprotein 
profiles (Kemnitz et al., 1994; Lane et al., 1999), decreased oxidative stress 
(Sohal and Weindruch, 1996). Dietary restriction has been found to exert 
positive effects also in the CNS (Duan et al., 2001). It has been shown that DR 
can extend lifespan and improve behavioural outcome in some experimental 
animal models of neurodegenerative disorders (Mattson et al., 2001). The 
neuroprotective properties of DR can attenuate brain injury and delay the onset 
of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease 
(Duan and Mattson, 1999; Love, 2005; Patel et al., 2005; Pasinetti et al., 2007). 
Also the age-related cognitive decline and molecular mechanisms associated 
with learning and memory are improved upon dietary restriction (Eckles-Smith 
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et al., 2000; Fontan-Lozano et al., 2007; Zhao et al., 2007; Witte et al., 2009). 
Further, cognitive function in rodents is enhanced upon caloric restricted diet 
(Ingram et al., 1987; Stewart et al., 1989; Gorjao et al., 2007). DR can reverse 
age and disease-related behavioural and mental impairment (Means et al., 
1993; Halagappa et al., 2007; Adams et al., 2008). In rodents it has been 
observed that AHN increases upon DR (Barnett et al., 2000; Lee et al., 2002) 
One factor that supports AHN is BDNF which is increased upon dietary 
restriction in the brain especially in the hippocampus and the cortex (Lee et al., 
2000). SIRT1 levels are also elevated upon DR as well as after RSVL treatment 
(Table 1-2). Another factor that is increased by both RSVL and DR is 
adiponectin, a endocrine factor that has antidiabetic and insulin sensitising 
properties (Berg et al., 2002). The effect of dietary restriction on the brain health 
has been reviewed in (Qiu et al., 2010).  
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1.3.4 Intermittent fasting (Pilot work) 
Although it was assumed that the increased AHN in DR was due solely to 
reduced calorie intake, unpublished pilot work by Sandrine Thuret’s lab has now 
shown that increased AHN in DR paradigms is not only dependant of calorie 
intake but also depends on meal frequency in the form of intermittent fasting. 
Intermittent fasting (IF) is defined as eating every other day ad libitum. Animals 
were divided into three groups: Ad libitum (AL), Caloric restriction (CR) and 
Intermittent fasting (IF). 
1.3.4.1 Behavioural experiments 
The probe trials in the Morris Water Maze for this experiment were 24h and 48h 
after the acquisition trails. The animals in the three different groups all learn the 
task and displayed no significant difference in the latency to reach the platform. 
During the probe trials after 24h all three groups spent significantly more time in 
the quadrant previously containing the platform; however after 48h only the IF 
group spent significantly more time in the correct quadrant. This suggests that 
IF improves retention memory. 
1.3.4.2 Cell proliferation and Cell fate 
The absolute number of BrdU positive cells per hippocampus is significantly 
increased after three months of an IF or CR diet compared to an AL diet. 
Proliferation is increased and the majority of the newly born cells have survived 
at least 4 week and are now likely to be integrating into the circuit. 
Furthermore, the absolute number of newborn neurons is only significantly 
increased in the F group compared to the AL group. This demonstrates that in 
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the hippocampus of the IF animals, proliferation and neurogenesis are 
increased. 
1.3.4.3 Gene expression 
Microarray and Q-PCR validationshowed that the expression of over 20 genes 
has been significantly either up or down regulated. The expression of one 
particular gene: the longevity gene Klotho is twofold increased in the 
hippocampus of mice kept on an IF feeding regime for three months compared 
to AL or CR. 
The molecular effects of dietary modulation on AHN are mediated by specific 
molecular mechanisms that are still unknown. Therefore the gene expression 
array data from the Thuret Lab showing changes in gene expression levels 
upon intermittent fasting in the hippocampus is an excellent starting point to 
uncover some of these molecular mechanisms. The gene Klotho is of particular 
interest as its mRNA is specifically expressed in the two neurogenic areas, the 
hippocampus and the SVZ (Figure 1-12), and its expression is up-regulated by 
twofold upon increased AHN mediated by IF.  
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Figure 1-12 Klotho expression in the adult mouse brain  
Images show sagital section of adult mouse brain a.) and b.) in situ hybridisation c.) 
and d.) expression intensity. Available from the Allen brain atlas: http://mouse.brain-
map.org.  
 
Klotho is known to be involved in pathways associated with extended live span 
(Kurosu et al., 2005; Fischer et al., 2010), phosphate excretion involving 
FGF23, synthesis of Vitamin D in the kidney (Urakawa et al., 2006; Goetz et al., 
2010), suppression of growth factor signalling, suppression of oxidative stress, 
regulation of ion channels and transporters in the kidney (Ikushima et al., 2006; 
Bloch et al., 2009; Hsieh et al., 2010; Cheng et al., 2011). Most of the published 
work to date has been conducted in the kidney; however as shown in Figure 
1-12 Klotho mRNA is very specifically expressed in the hippocampus. All 
together, these preliminary data and prior published work suggest Klotho as an 
interesting candidate to pursue as a potential molecule mediating the effect of 
IF, not only on longevity, but particularly on AHN in the context of this thesis. 
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1.4 Klotho 
Klotho is known as the ‘ageing suppressor gene’, due to the symptoms of a 
mutant mouse resembling human aging (Kuro-o M et al., 1997). In turn in a 
mouse model over expressing Klotho live span is extended up to 30% (Kurosu 
et al., 2005). Klotho is a single-pass transmembrane protein that is 
predominately expressed in the kidney (Fischer et al., 2010). The gene Klotho 
shown in Figure 1-13 is composed of 5 exons. The protein consists of two 
external β-glucosidase-like domains (hKL1 and hKL2), a transmembrane 
domain and very short cytoplasmic domain. Glucosidases, also called glycosid 
hydrolases, are enzymes that hydrolyse glycosidic linkages to release small 
sugars from carbohydrates, glycoprotein and glycolipids. However, it lacks the 
essential active site Glu residues at positions 241 and 874, suggesting it may 
be inactive as a glycosidase in vivo. The external domain can be shed by 
alternative splicing of the mRNA and proteolytic cleavage of the protein in the 
area of Exon 3 leading to a secreted form of Klotho (Airan et al., 2007; Bloch et 
al., 2009; David et al., 2009). The secreted Klotho has so far been found in 
blood, urine and Cerebrospinal fluid (CSF) (Imura et al., 2004). For a review see 
(Wang and Sun, 2009). Table 1-3 shows differences and similarities in genetic 
location and size in human, mouse and rat. To date the majority of research on 
Klotho function and expression has been conducted in relation to kidney or 
cardiovascular diseases in rodents. Recently, German et al. has described the 
expression of Klotho transmembrane protein in the mouse brain. Klotho is 
predominantly expressed in the choroid plexus off the SVZ, and cerebellar 
Purkinje cells. It was found in the plasma membrane as well as near the nuclear 
membrane (German et al., 2012). 
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Figure 1-13 Klotho: genomic and protein structure 
The gene Klotho is composed of 5 exons, resulting in a single-pass transmembrane 
protein with two β-glucosidase-like domains (hKL1 and hKL2), signal sequence (red), 
transmembrane domain (blue) and short cytoplasmic domain. A secreted form is 
genereated by alternative splicing of the mRNA and proteolytic cleavage of the protein 









Gene location 13q12 5 G3 12q12 
Membrane form (mRNA) 






Membrane protein length 







Table 1-3: Comparison between human, mouse and rat Klotho gene and protein 
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The membrane Klotho is necessary for FGF23 signalling for facilitating the high 
affinity binding of FGF23 to the FGF receptor (FGFR) (Urakawa et al., 2006; 
Goetz et al., 2010; Cheng et al., 2011). It is therefore not surprising that FGF23-
deficient mice and Klotho deficient mice display similar phenotypes. FGF23 and 
Klotho have implications in the endocrine regulation of phosphate homeostasis 
as part of a bone-kidney-parathyroid axis also involving Vitamin D or Calcitriol 
(Razzaque et al., 2006). This mechanism has been shown to be a key player in 
chronic kidney disease and ageing (reviewed in (Kuro-o, 2006).  
The secreted domain of Klotho acts as a humoral regulator and has pleiotropic 
functions on glycoproteins located on cell surfaces. It also activates the ion 
channel Transient Receptor Potential Vanilloid type isoform-5 (TRPV5), which is 
located in the kidney and has important functions in transephitelial calcium 
absorption (Aoki et al., 2005; Mensenkamp et al., 2006; Adams et al., 2008). It 
further activates the Renal Outer Medullary Potassium channel ROMK1 which 
causes an increase in potassium efflux (Cha et al., 2009). The type-III sodium-
dependent phosphate co-transporters Pit-1 and Pit-2 are suppressed by 
secreted Klotho. They are expressed ubiquitously and mediate cellular 
phosphate uptake (Hu et al., 2011). Secreted Klotho also regulates several 
growth factors such as insulin/insulin-like growth factor-1 (IGF1) in L6 myoblast 
cells or rat hepatoma cells (H4IIE) (Kurosu et al., 2005), Wnt signalling in HEK-
293 cells (Liu et al., 2007) and transforming growth factor-β1 (TGF-β1) in mice 
kidneys and kidney (NRK52E) and lung (A549) cells culture (Doi et al., 2011). 
Although the underlying molecular mechanisms are not yet fully understood, 
Insulin/IGF-1 signalling is suppressed by Klotho in the blood of Klotho over 
expressing mice which may be responsible for the anti-ageing properties and 
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the extended life-span in mice over expressing Klotho (Ballen et al., 2000; 
Kenyon, 2005; Kurosu et al., 2005; Kirstetter et al., 2006; Scheller et al., 2006; 
Chateau et al., 2010). However, data from the Vischer lab suggested that 
decreased Klotho expression is not a general feature of rodent models of insulin 
resistance and that the soluble Klotho protein does not inhibit IGF-1 and/or 
insulin signalling in HEK293, L6, and HepG2 cultured cells, arguing against a 
direct role of Klotho in insulin signalling (Lorenzi et al., 2010). The mechanism 
by which Klotho impacts on insulin signalling needs yet to be determined. Wnt 
signalling is inhibited by amino-terminal portion of Klotho's KL1 extracellular 
domain (amino acids 1 to 285) binding directly to Wnt ligands prohibiting its 
activation in hematopoietic stem cells (HSC) and HEK-293 cells. (Ballen et al., 
2000; Kirstetter et al., 2006; Scheller et al., 2006). Wnt signalling plays a key 
role during proliferation in the adult hippocampus (Lie et al., 2005). In Klotho 
mutant mice Wnt signalling is amplified which leads to an exhaustion of the 
stem cell pool in primary mouse embryonic fibroblasts and HSC. 
Interestingly, Klotho has been shown to be a target gene of PPARγ, a 
transcription factor activated by Resveratrol (Zhang et al., 2008). Peroxisome 
proliferator-activated receptors are a group of nuclear receptor proteins that 
function as transcription factors regulating the expression of genes (Greene et 
al., 1995). PPARs play essential roles during cellular differentiation, 
development metabolism and tumorigenesis (Fajas et al., 1997). PPARγ is 
further a target gene of RSVL in a mouse model (Inoue et al., 2003) and is 
highly expressed in the SVZ, the hippocampus and the RMS (Morales-Garcia et 
al., 2011). PPARγ and Klotho therefore provide a potential link between RSVL 
and AHN.  
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Up to now, nothing was known about the impact of Klotho on AHN and its action 
in the brain. However, as described in section 1.3.4, the Thuret Lab found that 
Klotho expression is increased upon intermittent fasting in the hippocampus in 
mice leading to an improved retention memory.  
Altogether this makes Klotho an interesting candidate for studying its role in the 
regulation of adult hippocampal neurogenesis and depression. 
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1.5 PPARγ 
Peroxisome proliferator-activated receptors are a group of nuclear receptor 
proteins that function as transcription factors regulating the expression of genes 
(Greene et al., 1995) during cellular differentiation, development metabolism 
and tumorigenesis (Fajas et al., 1997). PPARs form heterodimers with retinoid 
X receptors (RXRs) and these heterodimers regulate transcription of various 
genes. Three subtypes of PPARs are known: PPARα, PPARδ, and PPARγ. 
PPARγ is predominantly expressed in adipose tissue, macrophages, colon 
epithelium and also in small intestine and skeletal muscle, explaining its 
implication in the pathology of numerous diseases including obesity, diabetes, 
atherosclerosis and cancer. All three PPARs are expressed at different levels 
and areas in the rat brain; PPARγ is expressed in the granular cells in the DG 
(Braissant et al., 1996) and as shown in Section 2.1.1 in HPC03A/07. Activation 
of PPARγ up-regulates neural stem cell proliferation and differentiation in vivo 
and in vitro (Morales-Garcia et al., 2011). Klotho has been shown to be a target 
gene of PPARγ in HEK293 cells (Zhang et al., 2008) and moreover PPARγ is a 
target gene of RSVL in murine primary cortical cultures, bovine brain 
microvessel vascular endothelial cells (BBMEC), human umbilical venous 
endothelial cells (HUVEC) and bovine arterial endothelial cells (BAEC) (Inoue et 
al., 2003). PPARγ and Klotho therefore provide a potential link between diet 
(RSVL) and AHN. The question addressed in Section 0 is whether RSVL acts 
exclusively via a PPARγ and Klotho dependent pathway or whether RSVL 
affects Klotho and AHN via a PPARγ independent pathway. RSVL has similar 
effects on longevity and health as CR and IF which suggests that they have 
common molecular targets and pathways. Table 1-2 shows some of the 
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molecular targets that are affected by both caloric restriction and Resveratrol 
treatment. Increasing the RSVL uptake using supplements is more feasible for 
human beings than living on a by 30-40% CR or IF diet. Further using RSVL 
might help to discover pathways that will uncover the molecular mechanism of 
increased AHN and longevity involving PPARγ and Klotho or even new, yet 
unknown pathways. 
1.6 Summary and hypothesis 
Based on the evidence above I hypothesis that Omega-3, Omega-6 FA, 
Resveratrol, intermittent fasting, PPARγ and Klotho are involved in regulating 
AHN and ultimately might be able to influence depressive behaviour. 
Uncovering the cellular mechanisms by which Omega-3, Omega-6 FA, RSVL 
and Klotho modulate AHN could provide new fundamental molecular and 
cellular data on the functioning of depression and eventually help to prevent and 
support its treatment. Figure 1-14 gives a brief overview of how RSVL, Klotho 
and PPARγ act on AHN to the knowledge before this thesis. 
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Figure 1-14 Working hypothesis: Linking AHN, Klotho, PPARγ, Resveratrol and 
intermittent fasting 
Green arrows: upregulation or activation, Question marks: not known yet 
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1.7 Aims  
1.7.1 Aim 1 
Diet in form of Omega-3 fatty acids is known to have beneficial effects on 
learning/memory and mood. Interestingly, it has been hypothesised that anti-
depressants may exert their effects by increasing AHN. This raised the 
possibility that certain diets may help protect against depression via modulating 
AHN. To determine the possible preventative properties of Omega-3s and 
RSVL, an in vitro model of stress was employed where cells were treated with 
cortisol to induce stress and decrease proliferation and neurogenesis in 
HPCOA07/03 (Section 2.1.5.1). The ability of these compounds to overcome 
the effect of Cortisol will provide evidence that diet can potentially be beneficial 
for depression via modulating neurogenesis. 
1.7.2 Aim 2 
The expression of Klotho, the longevity gene, is increased upon intermittent 
fasting (IF) (section 1.3.4) and correlates with increased AHN and retention 
memory (section 1.3.4). To determine whether Klotho has a direct influence on 
AHN, this gene was over-expressed or suppressed in HPCOA07/03 cells in 
vitro. These experiments will provide insight in the role of Klotho on proliferation 
and differentiation. 
1.7.3 Aim 3 
To further investigate the molecular pathways regulating Klotho expression I 
focused on PPARγ, a nuclear receptor transcription factor known to activate 
Klotho. Interestingly, Resveratrol is known to activate PPARγ. After I have 
shown under Aim 1 that RSVL increases proliferation and differentiation in 
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HPCOA07/03 cells, in these experiments the ability of RSVL to activate Klotho 
via PPARγ was investigated in HPCOA07/03 where either Klotho or PPARγ 
expression was knocked down or blocked respectively. These experiments will 
test the hypothesis that PPARγ provides a direct link from diet (RSVL) to AHN. 
 
  










Chapter 2 Materials and Methods 
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If not stated in the text, please see Appendix for a detailed list of all the material, 
reagents and the concentrations used in this thesis. 
2.1 Tissue culture 
2.1.1 The embryonic hippocampal progenitor cell line HPC03A/07 
To conduct the experiments in this thesis, the human fetal hippocampal 
progenitor cell line HPC03A/07 from ReNeuron (Surrey, U.K.) was used. This 
neural progenitor cell line (NPC) was used as an in vitro model of hippocampal 
neurogenesis to assess the effects of Omega-3 fatty acids, Omega-6 fatty 
acids, RSVL and the gene Klotho on cell proliferation and fate, and to begin to 
elucidate the molecular mechanisms governing their mode of action. Cells were 
cultured at 37˚C, in saturated humidity and 5% CO2 and medium was 
exchanged fully every second day.  
The human foetal hippocampal progenitor cell line HPC03A/07, is a 
karyotypically normal human NPC line generated from cells isolated from a first 
trimester foetal brain. It is a conditionally immortalised multipotent progenitor 
cell line with the ability to self-renew for long periods of time and to differentiate 
into specialised cells with specific functions. However, these cells are limited in 
their ability to differentiate, meaning that they can give rise to neural cells, glia 
and very few oligodendrocytes, but not to other cell types outside of the brain. 
HPC03A/07 cells contain the c-myc-ERTAM sequence that is conditionally 
activated by 4-hydroxytamoxifen (4-OHT) and controls cell proliferation and 
differentiation. See Figure 2-1. Grown in the presence of 4-OHT and the growth 
factors recombinant human Fibroblast Growth Factor-basic (FGF2) and 
recombinant human epidermal Growth Factor (EGF) the cells express the gene 
c-myc within the nucleus. Under these conditions the cells proliferate indefinitely 
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and produce stable cell lines in culture. Once the growth factors and the 4-OHT 
are removed from the media the cells cease to proliferate and start to 
differentiate (Pollock et al., 2006). 
 
Figure 2-1 ReNeuron’s HPC03A/07 cells with c-mycER technology.  
The human foetal hippocampal progenitor cells stably express the c-mycER transgene 
and proliferate in the presence of the growth factors EGF and bFGF, and the synthetic 
compound 4-hydroxytamoxifen (4-OHT) which activates c-mycER. Upon removal of 
EGF, bFGF and 4-OHT, HPC03A/07 cells stop to proliferate and start to differentiate 
into neurons, astrocytes and oligodendrocytes. (Scalebar: 20µm) Picture source: 
www.reneuron.com 
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The HPC03A/07 cells were cultured as previously described by (Johansson et 
al., 2008) with minor modifications, in DMEM:F12 medium supplemented with a 
range of components here referred to as full growth medium (Table 7-1). Cells 
were grown on laminin (Sigma 20µg/ml) coated nunc flasks, nunc 96 well plates 
(both Nunclon, Roskilde, Denmark) or glass slides with reusable chambers 
(flexiPERM, Greiner bio-one) at a seeding density of 1.6x104/cm2 (1.2 x106 per 
nunc T75 flask). In the proliferating state the cells had a doubling time of 72h 
and were therefore passaged every 72 hours at 70-80% confluence (Johansson 
et al., 2008). Cells were passaged using 1x Trypsin/EDTA (Invitrogen) for 5min 
at 37°C followed by soya bean trypsin inhibitor 0.5 mg/ml (Sigma). The 
suspended cells were centrifuged in a centrifuge tube (Corning) (900g for 5min 
at room temperature (RT)), resuspended in full growth medium and plated at an 
appropriate concentration as stated above. 
Below the basic timeline for growing the HPC03A/07 cells is described, however 
this may vary depending on the experiment. Please see the timelines for each 
set of experiments in the results chapter. For the proliferation assay cells were 
cultured for 3 days under proliferation conditions. For the differentiation assay 
medium without growth factors and 4-OHT was used and cells were 
differentiated for 3 days or 7 days. These times have initially been chosen to 
capture differentiation at an early and later stage, however after initial 
experiments only the 7 day differentiation time point was used for further 
experiments as no significant differences could be seen between 3 days and 7 
days. See Figure 2-2 and the experimental timeline for each set of experiments 
for details. To be able to clearly see changes during early neuronal 
development caused by Klotho, Omega-3/6 fatty acids or RSVL, no 
neurotrophic factors to artificially promote neuronal differentiation were added. 
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This model therefore excludes such compounds as confounding factors from 
the analysis. 
To validate the usefulness and appropriateness of the HPCO3A/07 cell line for 
my studies, I had to confirm the expression of genes of interest (Klotho, PPARγ) 
and protein of interest (Klotho) in this cell line as well as establish the 
immunocytochemical profile during proliferation and differentiation of the 
HPCO3A/07 cell line.  
 
Figure 2-2 Timeline for growing HPC0A07/03A cells. 
1.) Proliferation assay, 2.) 3 day Differentiation assay 3.) 7 day Differentiation 
assay 
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2.1.2 Immunocytochemical cell culture characteristics of HPC03A/07 
during proliferation and differentiation 
To assess the phenotypic characteristics of HPC03A/07 during proliferation, 
cells were allowed to proliferate for three days before they were fixed and 
stained with a range of indicative markers: the proliferation marker Ki67; the 
stem cell markers SOX2 and Nestin; the apoptosis marker activated Caspase-3, 
as well as Klotho, the protein of the longevity gene (my protein of interest; see 
section 2.2 for details). In all cases, DAPI was used as a nuclear counter stain 
(Figure 2-3). After 3 days under proliferation conditions condition (Figure 2-3), 
50.2±2.9% of the cells expressed Ki67, while 100% of the cells expressed 
SOX2 and Nestin (Figure 2-3a-d). 3.4±0.5% of the total cells expressed Klotho 
and 3.3±0.7% express activated Caspase-3 (Figure 2-3e-g). This suggests that 
50% of the cells are dividing and all cells express stem cell markers. Klotho and 
activated Caspase-3 are expressed in a very small proportion of the cultures.  
To determine the immunocytochemical characteristics of HPC03A/07 during 
differentiation, cells were differentiated for seven days and then stained as 
described above. These differentiated cells were further stained for Dcx 
(neuroblasts/early neurons marker), MAP2 (mature neurons marker) and the 
astrocyte marker S100b. Figure 2-4 shows that after 7 days of differentiation the 
proportion of Ki67 expressing cells decreased to 21.8±2.8%, as might be 
expected, however the percentage of both SOX2 and Nestin expressing cells 
remained at almost 100 % (SOX2: 99.4±0.3%, Nestin: 99.1±0.3%, ), although 
differentiation was started. The SOX2 and/or Nestin proteins might not have 
been degraded after 7 days. A longer differentiation period might be necessary 
for the NPC marker to degrade. Within the experiments described in the 
subsequent chapters, their expression never changed except under conditions 
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where Klotho was over expressed in the HPC03A/07cells (see 4.2). Upon 
differentiation, the proportion of Klotho expressing cells more than doubled to 
7.9±1.8%, the percentage of activated Caspase-3 positive cells did not change 
with 3.2±0.5%. The astrocyte marker S100b was expressed in 13.6±0.7% of the 
cells. Further, the early neuronal marker Dcx was expressed in 14.4±0.2% and 
MAP2, a marker for mature neurons in 11.2±0.3% of the total cells (Figure 2-5). 
These results suggest that SOX2 and Nestin positive cells must co-label with 
Klotho, astrocytic and neuronal markers. In this thesis cells were only co-
labelled for SOX2 and Nestin but not for SOX2 or Nestin with marker for 
dividing or differentiating cells. However, in vivo studies show that neuronal 
markers, such as Dcx, MAP2, NeuroD1, NeuN and Tuj1 are mutually exclusive 
with SOX2, however NeuroD1 positive cells do co-localise with Nestin in the 
hippocampus of adult mice (Suh et al., 2007; Kuwabara et al., 2009). 
Throughout experiments using the HPC03A/07 cell line conducted by 
colleagues in the department and elsewhere, the SOX2 and Nestin proportion 
did not decrease after 7 days of differentiation. As described above, 7 days of 
differentiation might not be long enough for SOX2 and Nestin to be degraded, 
leading to fate committed cells still expressing SOX2 and Nestin. Co-labelling 
with markers for dividing and differentiating cells as well as extending the 
differentiation period would be interesting experiments to further characterise 
this cell line. Further, BrdU labelling to determine proliferation rate has been 
conducted. However due to technical problems for certain replicates, the BrdU 
experiments will not be presented in this thesis. 
  




Figure 2-3 Expression of Ki67, SOX2, Nestin, Klotho and activated Caspase-3 
in HPC03A/07 cells after 3 days under proliferation conditions. 
a.) DAPI and Ki67 b.) DAPI and SOX2 c.) DAPI and Nestin d.) Quantification of the 
percentage of DAPI cells expressing Ki67, SOX2 and Nestin e.) DAPI and Klotho f.) 
DAPI and activated Caspase-3 h.) Quantification of the percentage of DAPI cells 
expressing Klotho, activated Caspase-3. (Scalebar: 20µm, Error bars are the Standard 
Error of the Mean (SEM). 
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Figure 2-4 Expression of Ki67, SOX2, Nestin, Klotho, activated Caspase-3 and 
S100b in HPC03A/07 after 7 days under differentiation conditions. 
a.) DAPI and Ki67 b.) DAPI and SOX2 c.) DAPI and SOX2 d.) Quantification of the 
percentage of DAPI cells expressing Ki67, SOX2 and Nestin. e.)DAPI and Klotho f.) 
DAPI and activated Caspase-3 g.) DAPI and S100b h.) Quantification of the 
percentage of DAPI cells expressing Klotho, activated Caspase-3 and S100b. 
(Scalebar: 20µm, Error bars are the Standard Error of the Mean (SEM). 
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Figure 2-5 Expression of Dcx and MAP2 in HPC03A/07 after 7 days under 
differentiation conditions. 
a.) DAPI and Dcx b.) DAPI and MAP2 c.) Quantification of the percentage of DAPI cells 
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2.1.3 HPC03A/07 cells express Klotho and PPARγ mRNA 
To determine the influence of Klotho on hippocampal neurogenesis its 
expression was either knocked down or over-expressed. Details of this analysis 
are presented in Section 0. As only a small percentage of cells express Klotho I 
wanted to determine the level of Klotho mRNA to be able to quantify the level of 
Klotho knock down or over-expression respectively. 
HPC03A/07 cells were maintained for 3 days under proliferation conditions or 
for 3 and 7 days under differentiation conditions before RNA was extracted and 
processed as described in section 2.4 to generate cDNA. For the PCR SYBR 
green was used. All details are described under section 2.4.4. Klotho mRNA 
was detected in HPC03A/07 cells under all three conditions. However, its 
expression was very low and the Ct value was out of the dynamic range, 
making an accurate quantitative analysis for the knock down experiment very 
difficult. (Data not shown)  
However, despite the small proportion of cells expressing Klotho protein and the 
low expression of Klotho mRNA these HPC03A/07 cells were still a good model 
to study Klotho as the immunocytochemistry is very clear and when Klotho is 
over expressed immunocytochemistry, mRNA (Figure 4-4) and also Western 
Blot (Figure 4-5) results are well-defined. Therefore these cells may be not an 
ideal model for Klotho knock down but a very good model for Klotho over-
expression, which will allow me to assess the effect of Klotho on proliferation 
and differentiation in HPC03A/07. 
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear 
receptor proteins that function as transcription factors regulating the expression 
of genes (Greene et al., 1995). PPARs play essential roles during cellular 
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differentiation, development, metabolism and tumorigenesis (Fajas et al., 1997). 
Furthermore, PPARγ is a target gene of RSVL (Inoue et al., 2003). And 
moreover Klotho has been shown to be a target gene of PPARγ (Zhang et al., 
2008). PPARγ and Klotho therefore provide a potential link between diet in the 
form of RSVL and AHN. To be able to investigate the role of PPARγ in 
relationship to RSVL and Klotho, I wanted to confirm the expression of PPARγ 
in this model, using Q-PCR (SYBR Green). PPARγ is expressed in HPC03A/07 
cells upon 3 day proliferation and 7 day differentiation (Ct 27). (Figure 2-7) 
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2.1.4  Summary 
HPC03A/07 cells express Ki67 and the neural progenitor cell marker SOX2 and 
Nestin under proliferative conditions. Additionally, they express the early 
neuronal marker Dcx and the mature neuronal marker MAP2 under 
differentiation conditions. Also S100b a marker for astrocytes is expressed 
under differentiation conditions.  
Figure 2-6 shows a summary of Klotho (images) and PPARγ expression during 
proliferation and differentiation. Klotho mRNA and protein are expressed in 
HPC03A/07 after 3 days of proliferation as well as after 3 days and 7 days 
differentiation. Klotho co-labels with Ki67 (Figure 4-11c), Dcx (Figure 4-9c), 
MAP2 (Figure 4-9d) and activated Caspase-3 (Figure 4-12c) in some cells but 
never with S100b (Figure 4-10c). This indicates that Klotho is expressed in 
proliferating, differentiating and apoptotic cells but not in astrocytes. PPARγ 
mRNA was expressed after 3 days proliferation and after 3 and 7 days 
differentiation. See Figure 2-7.  
This demonstrates that HPC03A/07 cells make a good system to investigate the 
effect of Klotho, RSVL and PPARγ on cell proliferation and cell fate. Further it is 
a good model to study the effects of Omega-3 fatty acids on cell proliferation 
and fate as it is a human hippocampal cell line that allows extrapolation from the 
results in vitro to changes in the hippocampus and to their possible impact on 
behaviour. 
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Figure 2-6 Summary of Klotho expression in HPC03A/07 
Klotho mRNA and protein is expressed in cultures after 3 days proliferation and after 3 
days and 7 days differentiation 
 
 
Figure 2-7 PPARγ expression in HPC03A/07 cells  
a.) CT values using SYBRgreen b.) band for 3 days proliferation on gel 
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2.1.5 Resveratrol and Omega 3 and Omega 6 fatty acids treatment 
To assess the effect of the stilbenoid Resveratrol and Omega-3s and Omega-6s 
in Table 2-1 on proliferation and differentiation, cells were seeded in 96 well 
plates for immunochytochemistry as described before and cultured for 24h in 
growth medium, before treatment was applied. Fatty acids and Resveratrol 
(Sigma) were dissolved in 100% Ethanol and diluted in growth medium to give a 
final concentration as indicated in Table 2-1. The growth medium containes 
human albumin, which binds the fatty acids and facilitates their transport and 
delivery into the cells. For the proliferation assay cells were further cultured for 6 
days under proliferation conditions. For the differentiation assay differentiation 
was started 6days after seeding and compounds were added at the same time. 
Cells were cultured under differentiation conditions for 7 days. These 
experiments were carried out to screen for the fatty acid with the most effect. 
After these experiments only EPA, DHA and RSVL were used for further 
experiments used in this thesis.  
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α-Linolenic Acid (ALA)  
(18:3 n-3) 10µM  
Eicosapentaenoic Acid (EPA)  
(20:5 n-3) 10µM  
Docosahexaenoic Acid (DHA)  
(22:6 n-3) 10µM  
Stearidonic Acid (SDA)  
(18:4 n-3) 2µM  
Arachidonic Acid (AA)  
(20:4 n-6) 10µM   
Resveratrol (RSVL) 1µM 
 
Table 2-1 Omega-3, Omega-6 fatty acids and RSVL 
Overview of reagents and their concentrations used in this study. All compounds are 
solved in 100% ethanol. Medium contains Albumin facilitating transport and delevery 
into the cell. 
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2.1.5.1 Cortisol stress model 
Glucocorticoid hormones, such as the human endogenous glucocorticoid, 
Cortisol, are consistently elevated in severely depressed patients and in animal 
models of chronic stress and depression. Importantly, high levels of 
glucocorticoid hormones have detrimental effects on learning, memory and 
mood and decrease adult hippocampal neurogenesis in rodents (Mirescu and 
Gould, 2006; David et al., 2009; Pariante, 2009). Diet in form of Omega-3 fatty 
acids is known to have beneficial effects on learning, memory and mood. 
Interestingly, it has been hypothesised that anti-depressants may exert their 
effects by increasing AHN. This raised the possibility that Omega-3 fatty acids 
may help to protect against depression by increasing proliferation and 
differentiation. Christoph Anacker (SPI lab, IOP, King’s College London) 
showed that proliferation and differentiation in HPC cells was decreased after 
treating them with high concentration (100µM) of Cortisol (Sigma). See Figure 
2-8. He also showed that Cortisol only decreases proliferation and 
neurogenesis when cells are treated during the mitotic phase, which is why I 
treated the cultures with Cortisol for 3 days under proliferation conditions before 
starting differentiation. 
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Figure 2-8 Cortisol decreases proliferation and differentiation in HPC03A/07 
cells 
a.) Proliferation and b.) Differentiation are significantly decreased in HPC03A/07 after 
treatment with high concentrations of Cortisol (100µM).  
 
Using these results I developed an in vitro stress model were high 
concentrations of Cortisol were used to mimic the increased Cortisol levels seen 
in depressed patients and in animal models of depressive behaviour. 
To determine the possible preventative properties of Omega-3s and RSVL 
using this in vitro stress model HPCOA03/07A were pre-treated with EPA, DHA 
or RSVL for 3 days under proliferating conditions before treatment with 100µM 
Cortisol was started. See Figure 2-9. EPA, DHA or RSVL treatment was either 
continued in parallel to Cortisol treatment for a further 3 days of proliferation or 
stopped after the pre-treatment of 3 days of proliferation before cultures were 
fixed for immunocytochemistry (section 2.2). For the differentiation assay EPA, 
DHA or RSVL treatment was either continued for 6 days of proliferation and 7 
days differentiation or stopped after the pre-treatment or after 6 days of 
proliferation before fixation with 4% PFA. This resulted in different experimental 
combinations for the proliferation assay as well as the differentiation assay as 
described in Table 2-2 and Table 2-3. Control cultures were treated with the 
equivalent concentration of Ethanol (1%).  
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Figure 2-9 Timeline for Omega 3 prevention experiment using the Cortisol 
stress model on HPC0A07/03A cells. 
1.) Proliferation assay, 2.) Differentiation assay Step 1: Cells were pre-treated with 
EPA, DHA or RSVL for 3 days under proliferation conditions. Step 2: Cortisol was 
added and EPA, DHA or RSVL treatment was either stopped or continued. For the 
proliferation assay cells were fixed for immunocytochemistry after an additional 3 days 
proliferation. Step 3: For the differentiation assay differentiation was started now and 
EPA, DHA or RSVL treatment was either stopped or continued leading to different 
combinations as described in Table 2-2 and Table 2-3   
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1.) Proliferation assay 
 Step 1 Step 2 
   
1. 3d pro 3d pro 
 O3 O3 
  Cort 
   
2. 3d pro 3d pro 
 O3  
  Cort 
   
   
 Step 1 Step 2 
   
3. 3d pro 3d pro 
  Cort 
   
4. 3d pro 3d pro 
 O3 O3 
   
5. 1% EtOH 
  
Table 2-2 Conditions for the omega-3 prevention experiment using the Cortisol 
stress model under proliferating conditions.  
Step 1: Cells were pre-treated with O3 for 3 days of proliferation, Step 2: Cortisol was 
added and O3 treatment was, depending on the condition continued or stopped before 
cultures were fixed. O3: DHA, EPA, RSVL; Cort: Cortisol; Pro: Proliferation  
 
2.) Differentiation assay 
 Step 1 Step2 Step 3 
    
1. 3d pro 3d pro 7d diff 
 O3 O3 O3 
  Cort Cort 
    
2. 3d pro 3d pro 7d diff 
 O3 O3  
  Cort Cort 
    
3. 3d pro 3d pro 7d diff 
 O3   
  Cort Cort 
    
 Step 1 Step 2 Step 3 
    
4. 3d pro 3d pro 7d diff 
  Cort Cort 
    
5. 3d pro 3d pro 7d diff 
 O3 O3 O3 
    
6. 1% EtOH  
   
   
   
   
Table 2-3 Conditions for omega-3 prevention experiment using the Cortisol 
stress model under differentiation conditions. 
Step1: Cells were pre-treated with O3, Step 2: Cortisol was added and O3 treatment 
was, depending on the condition either continued or stopped, Step 3: Differentiation 
was started, cortisol continued and O3 treatment depending on condition either 
continued or stopped before cultures were fixed. O3: DHA, EPA, RSVL; Cort: Cortisol; 
Pro: Proliveration; Diff: Differentiation  
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2.1.6 Modulation of PPARγ activity 
To assess whether the effects of RSVL on proliferation and differentiation are 
mediated via the transcription factor PPARγ and the gene Klotho, cells were 
treated with the PPARγ activator Rosiglitazone or with the irreversible PPARγ 
blocker GW9662 or with specifically designed siRNAs binding Klotho mRNA to 
knock down Klotho expression. The drugs (Table 2-5) were dissolved in 100% 
Dimethyl sulfoxide (DMSO) and diluted in growth medium. See Table 2-5 for 
final concentration of compounds. The final DMSO concentration was 0.003% 
and control cultures were treated with an equivalent concentration of DMSO. 
Cells were seeded in 96 well plates for immunocytochemistry as described 
before and cultured for 24h in growth medium, before starting treatment. To 
assess whether RSVL exerts its effect on AHN via Klotho, Klotho expression 
was knocked down 24h after seeding. After 24h under proliferation conditions 
RSVL or Rosiglitazone (ROSI), a PPARγ agonist, were added.  
To assess whether the effects of RSVL on proliferation and neurogenesis are 
mediated via the transcription factors PPARγ and Klotho, HPC03A/07 cells 
were treated with the specific PPARγ agonist Rosiglitazone or with the 
irreversible PPARγ antagonist GW9662 or with siRNAs binding Klotho mRNA to 
knock down Klotho protein expression. Rosiglitazone belongs to the class of 
drugs of thiazolidinediones that acts by activating PPARs. Rosiglitazone 
specifically -and with high affinity (Kd=40nM) targets and activates PPARγ 
(Lehmann et al., 1995). 
GW9662 is an irreversible PPARγ antagonist that binds PPARγ with IC50 in 
nanomolar range (5.4±0.6 nM), and is 10- and 600-fold less potent in binding 
PPARα and PPARδ, respectively (Leesnitzer et al., 2002; Seimandi et al., 
2005). GW9662 was therefore used at 80 nM to avoid blocking of PPARα and 
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PPARδ. The functional activity of GW9662 as an antagonist of PPARγ was 
confirmed in an assay of adipocyte differentiation (Lehmann et al., 1995; 
Braissant et al., 1996). The antagonistic effect of GW9662 was also measured 
by the inhibition of CD36 expression in peritoneal macrophages stimulated by 
various ligands, including Rosiglitazone. It further maintains its activity in tissue 
culture (Huang et al., 1999; Leesnitzer et al., 2002). 
For the proliferation assay cultures were grown for 3 days under proliferation 
conditions. (Figure 2-10 1.)) For the differentiation assay, differentiation was 
started at the same time as RSVL or ROSI were added and grown for 7 days 
under differentiation conditions as shown in Figure 2-10, 2.) and Table 2-4, 
conditions 1 and 2. 
After 24h under proliferation conditions cells were then treated with RSVL or 
ROSI and maintained under proliferation conditions for 3 days. For the 
differentiation assay differentiation was started at the same time as RSVL or 
ROSI were added and grown for 7 days under differentiation conditions as 
shown in Figure 2-10 and Table 2-4.  
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Figure 2-10 Timeline for PPARγ experiment on HPC0A07/03A cells  
1.) Proliferation assay, 2.) Differentiation assay. Cells were cultured for 24h after 
seeding before siRNA or GW9662 were added, after 24h proliferation RSVL or ROSI 
were added. For the proliferation assay cells were then maintained under proliferation 
conditions for 3 days, for the differentiation assay differentiation was started 
simultaneously and maintained for 7 days. 
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1.   24h pro  24h pro 7d diff 
  siRNA RSVL 
    
    
2.   24h pro  24h pro 3d/7d diff 
  siRNA Rosi 
    
    






5.   24h pro  24h pro 3d/7d diff 
  RSVL RSVL 
    
    
6.  0.003% DMSO  
   
   
   
   
Table 2-4 Conditions for PPAR experiment.  
Cells were cultured for 24h after seeding before siRNA transfection or GW9662 was 
added. After 24h RSVL or ROSI was added. For the proliferation assay cell were 
maintained for 3 days under proliferation conditions. For the differentiation assay 
differentiation was stared simultaneously and maintained for 7 days. Pro: Proliferation; 
Diff: Differentiation 
 
Compounds Solvent Function 
Final 
concentration 




Rosiglitazone (Rosi) DMSO PPARactivator 3µM 




Table 2-5 PPARγ activator and blocker, function and concentration.  
All compounds in this table have been dissolved in DMSO and diluted in media to their 
final concentration. 
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2.1.7 RNA interference (RNAi) 
To suppress the protein expression of Klotho, cells were transfected with stealth 
siRNA (Invitrogen) that specifically binds Klotho mRNA in the cytoplasm (see 
Table 2-6 for sequences). The transfection method for HPCOA07/03 cells was 
already in place in the lab. They were transfected using the N-TER Nanoparticle 
siRNA Transfection System (5nM) (Sigma N2913) and again BLOCK-iT Alexa 
Fluor red Fluorescent Oligo (5nM) (Invitrogen) was used to determine the 
efficiency of transfection which was estimated at >80% (Figure 2-12). Cells 
were then either fixed for immunocytochemistry (Section 2.2) or harvested for 
RNA (Section 2.4) or protein extraction (Section 2.3). 
 
 
Figure 2-11 Timeline for siRNA transfection of HPCA07/03A cells.  
For the proliferation assay (line 1) cells were transfected using the N-TER Nanoparticle 
siRNA Transfection System 24h after seeding and maintained for 3 days. For the 
differentiation assay (line 2 and 3) cells were kept for 24h under proliferation was 
started and maintained for 3 or 7 days. 
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Figure 2-12 HPCOA07/03 after transfection/nucleofection  
Cultures were transfected/nucleofected with Block-iT Alexa Flour red Fluorescent Oligo 
using the N-TER Nanoparticle siRNA Transfection System. Transfection efficiency was 
>80%. 
 
siRNA sequences used in HPCOA07/03 










Table 2-6 Sequences of stealth siRNA’s (Invitrogen) used for the Klotho knock 
down in HPCOA07/03.  
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2.1.8 Generation of a cell line conditionally over expressing Klotho 
To assess the effect of the secreted form of the gene Klotho on the proliferation 
and differentiation of HPC0A07/03A cells, these cells were genetically 
engineered to conditionally over-expressing the secreted form of Klotho using 
the Lenti-XTM Tet-On® Advanced Inducible Expression System (Clonetech). 
Gene expression is activated in this system using the tetracycline Doxycycline. 
The Lenti-XTM Tet-On® Advanced Inducible Expression System consists of a 
regulator vector: pLVX-Tet-On Advanced, and a response vector: pLVX-Tight-
Puro. The regulator vector constitutively expresses a tetracycline-controlled 
transactivator (rtTA-Advanced) that, in the presence of Doxycycline binds to the 
inducible promoter (Ptight) of the gene of interest in the response vector and 
activates transcription. Ptight consists of a Tet-Responsive Element (TRE) joined 
to a minimal CMV promoter. Induction of the system produces high-level 
transcription of the gene of interest. See Figure 2-13. 
 
Figure 2-13 Lenti-XTM Tet-On® Advanced Inducible Expression System.  
The Lenti-XTM Tet-On® Advanced Inducible Expression System consists of a regulator 
vector: pLVX-Tet-On Advanced, and a response vector: pLVX-Tight-Puro. The 
regulator vector constitutively expresses a tetracycline-controlled transactivator (rtTA-
Advanced) that, in the presence of Doxycyclin binds to the inducible promoter (Ptight) of 
the gene of interest in the response vector. Ptight consists of a Tet-Responsive Element 
(TRE) joined to a minimal CMV promoter. Induction of the system produces high-level 
transcription of the gene of interest. Picture source: www.clontech.com. 
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2.1.8.1 Cloning of Kotho secreted into the pVLX-Tight-Puro vector 
The human Klotho secreted plasmid in pcDNA3.1/V5/His-TOPO back bone 
(17713) was purchased from Addgene (Cambridge, USA) and was then cloned 
into the pLVX-Tight-Puro vector (ClonTech 632162) using the enzymes BamHI 
and Xba1 (NEB), as follows: The vector and the target gene plasmid were 
digested using the same enzymes to create matching sticky ends. The cutting 
site of the enzyme Xba1 (T/CTAGA) is blocked by overlapping dam methylation. 
Dam methylase–methylation occurs at the N6 position of the adenine in the 
sequence GATCT (Marinus and Morris, 1973; Geier and Modrich, 1979). To be 
able to digest the blocked Xba1 site, the plasmids were transferred into 
StellarTM dam-/dcm- competent cells (Clontech) following manufacturer’s 
instructions to prevent blocking of the site through dam methylation. The 
plasmids were extracted using the Sigma GenElute miniprep (PCN70-1KT) 
following manufacturer’s instructions. To isolate the specific fractions, vector 
and insert, the plasmids were then subjected to a double digest with BamHI and 
Xba1 using 5ug of DNA. The products of the digest were concentrated using 
QIAprep Spin Miniprep Kit (Qiagen) following manufacturer’s instructions, 
checked for quality on an ethidium bromide gel and separated using a Crystal 
blue gel. The insert and vector were then purified from the gel using QGbuffer 
(Qiagen) and the GeneJetPlasmidMiniprep kit (Fermentas) following 
manufacturer’s instructions. For ligation, the insert DNA and the vector DNA 
were mixed with 1µl ligase (NEB) and 2µl 10x ligation buffer (NEB) in a total 
reaction volume of 10µl and incubated for 30min at RT. The plasmid was then 
transformed into dam-/dcm- competent cells and sequenced for the correct 
insertion of the target gene as described in section 2.1.8.2. The plasmid was 
then extracted and purified using PureYield Plasmid Maxiprep (Promega) 
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following manufacturer’s instructions. A glycerol stock of the E.Coli carrying the 
Klotho secreted pLVX-Tight-Puro Plasmid was stored at -80°C. 
2.1.8.2 Sequencing of the Klotho secreted pVLX-Tight-Puro plasmid 
The plasmid was amplified using the BigDye® Terminator v1.1 Cycle 
Sequencing Kit (Applied Biosystems) using the primers in Table 2-7 and the 
conditions in Table 2-8 on the BioRad Opticon 2. To remove unincorporated 
nucleotides, the sequencing PCR product was cleaned up using the 
Ethanol/EDTA precipitation protocol following manufacturer’s instructions 
(Applied Biosystems), resuspended in Hi-Di Formamide (Applied Biosystems) 
and assayed on a Applied Biosystems 3130 genetic analyzer. The resulting 
sequence electropherograms were then analysed using BioEdit and 
CodonCode Aligner software. 
  











Rev1:   GGGGAACTTCCTGACTAGGG 
Rev2: TAGGGCTTGGTGAGACTGCT 
Rev3 GGTCCAAAGCAAAGAGCAAA 
Table 2-7 Sequencing primer:  
Primer used for sequencing the correct insertion of the Klotho secreted insert into the 
pVLX-Tight-Puro vector  
 
96.0°C 01:00 min 
96.0°C 00:08 min 
50.0°C 00:07 min 
60.0°C 01:30 min 
Go to line 2 for 14 more times 
96.0°C 00:08 min 
50.0°C 00:07 min 
60.0°C 01:45 min 
Go to line 6 for 4 more times 
96.0°C 00:08 min 
50.0°C 00:07 min 
60.0°C 02:00 min 
Go to line 10 for 4 more times 
10.0°C 16:00:00 
End 
Table 2-8 PCR protocol used for amplifying the Klotho secreted pLVX-Tight-
Puro Plasmid  
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2.1.8.3 Lentivirus generation 
For the transfection of the HPC03A/07 the modified Lenti-XTM Tet-On® 
Advanced Inducible Expression System (Clonetech) has been used. To 
generate and package this virus the envelope plasmid pMDG: VSV-G and the 
packaging plasmid P8.91: GAG-POL was used instead of the Lenti-X HT 
packaging mix, and the transfection was conducted using Lipofectamine instead 
of Lentiphos HT, as this set up was already in place in the lab. To generate the 
two viruses, one with the regulator vector and one with the response vector, 
HEK cells were transfected using Lipofectamine following manufacturers’ 
instructions with a total of 30µg of DNA containing the envelope plasmid 
pMDG:VSV-G, the packaging plasmid P8.91:GAG-POL (provided by Graham 
Cocks, IOP, King’s College London, U.K.) and either the regulator or the 
response plasmid. The virus was collected 24h and 48h after the transfection 
and concentrated using the Lenti-X concentrator (Clontech) following 
manufacturers’ instructions. The concentrated virus was stored in aliquots at -
80°C. See Figure 2-14 for an overview of the lentivirus generation and cell 
transduction. 
2.1.8.4  Transduction of the HPC03A/07 cell line using Lentivirus 
HPC03A/07 cells were cultured for 48h as described previously, media was 
changed 24h before the viral transduction. Cultures were transducted in 6 well 
plates (nunc) at 60% confluency. 5µl of regulator virus and 10µl of response 
virus were added to 2ml of media and centrifuged for 45min at 750g, 32°C. After 
30min incubation at 37°C the media was changed and 48h later the cells were 
subjected to antibiotic selection using 0.2µl/ml Puromycin. The Klotho secreted 
pVLX-Tight-Puro expresses resistance to the antibiotic Puromycin. To ensure 
only successfully transducted cells were cultured further the cells were 
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subjected to Puromycin for 2 days. Cells not carrying the plasmid were dead 
after 2 days. The pLVX-Tet-On-Advanced plasmid expresses resistance to the 
antibiotic Neomycin; however the HPC03A/07 cells are already resistant to 
Neomycin after they have been made conditionally immortalised with the c-myc-
ER. None the less the successful transduction of both plamids was confirmed 
by immunocytochemistry against the secreted form of Klotho, the gene of 
interest. The protein of the gene of interest can only be expressed if the cell 
carries both plasmids, the regulator and the response vector. Cells, further 
referred to as Klover, were then passaged into a T75 flask (nunc) and cultured 
or frozen as needed for the experiment.  
 
 
Figure 2-14 Establishing an inducible expression system in the HPC03A/07 cell 
line with Lenti-X TetOn Advanced:  
1. The response and the regulator lentivirus were produced using the enveloping 
plasmid pMDG: VSV-G, the packaging plasmid P8.91: GAG-POL and 293T cells. 2. 
Virus was harvested in the supernatant of the cell culture. 3. HPCOA7/03A cells were 
coinfected with to two viruses. 4. Cells were harvested for experiments Picture slightly 
modified from www.clontech.com 
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2.1.8.5 Klover experiment 
To induce expression of the secreted form of Klotho in the Klover HPC03A/07 
cells, the cultures were treated with Doxycycline (Sigma) (1µg/ml) 24h after 
seeding. For the proliferation assay cells were cultured for 3 days under 
proliferation conditions, for the differentiation assay differentiation was started at 
the same time as Klotho expression was started by adding Doxycycline (Figure 
2-15).  
 
Figure 2-15 Timeline for the experiment using Klover HPC03A/07 cells 
Cells were treated with 1µg/ml Doxycycline 24h after seeding. Cultures were then 






Protein or RNA harvest
4 hours BrdUpulse
7d Differentiation24h Proliferation
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2.1.9 Analysis of cell proliferation 
The thymidine analogue 5’-bromo-2’-deoxyuridine (BrdU) is commonly used to 
assess cell proliferation as the synthetic nucleotide incorporates into the DNA of 
cells undergoing DNA replication during S-phase. BrdU at 10µM has been 
added for 4h, the time of the S-phase, before fixation. Staining for incorporated 
BrdU with commercially available antibodies is used to investigate the rate of 
cell proliferation (Wojtowicz and Kee, 2006). 
For BrdU detection via antibodies the DNA needs to be denaturised so the 
antibody gains access to the DNA-integrated BrdU (Kee et al., 2002). This was 
achieved by incubating the fixed cells in 2N Hydrochloric acid HCL for 15min at 
RT. Subsequently cells were rinsed with PBS three times for neutralisation. The 
staining was then carried out as described in section 2.2 below. 
Proliferating cells were also identified using the marker Ki67. Ki67, a nuclear 
protein expressed throughout the cell cycle phases except during the G0 and 
early G1 phase, is a reliable marker for proliferation that is expressed 
exclusively during mitosis and has a very short half-life. (Kee et al., 2002) 
2.2 Immunocytochemistry 
A range of antibodies (Table 7-3) were used to assess the proliferation, 
differentiation and survival of progenitor cells after they have been exposed to 
various compounds. 
To overcome non-specific background staining of the secondary antibodies that 
were raised in Donkey, cultures were blocked with PBS containing 5% Normal 
Donkey Serum (NDS) and 0.1% Triton-X-100, for 1h at RT and then incubated 
with one or two primary antibody (Table 7-3) over night at 4°C. The next day 
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cultures were rinsed three times with PBS, blocked for 30min at RT, incubated 
with the appropriate secondary antibody (Table 7-4) for 2h at RT. See Table 7-5 
and Table 7-7 for detailed combinations of primary and secondary antibodies. 
For a nuclear counter stain cultures were rinsed in PBS containing 300nM 4',6-
diamidino-2-phenylindole (DAPI) (Sigma) for 2min followed by two PBS washes. 
DAPI binds strongly to DNA of fixed and live cells. Finally, cultures were either, 
in case cells were grown on glass objective slides using the reusable chamber 
slides, mounted with cover slips and ProLong® Gold (Invitrogen) or, in the case 
of 96 well plates, stored in 200µl PBS plus 0.05% Sodium azide (to prevent 
bacterial growth) at 4°C. As a negative control fixed cultures underwent the 
same treatment as above but without adding the primary antibody. 
BrdU staining was also conducted, however because of technical issues the 
data could not be presented in this thesis. 
2.3 Quantitative protein analysis 
2.3.1 Protein extraction 
In order to relatively quantify the amount of Klotho protein in the Klover cells 
and the HPC03A/07 after Klotho knock down using siRNA, cells were lysed into 
ice cold modified RIPA lysis buffer (Table 7-8) containing protease and 
phosphatase inhibitors (Sigma/ Roche), constantly agitated for 30 minutes at 
4°C before being centrifuged in a microcentrifuge at 4°C (12,000g, 20min). The 
supernatant was transferred into a fresh tube and stored at -80˚C. Protein 
concentration was determined using the BCA Protein Assay Kit from Novagen 
(71285-3) according to manufactureres instructions. 
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2.3.2 Protein separation and detection 
Samples were thawed at 4˚C before being boiled at 90˚C for 5 minutes to 
denature proteins. A total of 5ug of protein was loaded on a reducing 10% SDS-
PAGE gel (Table 7-9) for 1 hour at 200V. Proteins were then electrophoretically 
transferred to a nitrocellulose membrane, 0.2 µm pore size (Invitrogen) at 25V 
for 1.5h at RT. Transfer efficiency was controlled by Precision Plus Protein Dual 
Color Standards (BioRad). Unspecific binding sites were blocked for 1h in 4% 
non-fat dry milk in TBS and immunoprobed with the KM2076 antibody (Kyowa 
Hakko Kirin) against Klotho’s secreted form (expected band size 60kD) in 
background reducing antibody diluents (DAKO) at 4°C overnight. The next day, 
membranes were washed three times with TBS containing 0.1% Tween-20 
(TBS-Tween) and incubated with a Alexa-Flour Goat anti rat 680 secondary 
antibody (Invitrogen, 1:3000) in 4% non-fat dry milk in TBS for 1h at RT before 
being washed three times in TBS-Tween. Proteins were visualised using the 
Odyssey detection system. The relative density of the Western blot bands was 
analysed using ImageJ software.  
2.4 Quantitative RNA analysis 
2.4.1 RNA extraction 
RNA was extracted from cell lines and rat brains using the TRI Reagent 
(Ambion) procedure according to manufacturer’s instructions. Samples were 
stored at -80°C. 
2.4.2 DNAs treatment 
To remove genomic DNA from the sample it was treated with the DNA-free™ 
DNase Treatment and Removal Reagents (Ambion) according to 
manufacturer’s instructions. RNA was quantified using spectrophotometry 
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(NanoDrop) and the purity determined via the 260/230 ratio to assess quality, 
clean RNA for the following cDNA synthesis. Only RNAs with a ratio above 1.80 
were included. 
2.4.3 cDNA synthesis 
cDNA synthesis was completed with the Superscript III (Invitrogen) using 1μg of 
RNA and random decamers (Sigma) at 250ng, as described by the 
manufacturer. The parameters used for the PCR reaction are given below. The 
samples were dilute 1:10 with DEPC water and stored at -20°C. 
Denaturing  
65ºC for 5min 
Place straight on ice for ~1min 
 
RT Protocol 
25 ºC  5 min 
42 ºC  120min 
70 ºC  15min 
 4 ºC  60min 
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2.4.4 Quantitative PCR 
qPCR was used to detect and ultimately quantify the expression level of the 
gene Klotho and PPARγ. See Table 2-9 for details. 
Genes of interest 
Klotho 
sec 232bp >F TTGGAATCTCCCAACCTGAG 
 
  
>R ACTCGAAACCATCCATGAGG Exon2-3 




    Housekeeping genes 
UBC 133bp >F ATTTGGGTCGCGGTTCTTG  
 
  
>R TGCCTTGACATTCTCGATGGT  
 
    HPRT1 94bp >F TGACACTGGCAAAACAATGCA 
 
  
>R GGTCCTTTTCACCAGCAAGCT  
 




 Table 2-9 Q-PCR primer 
Sequences, length of PCR product and binding area of the primer used in this thesis. 
qPCR quantifies the gene copy number through continuous monitoring of a 
fluorescent signal that is only emitted if the fluorescent dye is bound to a double 
stranded product generated during PCR. This fluorescent signal is proportional 
to the DNA concentration. For all qPCRs the BioRad Opticon 2 has been used 
(Protocol below).The master mix contained 4µl 5xHOT FIREPol EvaGreen 
qPCR Mix (Solis BioDyne), 4µl of 1µM forward and reverse primer at a final 
concentration of 100nM and 8µl of water. The final reaction volume was made 
up of 16µl Master Mix and 4µl cDNA (1:10). The primers, all custom made by 
Sigma or IDT, were tested for primer dimers and the concentration optimized 
using cDNA from human or rat hippocampus.  
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Q-PCR cycle 
1 95ºC  00:15:00 
2 95 ºC  00:00:30 
3 60 ºC  00:00:30 
4 72 ºC  00:00:30 
5 see below 00:00:10 
6 Plate read 
7 Go to line 2 for 44 more times 
8 Melting curve: from 60 ºC-95 ºC, read every 1 ºC and hold for 10min 
 
Step 5:  Normal:  80.0 ºC 
FGF23:  80.5 ºC 
Wnt3a: 81.5 ºC 
MAPT:  82.0 ºC 
2.5 Immunohistochemistry on free floating rat brain sections 
These experiments were carried out to evaluate the functionality of the Klotho 
antibody and to find out which cell types express Klotho. 
2.5.1 Fluorescence staining 
Control mouse brain sections were co-stained for Klotho protein and markers 
for proliferation SOX2, markers for differentiation NEUN and the glial marker 
GFAP to see which cell types co-express Klotho. See Table 7-3. Sections were 
stained free floating using net carriers in 6-well plates. First, the cryoprotective 
solution was rinsed off with PBS on a shaker for 5min. This wash was repeated 
three times. Sections were then blocked with 3% Normal Donkey serum in PBS 
with 0.25% Triton-X for 60min at RT to prevent unspecific binding of the 
secondary antibody that was raised in Donkey. Sections were then incubated 
with primary antibodies overnight at 40C on a shaker. The next day the sections 
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were given three 5min washes in PBS, blocked for 30min and then incubated 
with the appropriate secondary antibody (Table 2-10) for 2h at RT. Finally 
sections were rinsed in DAPI for 5min, twice in PBS and then mounted on glass 
slides using ProLong® Gold (Invitrogen). As negative control a section 
underwent the same treatment as described above however without adding a 
primary antibody. 
Primary antibodies Secondary antibodies 
KM2119 (rat) 
Ki67 (rabbit) 
Anti rat 488 
Anti rabbit 594 
KM2119 (rat) 
NEUN (mouse) 
Anti rabbit 488 
Anti mouse 594 
KM2119 (rat) 
GFAP (rabbit)  
Anti rabbit 488 
Anti mouse 594 
Table 2-10 Primary and secondary fluorescent AB combinations for sections 
 
2.5.2 3,3'-Diaminobenzidine (DAB) staining for stereology 
Sections (1:6) for stereology of the IF mouse model (explained in detail in 
2.6.1.2) were stained for the proliferation marker Ki67, Dcx, a marker for early 
neurons and Klotho (SC) (Table 2-11) to explore any differences in their 
expression in the hippocampus of these mice. 
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Klotho (E-21) goat Santa Cruz BT SC-22220 1:500 
Ki67 rabbit abcam Ab15580 1:500 
Dcx rabbit abcam Ab18723 1:10000 
Table 2-11 Primary antibodies used for DAB staining 
 
Sections were incubated in 1% H202 in TBS for 40 minutes at RT to quench 
endogenous peroxidase activity. Next, sections were rinsed in TBS before being 
blocked in 15% normal serum (NS) in TBS-T (TBS + 0.3% Triton-X) for 30 min. 
Incubation with primary antibodies (Table 7-3) was carried out in a dilution of 
10% NS in TBS-T at 4°C overnight. The following day sections were rinsed in 
TBS and incubated with the appropriate biotinylated secondary antibody diluted 
in 10% NS in TBS-T for 2h. Sections were then rinsed again before an avidin-
biotin-peroxidase complex, diluted at 1:1.000 in TBS, was applied for 2h 
(Vectastain Elite ABC kit, Vector Laboratories). Finally the staining was 
visualised by a standard DAB reaction (0.05% 3,3’-diaminobenzidine 
tetrahydrochloride HCl; Sigma) for 5-15 minutes, before sections were rinsed 
and mounted onto chrome-gelatine coated slides, dried overnight, cleared and 
dehydrated in 100% IMS and 100% xylene before being coverslipped with DPX 
(VWR). 
As a negative control, sections were treated following the protocols above but 
instead of the primary antibody they were incubated in PBS and then incubated 
with secondary antibody. 
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2.6 Microscopy 
2.6.1.1 Fluorescence  
Pictures of immunocytochemically stained cells were taken on a fluorescence 
microscope Axio Imager microscope (Carl Zeiss Inc.) using the Axio vision 
Digital Image Processing Software Version 4.67.1 (Carl Zeiss Inc.). Bright field 
images and images of immunocytochemically stained cells in 96 well plates 
were taken with the Olympus 1x70 inverted microscope using the same imaging 
software. Pictures were imported into ImageJ for further processing. 
2.6.1.2 Stereology 
Stereology is a tool used to obtain quantitative properties about structure, 
regional volumes, cell numbers and other biological parameters of 3D objects 
from 2D sections through an object (Schmitz and Hof, 2005). Stereology has 
become the gold standard for the analysis of quantitative information in the 
CNS. The random, systematic sampling guarantees the collection of unbiased, 
accurate results from small sample sizes with statistical efficiency. To assure 
equal sampling, a series of regularly spaced sections is required spanning the 
whole area of interest (Gundersen and Jensen, 1987). A grid of known spacing 
is then applied and provides a series of systematic sampling sites. In this study 
murine sections of 40µm thickness were used to quantify the amount of Klotho 
expressing cells in the DG. The randomly but systematic applied grid provides 
an unbiased dissector frame through which small regions of the area of interest 
are quantified independent of orientation, size and shape of the analysed 
objects (Gundersen et al., 1988; Molteni et al., 2002). The sizes of the sampling 
sites and the dissector frame are predetermined according to the size of the 
region of interest and the number of sections was kept constant throughout the 
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analysis of the experiment in order to produce a Gundersen coefficient of error 
of less than 0.1. The parameter for the grid size in this study were X: 234.01µm, 
Y: 80.81µm and 37µm x 37µm for the counting frame. Throughout the study the 
x40 objective was used for counting. 
All stereological analyses were performed using StereoInvestigator software 
(Microbright Field, Williston, VT) on a Zeiss Axioskop2 MOT microscope (Carl 
Zeiss Ltd) and a DAGE-MTICCD-100 camera (DAGE-MTI Inc.). The optical 
fractionator method was used to quantify Klotho positive cells in the Dentate 
Gyrus. It uses thick sections and estimates the total number of cells from the 
number of cells sampled with a Systematic Randomly Sampled (SRS) set of 
unbiased virtual counting spaces covering the entire region of interest with 
uniform distance between unbiased virtual counting spaces in directions X, Y 
and Z (Gundersen et al., 1988). Analysis was carried out as previously 
described by (Thuret et al., 2009) with a randomly selected starting section 
followed by every sixth section thereafter. 
2.6.1.3 Threshold analysis 
For quantitative threshold image analysis of Klotho immunoreactivity in the DG, 
different sections were DAB stained simultaneously. Ten non-overlapping 
images were captured from three consecutive sections per animal. Images were 
obtained, blind to genotype, with a live video camera (JVC, 3CCD, KY-F55B), 
mounted onto a Zeiss Axioplan microscope using a 5X objective. Parameters 
including lamp intensity, video camera setup and calibration were kept constant 
throughout the analysis. Subsequently images were analysed using the Image-
Pro Plus 4.0 (Media Cybernetics) image analysis software. For this analysis an 
appropriate threshold was applied that selected foreground immunoreactivity 
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above background, which was applied as a constant for all images analysed. 
The recorded data was transferred to an Excel spreadsheet, analysed 
statistically and displayed as the mean percentage area of immunoreactivity per 
field (± SEM). 
2.7 Statistical analysis 
Data are presented as mean ± SEM. All statistical analyses were performed 
with GraphPad Prism 5 on independent biological replicates (indicated as n). 
The number of biological replicates was three if not otherwise stated. One-Way 
ANOVA with Newman-Keuls post hoc test was used for multiple comparisons 
among treatment groups. Student’s t-test was used to compare means of two 
independent treatment groups. P-values <0.05 were considered significant. 
P-values 0.01 – 0.05: *; P-values0.001 – 0.01: **; P-values <0.001: ***, 
P-value <0.0001: ****.  










Chapter 3 Effects of Omega-3 fatty acids and Resveratrol on 
HPC03A/07  
Page 116 of 318 
 
In this chapter I investigated the effect of Omega-3 fatty acids and RSVL on 
hippocampal neurogenesis in an in vitro model of hippocampal neurogenesis 
using the human embryonic hippocampal progenitor cell line HPC03A/07, 
specifically I have: 
Investigated the effects of the Omega-3 fatty acids eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) and the stilbenoid Resveratrol (RSVL) on 
HPC03A/07 during proliferation and differentiation.  
Determined the possible preventative properties of Omega-3 and RSVL in an in 
vitro model of stress. The model used the HPC03A/07 cells treated with Cortisol 
to mimic stress resulting in a decrease in proliferation and neurogenesis (see 
Section 2.1.5.1 for details). 
3.1 EPA and DHA decrease apoptosis and increase the proportion of 
dividing cells and neuronal cells in HPC03A/07  
In order to determine the effects of EPA or DHA on proliferating and 
differentiating HPC03A/07 cells, cells were cultured as described in Section 
2.1.1. The concentration of 10µM was determined previously in the Thuret lab 
by titration (data not shown) and did prove to result in the highest increase in 
proliferation. After 24h under proliferating conditions EPA or DHA treatment was 
started and for the proliferation assay cells were maintained for further 6 days 
under proliferation conditions before being fixed with 4% PFA. Media was 
changed after 3 days. For the differentiation experiment, cell differentiation was 
started after 6 days of proliferation. Cultures were maintained for 7 days before 
being fixed for immunocytochemistry. See Figure 2-9. Cultures were then 
stained for the proliferation marker Ki67 and the apoptosis marker activated 
Caspase-3. Cultures were double labelled for the NPC marker SOX2 and 
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Nestin. In the differentiation experiment cells were also stained for the 
neuroblast marker Dcx and the mature neuronal marker MAP2.  
3.1.1 Eicosapentaenoic acid increases the proportion of dividing cells and 
decreases apoptosis in proliferating HPC03A/07  
In proliferating HPC03A/07 cells treated with EPA the percentage of Ki67 
positive cells was significantly increased by 13.7±1.2%, p<0.001 compared to 
vehicle treated cells to a total of 39.3±0.4% (Figure 3-1a,b). The percentage of 
cell expressing activated Caspase-3, however, was significantly decreased by -
40.1±11.7%, p<0.05 compared to control to a total of 5.4±1.1% (Figure 3-1c,d). 
The percentage of cells expressing SOX2 or Nestin expression showed no 
changes. 
EPA increased the proportion of dividing cells and decreases apoptosis in 
proliferating HPC03A/07, suggesting an increased survival of dividing cells. 
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Figure 3-1 Ki67, activated Caspase-3 in proliferating HPC03A/07 treated with 
EPA 
a, c, e, g depict the percentage of positive cells relative to absolute cells. b, d, f, h show 
the percentage change of the marker in EPA treated cultures compared to EtOH 
(vehicle) treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 
expressing cells. Abbreviations: EtOH: Ethanol control; EPA: eicosapentaenoic acid (p-
values were generated using Student’s t-test, Error bars are the Standard Error of the 
Mean (SEM), *p<0.05, ***p<0.001).  
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3.1.2 Eicosapentaenoic acid increases the proportion of dividing cells and 
of mature neuronal cells and decreases apoptosis in differentiating 
HPC03A/07  
To assess the effect of EPA during differentiation, HPC03A/07 cells were 
treated with EPA as described in Section 3.1. The percentage of Ki67 positive 
cells was significantly increased by 21.8±1.1%, p<0.05 when EPA cultures were 
compared with EtOH treated controls to a total of 33.6±0.3% (Figure 3-2a,b). No 
change was observed in the proportion of Dcx expressing cells present under 
experimental compared to control conditions (total percentage 16.3±0.5%, 
Figure 3-2c,d). However, the percentage of MAP2 expressing cells was 
significantly increased by 45.0±0.9%, p<0.0001 to a total of 28.2±0.2% (Figure 
3-2e,f). While the percentage of cells labelled with activated Caspase-3 was 
significantly decreased by -44.2±8.9%, p<0.01 to a total of 7.9±1.3% (Figure 
3-3a,b). SOX2 showed no changes (Figure 3-3c,d) whereas the percentage of 
Nestin expressing cells was decreased by -1.8±0.3%, p<0.01 to a total of 
98.0±0.3% (Figure 3-3e,f).  
These data suggest that EPA still increases the percentage of dividing cells in 
HPC03A/07 after 7 days of differentiation but also increases differentiation 
along a neuronal pathway, resulting in an increased proportion of ‘mature’ 
MAP2 expressing neurons but not immature DCX expressing neurons. It further 
significantly decreased the percentage of apoptotic cells and Nestin expressing 
cells. This suggests that EPA treatment facilitates a fast differentiation into 
maturing neurons and enables their survival. Further, the continuing division of 
some might be due to asymmetric division, meaning cells divide and one 
daughter cells starts differentiation (in this case into neuronal cells) the other 
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keeps her progenitor cell properties (here Ki67 positive cells) and continues to 
divide.  
Page 121 of 318 
 
 
Figure 3-2 Ki67, Dcx and MAP2 expression in differentiating HPC03A/07 under 
EPA treatment 
a, c and e show the percentage of Ki67, DCX and MAP2 expressing cells respective in 
EPA treated and control cultures. b, d and f show the percentage change of each 
marker in EPA treated cultures compared to control EtOH treated cells. EPA treatment 
results in a significant increase in Ki67 expressing cells (a,b) and MAP2 expressing 
cells (e,f) but no change in DCX expressing cells (c,d). Abbreviations: EtOH: Ethanol 
control; EPA: eicosapentaenoic acid (p-values were generated using Student’s t-test, 
Error bars are the Standard Error of the Mean (SEM), *p<0.05, **p<0.01, ****p<0.0001) 
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Figure 3-3 Activated Caspase-3, SOX2 and Nestin expression in differentiating 
HPC03A/07 under EPA treatment  
a, c and e show the percentage of activated Caspase-3, SOX2 and Nestin expressing 
cells respective in EPA treated and control cultures. b, d and f show the percentage 
change of each marker in EPA treated cultures compared to control EtOH treated cells. 
EPA treatment resutls in decreased activated Caspase-3 (a,b) and Nestin expression 
(e,f), but no change in SOX2 expressing cells (c,d). Abbreviations: EtOH: Ethanol 
control; EPA: eicosapentaenoic acid (p-values were generated using Student’s t-test, 
Error bars are the Standard Error of the Mean (SEM), **p<0.01) 
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3.1.3 Docosahexaenoic acid increases the proportion of dividing cells and 
decreases apoptosis in proliferating HPC03A/07  
Cultures were treated with DHA as described in Section 3.1. In proliferating 
HPC03A/07 cells the percentage of Ki67 positive cells was significantly 
increased by 30.0±4.3%, p<0.01 compared to EtOH treated control cultures to a 
total of 51.3±1.2%, (Figure 3-4a,b). The percentage of activated Caspase-3 
expressing cells did not significantly change (total of 8.2±0.6%), (Figure 3-4c,d). 
SOX2 or Nestin expression in DHA treated cultures were unchanged compared 
to vehicle. 
These results indicate that DHA significantly increases the percentage of 
dividing cells in proliferating HPC03A/07, without impacting on apoptosis and 
progenitor cells, suggesting that it increases the percentage of dividing cells 
without affecting survival, therefore DHA might affect proliferation. 
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Figure 3-4 Ki67 and activated Caspase-3 expression in proliferating HPC03A/07 
cells under DHA treatment 
a, c, e, g depict the percentage of positive cells relative to absolute cell numbers; b, d, 
f, h show the percentage change of the marker in DHA treated cultures compared to 
EtOH treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 
expressing cells. Abbreviations: EtOH: Ethanol control; DHA: Docosahexaenoic acid 
Abbreviations: (p-values were generated using Student’s t-test, Error bars are the 
Standard Error of the Mean (SEM), **p<0.01, ***p<0.001).  
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3.1.4 Docosahexaenoic acid increases the proportion of dividing cells and 
neuroblasts while decreasing apoptosis in differentiating 
HPC03A/07 cells  
To assess the effect of DHA during differentiation, HPC03A/07 cells were 
treated with DHA as described in Section 3.1. The percentage of Ki67 positive 
cells was significantly increased by 27.2±3.4%, p<0.05 compared to EtOH 
control treated cells to a total of 35.2±0.9%, (Figure 3-5a,b), so was the 
proportion of Dcx expressing cells by 13.5±0.7%, p<0.05 to a total of 
18.5±0.1%, (Figure 3-5c,d). The percentage of activated Caspase-3 expressing 
cells on the other hand was significantly decreased by -27.8±2.3%, p>0.001 to a 
total of 9.9±0.5%, (Figure 3-5g,h). Whereas MAP2 was non significantly 
decreased (total of 15.2±1.6%, Figure 3-5e,f). SOX2 or Nestin expression 
showed no changes. 
The increase of the proportion of dividing cells in HPC03A/07 cultures after 7 
days of differentiation might be due to decreased apoptosis and therefore result 
in increased survival. DHA treatment further increases the percentage of early 
neurons (Dcx) but not mature neurons (MAP2), suggesting that DHA treatment 
increases differentiation into neuroblasts but the maturation to mature neurons 
might require more time. It would be interesting to see the changes after a 
longer e.g. 14 days differentiation period. Further double labelling BrdU 
incorporating cells for neuronal markers and cell death markers would shed light 
on whether all the changes can be explained through increased survival. 
Moreover double labelling activated Caspase-3 positive cells with neuronal 
markers to examine which cells die. 
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Figure 3-5 Ki67, Dcx, MAP2 and Caspase expression in differentiating 
HPC03A/07 cells under DHA treatment 
a, c and e show the percentage of Ki67, DCX, MAP2 and activated Caspase-3 
expressing cells respective in DHA treated and control cultures. b, d and f show the 
percentage change of each marker in EPA treated cultures compared to control EtOH 
treated cells. DHA treatment results in increased Ki67 (a, b), Dcx (c, d) expression and 
decreased activated Caspase-3 expression. No changes in MAP2 expression. 
Abbreviations: EtOH: Ethanol control; DHA: Docosahexaenoic acid (p-values were 
generated using Student’s t-test, Error bars are the Standard Error of the Mean (SEM), 
*p<0.05, **p<0.01, ***p<0.001)  
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3.2 The stilbenoid Resveratrol increases the proportion of dividing 
cells and neuronal cells in HPC03A/07 cells 
In order to determine the effects of the stilbenoid RSVL on proliferating and 
differentiating HPC03A/07 cells, cells were cultured as described in Section 
2.1.1. After 24h under proliferating conditions RSVL treatment was started and 
for the proliferation assay cells were maintained for further 6 days under 
proliferation conditions before being fixed with 4% PFA. Media was changed 
after 3 days. For the differentiation assay cells were cultures for 24h before, 
RSVL was added and maintained for 6 days, media was changed after 3 days. 
Differentiation was started after a total of 6 days under proliferation conditions 
and cultures were maintained for 7 days under differentiation conditions before 
being fixed for immunocytochemistry. Cultures were then stained for the 
proliferation marker Ki67 and the apoptosis marker activated Caspase-3. 
Cultures were also double labelled for the NPC marker SOX2 and Nestin. In the 
differentiation experiment, cells were also stained for the neuroblast marker Dcx 
and the mature neuronal marker MAP2.  
3.2.1 Titration of Resveratrol concentration 
To determine the concentration of RSVL that promoted the most proliferation, 
HPC03A/07 cells were cultured for 3 days under proliferation conditions while 
being treated with various concentrations of RSVL: 10 µM, 5µM, 1µM, 500nM, 
300nM and 100nM. Concentration range was established based on literature 
research (0.1µM-10µM (Bruedigam et al., 2011) and preliminary experiments 
(data not shown)). Cultures were then fixed with 4% PFA and 
immunocytochemically stained for the proliferation marker Ki67. At 10µM most 
of the cells died after 24h (data not shown). Figure 3-6 shows that at 5µM the 
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percentage of cells expressing Ki67 was non-significantly decreased, at 1µM 
the percentage of Ki67 expressing cells was increased by 40.4±8.4%, p<0.01. 
At lower RSVL concentrations than 1µM the percentage of Ki67 expressing 
cells was still increased but to a lesser extent (500nM: 31.1±6.9%, p<0.05, 
300nM: 30.2±6.3%, p<0.01, 100nM 11.2±7.6%, p>0.05.). In conclusion, RSVL 
caused cell death at 10µM and a decrease in the percentage of dividing cells in 
HPC03A/07 cells at the 5µM, but significantly increased the percentage of 
dividing cells at lower concentration, with 1µM giving the greatest effect.  
Based on my hypothesis that RSVL has a positive effect on proliferating and 
differentiating HPC03A/07 cells I chose 1µM as it increased the proportion of 
dividing cells most. 
 
Figure 3-6 RSVL titration curve after 3 days of proliferation 
Quantification of Ki67 positive cells in HPC03A/07 cultures treated with decreasing 
concentrations of RSVL. Abbreviations: EtOH: Ethanol, RSVL: Resveratrol; (biological 
replicates n=1, technical replicates n=3; P-values were generated using One-Way 
ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of the 
Mean (SEM), *p<0.05, **p<0.01) 
  
Page 129 of 318 
 
3.2.2 Resveratrol increases the proportion of dividing cells in proliferating 
HPC03A/07 cells 
In order to determine the effects of RSVL treatment on proliferation in 
HPC03A.07 cells, cultures were treated with 1µM RSVL as described in Section 
3.2. RSVL treatment significantly increased the percentage of Ki67 positive cells 
by 21.4±2.9%, p<0.001 compared to EtOH treated control cultures to a total of 
41.9±1.0% (Figure 3-7a,b). The proportion of activated Caspase-3 expressing 
cells was not significantly changed (total of 11.6±1.3%), Figure 3-7c,d. The 
percentage of SOX2 or Nestin expressing cells showed no changes.  
This suggests that RSVL impacts on dividing cells in proliferating HPC03A/07 
without affecting apoptosis, which suggests that this increase is due to an 
increased rate of division (proliferation) and not due to increased survival. 
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Figure 3-7 Ki67 and activated Caspase-3 expression in proliferating HPC03A/07 
cells under RSVL treatment 
a, c, e, g depict the percentage of positive cells relative to absolute cell numbers, b, d, 
f, h show the percentage change of the marker in RSVL treated cultures compared to 
EtOH treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 
expressing cells. Abbreviations: EtOH: Ethanol control; RSVL: Resveratrol (p-values 
were generated using Student’s t-test, Error bars are the Standard Error of the Mean 
(SEM), ***p<0.001)  
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3.2.3 Resveratrol increases the proportion of dividing cells, apoptosis and 
mature neurons  
To assess the effects of RSVL on HPC03A/07 under differentiation conditions 
cultures were treated as described in Section 3.2. The percentage of Ki67 
positive cells was significantly increased by 27.3±1.8%, p<0.01 compared to 
control treated cultures to a total of 35.2±0.5%, Figure 3-8a,b. Also MAP2 was 
significantly increased by 52.3±0.3%, p<0.0001 to a total of 36.7±0.1%, Figure 
3-8e,f, as was the percentage of activated Caspase-3 expressing cells by 
33.1±8.8%, p<0.01, to a total of 23.5±1.6%, Figure 3-8g,h. Whereas the 
percentage of Dcx expressing cells was not changed (total of 28.3±1.3%), 
(Figure 3-8c,d). SOX2 and Nestin expression showed no changes. 
These results indicate that RSVL significantly increases apoptosis but also the 
proportion of dividing and differentiating cells in form of mature neurons 
(MAP2). This might suggests that RSVL treatment during differentiation pushes 
the cells into cell fate commitment and also division on a fast route that leads to 
cell death, indicating increased asymmetric division: cells divide with one 
daughter cell remaining a dividing progenitor cell, the other cells undergoing cell 
fate commitment into the neuronal lineage. The increase in mature neurons but 
not neuroblasts indicates that cells that have committed to the neuronal lineage 
have already matured at 7 days differentiation and/or that some cells have died 
during neuronal maturation or cell division, due to an increased cell cycle. To 
verify the suspected increased proliferation rate, BrdU staining will have to be 
conducted. Also double staining for apoptotic cells with marker for proliferation 
and differentiation will reveal the type of dying cells.  
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Figure 3-8 Ki67, Dcx, MAP2 and activated Caspase-3 expression in 
differentiating HPC03A/07 cells 
a, c and e show the percentage of Ki67, DCX, MAP2 and activated Caspase-3 
expressing cells respective in RSVL treated and control cultures. b, d and f show the 
percentage change of each marker in RSVL treated cultures compared to control EtOH 
treated cells. RSVL treatment results in a significant increase in Ki67 expressing cells 
(a,b) and MAP2 expressing cells (e,f), a signifcant decrease in activated Caspse-3 
expressing cells, but no change in Dcx expressing cells (c,d). Abbreviations: EtOH: 
Ethanol control; RSVL: Resveratrol (p-values were generated using Student’s t-test, 
Error bars are the Standard Error of the Mean (SEM), **p<0.01, ***p<0.001, 
****P<0.000 ) 
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3.3 Summary 
Table 3-1 summarises the effect of the Omega-3s EPA and DHA and the 
stilbenoid RSVL on proliferating and differentiating HPC03A/07 cells described 
in Sections 3.1, 3.2 and 0. EPA and DHA both decrease apoptosis and increase 
the proportion of dividing cells and of neuronal cells, with EPA increasing the 
proportion of mature neurons and DHA increasing the proportion of neuroblasts. 
Further, EPA treatment during differentiation is the only condition observed 
where the expression of the NPC marker Nestin was significantly decreased, 
suggesting an increase in survival and differentiation. It might be possible that 
under EPA treatment at an earlier time point in differentiation (3 days) a 
significant increase of Dcx positive neuroblasts could occur and that after 7 
days these neuroblasts have already matured into MAP2 positive neurons. 
Whereas cell differentiation into mature neurons under DHA treatment might 
take longer and the proportion of MAP2 positive cells might only increase after 
e.g. 14 days under differentiation conditions. On the other hand the survival of 
the neuroblasts or the mature neurons might not be maintained during DHA 
treatment, and the cells might die on their way to becoming mature neurons. It 
will be necessary to characterise the nature of the apoptotic cells to explore 
what cell types die, especially as the proportion of activated Caspase-3 positive 
cells in DHA treated cultures is almost 2% higher compared to EPA treated 
cells. RSVL increases the proportion of dividing cells, mature neuronal cells and 
apoptosis. This suggests that RSVL treatment increases the rate of cell fate 
commitment and asymmetric division, however to confirm this BrdU staining will 
be necessary. The proportion of SOX2 and Nestin expressing cells showed no 
or very minor changes throughout the experiments of this thesis, except during 
Klotho over-expression in 4.2. As described in Section 2.1.1, 7 days of 
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differentiation might not be long enough for SOX2 and Nestin to be degraded, 
leading to fate committed cells still expressing SOX2 and Nestin. Also changes 
during proliferation as seen here with the decrease in Ki67 positive cells might 
not be reflected in the SOX2 and Nestin population as this human cell line might 
require longer periods of differentiation to reflect changes in SOX2 and Nestin 
population. Further, an increase in Ki67 cells cannot be reflected in the SOX2 
and Nestin population as almost 100% of cells are already expressing these 
markers. These observations were also made by colleagues within the 
department and appear to be typical for this cell line. Co-labelling with markers 
for dividing and differentiating cells as well as extending the differentiation 
period are necessary experiments to further characterise this cell line.  
To validate the Cortisol Stress Model to enable the investigation of the potential 
stress preventing properties of EPA, DHA and RSVL, I next went on to examine 
the effects of stress-relevant Cortisol concentrations on HPC03A/07 cells. 
 








Ki67 ↑↑↑ ↑↑ 
Dcx  - 
MAP2  ↑↑↑↑ 
Caspase ↓ ↓↓ 
SOX2 - - 







Ki67 ↑↑↑↑ ↑ 
Dcx  ↑ 
MAP2  - 
Caspase - ↓↓ 
SOX2 - - 







Ki67 ↑↑↑ ↑↑↑ 
Dcx  - 
MAP2  ↑↑↑↑ 
Caspase - ↑↑ 
SOX2 - - 
Nestin - - 
Table 3-1 Summary of the effect of EPA, DHA, RSVL on HPC03A/07 during 
proliferation and differentiation.  
↑ indicates the level of significantly increased expression; ↓ the level of signnificanlty 
decreased expression; - for no significant changes. DHA: Docosahexaenoic acid, EPA: 
eicosapentaenoic acid; RSVL: Resveratrol; Pro: Proliferation; Diff: Differentiation 
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Effects of Cortisol on HPC03A/07 (Stress Model) 
Glucocorticoid hormones, such as the human endogenous glucocorticoid 
Cortisol, are consistently elevated in severely depressed patients and in animal 
models of chronic stress and depression. Importantly, high levels of 
glucocorticoid hormones decrease adult hippocampal neurogenesis in rodents 
(Nestler et al., 2002). See 1.2.2 and 2.1.5.1. Anacker et al. showed that Cortisol 
only decreases proliferation and neurogenesis when cells are treated during the 
mitotic phase (Anacker et al., 2011), which is why I treated the cultures with 
Cortisol for 3 days under proliferation conditions before starting differentiation. 
Here I will first confirm and validate the negative effects of high concentrations 
(100µM) of Cortisol on HPC03A/07 during proliferation and differentiation in 
order to be able to use this model of stress to investigate the potential of EPA, 
DHA and RSVL in preventing the effect of stress on hippocampal neurogenesis.  
3.3.1 Cortisol decreases the proportion of cells dividing while increasing 
apoptosis 
Cultures were treated as described previously in Figure 2-9 in Section 2.1.5.1. 
100µM Cortisol were added after 4 days of proliferation and cells were 
maintained for a further 3 days under proliferation conditions. The percentage of 
Ki67 positive cells was significantly decreased by -23.97±7.6%, p<0.05 
compared to the EtOH control cultures to a total of 30.0±2.1% (Figure 3-9a,b). 
The percentage of activated Caspase-3 expressing cells was significantly 
increased by 72.66±23.5%, p<0.05 to a total of 15.5±2.1% (Figure 3-9c,d). 
SOX2 or Nestin expression showed no changes, please see Section 3.3. These 
data suggest that Cortisol decreases the proportion of dividing cells and 
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increases apoptosis in proliferating HPC03A/07 cells, affecting survival and cell 
division.   
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Figure 3-9 Ki67 and activated Caspse-3 expression in proliferating HPC03A/07 
under Cortisol treatment 
a, c, e, g depict the percentage of positive cells relative to absolute cell numbers, b, d, 
f, h show the percentage change of the marker in Cortisol treated cultures compared to 
EtOH treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 
expressing cells. Abbreviations: EtOH: Ethanol control; Cort: Cortisol, p-values were 
generated using Student’s t-test, Error bars are the Standard Error of the Mean (SEM), 
*p<0.05, **p<0.01  
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3.3.2 Cortisol decreases the proportion of dividing cells and neuronal 
cells while increasing apoptosis in differentiating cells 
To assess effects Cortisol has on differentiating HPC03A/07 cells, cultures were 
treated as described in Section 3.1. The percentage of Ki67 positive cells was 
significantly decreased by -17.53±4.5%, p<0.05 to a total of 24.8±0.7% (Figure 
3-10a,b), as was the percentage of MAP2 expressing cells by -49.5±3.3%, 
p<0.01 to 9.8±0.6% (Figure 3-10e,f) but the percentage of activated Caspase-3 
expressing cells was significantly increased by 43.1±5.9%, p<0.01 to a total of 
19.6±1.1% (Figure 3-10g,h). On the other hand, there was no significant change 
in the percentage of Dcx (14.8±0.4%, Figure 3-10c,d), SOX2 or Nestin, please 
see Section 3.3. 
These data confirm that Cortisol significantly decreases both the proportion of 
proliferating cells in the culture and the proportion of mature neurons. This could 
be explained by the increased cell death observed in these cultures. 
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Figure 3-10 Ki67, Dcx, MAP2 and activated Caspase-3 expression in 
differentiating HPC03A/07 cells under Cortisol treatment 
a, c and e show the percentage of Ki67, DCX and MAP2 expressing cells respective in 
Cortisol treated and control cultures. b, d and f show the percentage change of each 
marker in Cortisol treated cultures compared to control EtOH treated cells. Cortisol 
treatment results in a significant decrease in Ki67 expressing cells (a,b), Dcx 
expressing cells (c,d) and MAP2 expressing cells (e,f) and a significant increase in 
activated Caspse-3 expressing cells. Abbreviation: EtOH: Ethanol control; Cort: 
Cortisol, p-values were generated using Student’s t-test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001  
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3.4 Preventative effects of Omega 3 fatty acids EPA and DHA and 
the stilbenoid Resveratrol against stress relevant Cortisol 
levels in an in vitro stress model 
The endogenous glucocorticoid Cortisol is consistently elevated in severely 
depressed patients and in animal models of chronic stress and depression 
(Pariante, 2009). Increased levels of glucocorticoid hormones over a long time 
also have detrimental effects on learning, memory and mood and decrease 
adult hippocampal neurogenesis in rodents (Mirescu and Gould, 2006; David et 
al., 2009). My results in Section 0 also showed that high concentrations of 
Cortisol (100µM) decrease proliferation and neurogenesis and increase 
apoptosis in HPC03A/07. Diet in form of Omega-3 fatty acids is known to have 
beneficial effects on learning, memory and mood (van Gelder et al., 2007; 
Fedorova et al., 2009). Interestingly, it has been hypothesised that anti-
depressants may exert their effects by increasing AHN (Gould et al., 1997). This 
raised the question of whether certain diets may help protect against depression 
by increasing cell proliferation and neurogenesis in the brain and counteracting 
the negative effect of Cortisol. To test this hypothesis, in a controlled 
environment, I developed an in vitro stress model where a high concentration of 
Cortisol (100µM) was used to mimic the increased Cortisol levels and the 
decreased neurogenesis seen in depressed patients and in animal models of 
depressive behaviour. This model was used to investigate the potential 
preventative effects of the Omega-3s EPA and DHA and the stilbenoid RSVL by 
pre-treating HPC03A/07 cells with these compounds before starting the Cortisol 
treatment that would mimic stress. 
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In the following, I will describe the different treatment conditions: Step 1, 2 and 3 
indicate a media change with renewed or changed treatment with Step 1 being 
pre-treatment with EPA, DHA (both 10µM)  or RSVL (1µM), Step 2 start of 
Cortisol treatment and Step 3 start of differentiation. To determine the possible 
preventative properties of Omega-3s and RSVL on proliferation, differentiation 
and apoptosis using this in vitro stress model, HPCOA03/07A were pre-treated 
with EPA, DHA or RSVL for 3 days under proliferating conditions (Step 1) 
before treatment with 100µM Cortisol was started (Step 2). EPA, DHA or RSVL 
treatment was either continued together with Cortisol treatment for a further 3 
days of proliferation to examine whether EPA, DHA or RSVL supplementation is 
needed during Cortisol treatment or stopped after the 3-day pre-treatment, to 
investigate whether pre-treatment only is sufficient to prevent the effects of 
Cortisol. After the treatment course cultures were fixed for 
immunocytochemistry (Section 2.2). For the differentiation assay, cultures were 
also pre-treated with EPA, DHA or RSVL (Step 1). Cultures were either only 
pre-treated (Step 1) before Cortisol treatment was started (Step 2) or continued 
for a further 3 days of proliferation together with the Cortisol, before 
differentiation was started (Step 3). Cultures were treated with Cortisol during 
the second 3 days of proliferation (Step 2) and the following 7 days of 
differentiation (Step 3) to assess the effects of Cortisol and EPA, DHA or RSVL 
on HPC03A/07 cells before they start differentiation. These conditions were 
based on the results of a colleague, Christoph Anacker, who used a similar 
model to show that presence of antidepressants during proliferation is essential 
to induce neuronal differentiation (Anacker et al., 2011). Cultures were treated 
with EPA, DHA or RSVL either during Step 1 only, during Step 1 and 2 or during 
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Step 1-3. After the differentiation period (Step 3) cultures were fixed with 4% 
PFA. See Figure 3-11. 
Table 3-2 summarises the different experimental conditions during 1) 
proliferation and 2) differentiation, as well as giving the key to the abbreviations 
that will be used later in the graphs. O stands for treatment with Omega-3s EPA 
or DHA, R for Resveratrol, C for Cortisol and – stands for no treatment during 
this step with either EPA, DHA, RSVL or Cortisol. Briefly: During the 
proliferation assay (Table 3-2,1) the abbreviation OO -C indicates that cultures 
were pre-treated with EPA, DHA or RSVL (RR -C) for 3 days under proliferation 
conditions (Step1). After these 3 days, Cortisol treatment was started in parallel 
with the Omega-3 or RSVL treatment (Step 2) and maintained for 3 more days 
under proliferation conditions. O- -C indicates that after the 3 days pre-
treatment, Cortisol treatment was started while Omega-3 or RSVL (R- -C) 
treatment was stopped, leading to pre-treatment only. -C indicates the negative 
control where cultures did not undergo any pre-treatment (Step 1) before 
Cortisol treatment was started after 3 days of proliferation and maintained for 
further 3 days of proliferation. OO indicates the positive control where cultures 
have been continuously treated with EPA, DHA or RSVL (RR) for 6 days under 
proliferation conditions and were not exposed to Cortisol.  
For the differentiation assay explained in Table 3-2,2 OOO -CC indicates that 
cultures were pre-treated with EPA, DHA or RSVL (RRR -CC) for 3 days under 
proliferation conditions (Step 1). After these 3 days Cortisol treatment was 
started in parallel with the Omega-3 or RSVL treatment (Step 2) and maintained 
for 3 more days under proliferation conditions. Differentiation was started and 
Omega-3 or RSVL and Cortisol treatment was continued for 7 days under 
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differentiation conditions (Step 3). This condition mirrors full supplementation 
before and during stress under proliferation and differentiation conditions.  
OO- -CC indicates that after the 3 days pre-treatment Cortisol treatment was 
started in parallel with Omega-3 or RSVL (RR- -CC) and maintained for 3 more 
days under proliferation conditions (Step 2). Before differentiation was started 
(Step 3) Omega-3 or RSVL treatment was stopped and only Cortisol treatment 
was continued during differentiation. This condition mirrors EPA, DHA and 
RSVL supplementation before stress and during stress under proliferation 
conditions, however stress continues during differentiation but not the 
supplementation.  
O-- -CC indicates cultures that were only pre-treated with Omega-3 or RSVL 
(R-CC) for 3 days under proliferation conditions (Step 1). Thereafter Omega-3 
or RSVL treatment was stopped and cultures were maintained for 3 days under 
proliferation conditions (Step 2) followed by 7 days of differentiation conditions 
(Step 3) under Cortisol treatment. This condition mirrors pre-treatment only with 
EPA, DHA or RSVL before stress starts and the stress takes place during the 
following proliferation (Step 2) and differentiation (Step 3). –CC provides the 
negative control where cultures did not undergo any pre-treatment (Step 1) 
before Cortisol treatment was started after 3 days of proliferation and 
maintained for further 3 days of proliferation (Step 2) followed by 7 days under 
differentiation conditions (Step 3). OOO serves as positive control and indicates 
cultures that have been continuously treated with EPA, DHA or RSVL (RRR) 
during Step 1-3, and were not exposed to Cortisol. EtOH indicates vehicle 
control cultures that were treated with the equivalent concentration of Ethanol 
(1%) throughout the experiment. 
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After the course of each experiment cultures were fixed with 4% PFA and 
immunocytochemically stained. To assess the proportion of dividing cells and 
NPC, cultures were stained for the proliferation marker Ki67, the NPC markers 
SOX2 and Nestin. To examine the level of cell death, cultures were stained for 
activated Caspase-3. To assess neuronal differentiation, Dcx for early neurons 
and MAP2 for mature neurons were used. 
In this Section, I will describe the potential preventative effects of each 
treatment. 
 
Figure 3-11 Timeline for Omega 3 prevention experiment using the Cortisol 
stress model on HPC0A07/03A cells. 
1.) Proliferation assay, 2.) Differentiation assay Step 1: Cells were pre-treated with 
EPA, DHA or RSVL for 3 days under proliferation conditions. Step 2: Cortisol was 
added and EPA, DHA or RSVL treatment was either stopped or continued. For the 
proliferation assay cells were fixed for immunocytochemistry after an additional 3 days 
proliferation. Step 3: For the differentiation assay differentiation was started now and 
EPA, DHA or RSVL treatment was either stopped or continued leading to different 
combinations as described in Table 2-2 and Table 2-3  
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1.) Proliferation assay 
 Step 1 Step 2 
OO –C/ RR -C 
 3d pro 3d pro 
 O/R O/R 
 - Cort 
O- -C/ R- -C 
 3d pro 3d pro 
 O/R - 
 - Cort 
   
   
 Step 1 Step 2 
- C 
 3d pro 3d pro 
 - Cort 
OO/ RR 
 3d pro 3d pro 





2.) Differentiation assay 
Step 1 Step2 Step 3 
OOO –CC/ RRR -CC 
3d pro 3d pro 7d diff 
O/R O/R O/R 
- Cort Cort 
OO- -CC/ RR- -CC 
3d pro 3d pro 7d diff 
O/R O/R - 
- Cort Cort 
O- CC/ R- CC 
3d pro 3d pro 7d diff 
O/R - - 
- Cort Cort 
   
Step 1 Step 2 Step 3 
- CC 
3d pro 3d pro 7d diff 
- Cort Cort 
OOO/ RRR 
3d pro 3d pro 7d diff 








Table 3-2 Conditions for the omega-3 prevention experiment using the cortisol 
stress model  
under 1.) proliferating and 2.) differentiation conditions. Step 1: Cells were pre-treated 
with EPA, DHA or RSVL for 3 days of proliferation, Step 2: Cortisol was added, Step 3: 
Differentiation was started. O: DHA/ EPA; R: RSVL; C/ Cort: Cortisol; -: no treatment; 
Pro: Proliferation; Diff: Differentiation 
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3.4.1 Preventative effects of EPA on proliferating and differentiating 
HPC03A/07 cells in a Cortisol Stress Model 
In order to assess the effect of EPA pre-treatment on Cortisol-stressed 
HPC03A/07, cells were treated with 10µM EPA and 100µM Cortisol as 
described in Section 3.4 and immunocytochemical analysed to investigate 
changes in proliferation, differentiation and apoptosis. In Section 0 I showed 
that Cortisol decreases the percentage of dividing and differentiating cells while 
increasing apoptotic cells over control treatment, proving that the Cortisol Stress 
Model used in the following experiments works. I have also shown that EPA 
alone increases the percentage of dividing and neuronal cells but decreases 
apoptotic cells. Now I am investigating whether EPA has the potential to prevent 
the effects of Cortisol 
3.4.1.1 EPA pre-treatment prevents the Cortisol-induced decrease of the 
proportion of dividing cells and increase of apoptosis in 
proliferating HPC03A/07 
To investigate the preventative effects of EPA in the Cortisol stress model in 
proliferating HPC03A/07, cultures were treated with EPA and Cortisol as 
explained in Section 3.4 / Table 3-2,1. In the OO –C group, where cultures were 
supplemented with EPA before and during stress the percentage of Ki67 
positive cells is significantly increased by 28.5±3.2%, p<0.001 compared to the 
Cortisol negative control (-C) to a total of 39.8±0.9% (Figure 3-12a,b). The 
percentage of apoptotic cells was significantly decreased by -32.9±3.5%, 
p<0.05 to a total of 8.8±0.5%. Also in the O- -C group cultures that were pre-
treated only before Cortisol was added, the percentage of dividing cells was 
significantly increased by 26.5±2.0%, p<0.001 to 39.2±0.6% whereas the 
percentage of apoptotic cells was decreased by -31.6±3.8% to 6.9±1.9%. SOX2 
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and Nestin showed no changes; please see Section 3.3 for a possible 
explanation. 
Both treatment groups, continuous supplementation (OO –C) and pre-treatment 
only (O- -C) could prevent the effects of Cortisol, namely the decrease of 
dividing cells and increase of apoptosis. Both treatments increased the 
proportion of dividing cells to the level of EPA only (OO) (39.3±0.6%) and above 
the EtOH control group (34.5±0.9%). None of the treatments were able to 
decrease the percentage of apoptotic cells to the level of EPA only treatment 
(OO) (5.4±1.5%) but to the level of the EtOH control (9.0±0.5%). This indicates 
an increase in survival in HPC03A/07 cells after EPA treatment in the Cortisol 
stress model. 
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Figure 3-12 Ki67 and activated Caspase-3 expression In HPC03A/07 cells 
treated with EPA under the Cortisol Stress Model 
a, c, e, g depict the percentage of positive cells relative to absolute cell numbers; b, d, 
f, h show the percentage change of the marker in treated cultures compared to Cortisol 
treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 expressing 
cells; p-values were generated using One-Way ANOVA with Newman-Keuls post hoc 
test, Error bars are the Standard Error of the Mean (SEM), ***p<0.001; See Table 3-2 
for abbreviations.  
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3.4.1.2 EPA pre-treatment prevents the Cortisol-induced decreases of 
dividing and neuronal cells as well as increase of apoptosis in 
differentiating HPC03A/07  
To investigate the preventative effects of EPA in the Cortisol stress model in 
differentiating HPC03A/07, cultures were treated with EPA and Cortisol stress 
model as described in Section 3.4 / Table 3-2. In the OOO –CC group cultures 
were continuously supplemented with EPA before and during Cortisol 
treatment. The proportion of dividing cells was significantly increased by 
31.0±6.5%, p<0.001 to a total of 29.8±0.4% (Figure 3-13a,b,d) compared to the 
Cortisol only group (-CC), as was the percentage of MAP2 positive cells by 
154.7±8.3%, p<0.001 to total of 25.0±0.8% (Figure 3-15a,b,d). In turn, the 
percentage of activated Caspase-3 expressing cells was significantly decreased 
compared to the Cortisol group by -52.3±2.3%, p<0.001 to 12.2±0.6% (Figure 
3-16a,b,d). Dcx (Figure 3-14a,b,d), SOX2 and Nestin were not changed 
compared to the Cortisol group. This suggests that this condition prevents the 
effects of Cortisol and moreover increase the percentage of dividing cells above 
the level of the EtOH control (total: 27.6±1.4%, Figure 3-13a) and close to the 
level of EPA only treatment (OOO) with a total of 33.6±0.5% (Figure 3-13a). 
Also the percentage of mature neuronal cells was increased above the EtOH 
group (19.4±0.5%, Figure 3-15a) and just below the EPA only group (OOO) with 
a total of 28.2±0.2% (Figure 3-15a). This treatment decreased the percentage 
of apoptotic cells below the EtOH control (14.21±0.7%, Figure 3-16a) but not 
quite to the level of EPA only (OOO) with 7.9±2.2% (Figure 3-16a). SOX2 or 
Nestin were unchanged. The absence of an increase in the percentage of Dcx 
expressing cells mirrors the results in Section 3.1.2 where EPA only treatment 
during differentiation increased the proportion of mature neurons but not the 
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proportion of neuroblasts. This suggests that this treatment (OOO –CC) 
prevents the effects of Cortisol and increases the proportion dividing cells and 
mature neurons by increasing cell fate commitment and maturation even above 
the level of the vehicle control. This might be due to survival as it also 
decreases the percentage of apoptotic cells. In the (OO- -CC) cultures, 
pretreated with EPA and treated together with Cortisol during proliferation but 
not during differentiation, the percentage of Ki67 cells was significantly 
increased by 31.3±4.6%, p<0.001 compared to the Cortisol control group (-CC) 
to a total of 33.3±1.9% (Figure 3-13a,b,e), so was the percentage of Dcx (by 
26.5±3.3%, p<0.05, to a total of 16.0±0.4%, Figure 3-14a,b,e) and MAP2 
positive cells by 155.4±2.7%, p<0.001 to 25.1±0.3% (Figure 3-15a,b,e). The 
percentage of activated Caspase-3 positive cells was in turn decreased by 
-44.4±2.3%, p<0.001 to 14.1±0.6% (Figure 3-16a,b,e). SOX2 or Nestin were 
unchanged, please see Section 3.3. This treatment (OO- -CC) increased the 
percentage of dividing cells, neuroblasts and mature neuronal cells above the 
level of vehicle control (Ki67: 27.6±1.4, Figure 3-13a; Dcx: 15.1±0.9%, Figure 
3-14a; MAP2: 19.4±0.5%, Figure 3-15a) while decreasing the percentage of 
apoptotic cells to the level of the EtOH group with 14.2±0.7%, Figure 3-16a. 
These effects are mostly due to increased survival. In the O-- -CC group 
cultures were only pretreated with EPA before Cortisol treatment was started. 
The percentage of dividing cells was significantly increased by 24.1±2.0%, 
p<0.001 compared to the Cortisol only group to a total of 31.2±1.0% (Figure 
3-13a,b,f), as was the percentage of neuroblasts with 29.4±6.7%, p<0.05 to 
16.4±0.8% (Figure 3-14a,b,f) and the percentage of mature neuronal cells with 
141.0±9.0%, p<0.001 to 23.6±0.9% (Figure 3-15a,b,f). The percentage of 
apoptotic cells was decreased by 52.2±5.6%, p<0.001 to 12.1±1.4% (Figure 
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3-16a,b,f). SOX2 or Nestin were unchanged. The pre-treatment only also is 
enough to prevent the effects of Cortisol and increased the percentage of 
dividing cells, neuroblasts and mature neurons above the level of the EtOH 
(Ki67: 27.6±1.4, Figure 3-13a; Dcx: 15.1±0.9% Figure 3-14a; MAP2: 
19.4±0.5%, Figure 3-15a) and also decreases the percentage of apoptotic cells 
below the vehicle control (14.2±0.7%, Figure 3-16a). This suggests that even 
only pre-treatment with EPA can prevent the effects of Cortisol, namely 
decreasing the proportion of dividing and differentiating cells while increasing 
apoptotic cells over control treatment. This is most likely due to an increase in 
survival.  
All three treatments prevent the negative effects of Cortisol by increasing the 
proportion of dividing and neuronal cells while decreasing apoptosis. The 
differences between the three treatment groups are only marginal, apart from 
the absent increase of Dcx in the OOO –CC group. Also during the EPA only 
treatment in Section 3.1.2, EPA only increased the proportion of mature 
neurons but not of neuroblasts, which might be due to EPA increasing the rate 
of cell cycle commitment as well as maturation of neuronal cells to an extent 
that most Dcx positive cells have already matured. However there is no 
difference in MAP2 positive cells in the three treatments, suggesting that in the 
OOO –CC group, neuronal differentiation might stop after 7 days with no more 
neuroblasts following or Dcx positive cells might have died. To investigate this 
matter further, different time points for differentiation (earlier and later) will be 
required. Also BrdU staining is required for investigating the proliferation rate 
which will allow answers regarding a depleted stem cell pool and examining the 
effects of EPA and Cortisol treatment during proliferation and differentiation will 
enable to draw further conclusions. 
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Figure 3-13 Ki67 expression in differentiating HPC03A/07 cells treated with EPA 
in the Cortisol stress model 
a) Comparison of the absolute percentage of Ki67 positive cells. b) Percentage change 
of Ki67 expression c) Cortisol only; -CC d) continuous EPA treatment before and during 
Cortisol treatment; OOO –CC e) EPA pre-treatment and treated together with Cortisol 
during proliferation but not during differentiation, OO- -CC f) EPA pretreatment followed 
by Cortisol treament. (Scalebar: 20µm; p-values were generated using One-Way 
ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of the 
Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for abbreviations) 
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Figure 3-14 Dcx expression in differentiating HPC03A/07 cells treated with EPA 
in the Cortisol stress model 
a) Comparison of the absolute percentage of Dcx positive cells. b) Percentage change 
of Dcx expression c) Cortisol only; -CC d) continuous EPA treatment before and during 
Cortisol treatment; OOO –CC e) EPA pre-treatment and treated together with Cortisol 
during proliferation but not during differentiation, OO- -CC f) EPA pretreatment followed 
by Cortisol treament (Scalebar: 20µm; p-values were generated using One-Way 
ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of the 
Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for abbreviations) 
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Figure 3-15 MPA2 expression in differentiating HPC03A/07 cells treated with 
EPA in the Cortisol stress model 
a) Comparison of the absolute percentage of MAP2 positive cells. b) Percentage 
change of MAP2 expression c) Cortisol only; -CC d) continuous EPA treatment before 
and during Cortisol treatment; OOO –CC e) EPA pre-treatment and treated together 
with Cortisol during proliferation but not during differentiation, OO- -CC f) EPA 
pretreatment followed by Cortisol treament (Scalebar: 20µm; p-values were generated 
using One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for 
abbreviations)  
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Figure 3-16 Activated Caspase-3 expression in differentiating HPC03A/07 cells 
treated with EPA in the Cortisol stress model 
a) Comparison of the absolute percentage of activated Caspase-3 positive cells. b) 
Percentage change of activated Caspase-3  expression c) Cortisol only; -CC d) 
continuous EPA treatment before and during Cortisol treatment; OOO –CC e) EPA pre-
treatment and treated together with Cortisol during proliferation but not during 
differentiation, OO- -CC f) EPA pretreatment followed by Cortisol treament (Scalebar: 
20µm; p-values were generated using One-Way ANOVA with Newman-Keuls post hoc 
test, Error bars are the Standard Error of the Mean (SEM), *p<0.05, **p<0.01, 
***p<0.001; See Table 3-2 for abbreviations)  
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3.4.2 Preventative effects of DHA on proliferating and differentiating 
HPC03A/07 cells in a Cortisol Stress Model 
In order to assess the effect of DHA pre-treatment on Cortisol-stressed 
HPC03A/07 cells, cultures were treated with 10µM DHA and 100µM Cortisol as 
described in Section 3.4 and immunocytochemically analyzed to investigate 
changes in proliferation, differentiation and apoptosis. Cortisol decreases the 
proportion of dividing and differentiating cells while increasing apoptotic cells 
over control treatment, as shown in Section 0. I have also shown that DHA 
alone increases the proportion of dividing and neuroblasts but decreases 
apoptotic cells (Section 3.1.3 and 3.1.4). In the following I am investigating 
whether DHA has the potential to prevent the effects of Cortisol 
3.4.2.1 DHA pre-treatment prevents the Cortisol-induced decrease of 
dividing cells and increase of apoptosis in proliferating 
HPC03A/07 
To investigate the preventative effects of DHA in the Cortisol stress model in 
proliferating HPC03A/07, cultures were treated with DHA and Cortisol as 
explained in Section 3.4 / Table 3-2,1. In the OO –C group cells were pretreated 
with DHA for 3 days and then treated with DHA and Cortisol together for further 
3 days of proliferation. The percentage of Ki67 expressing cells was significantly 
increased by 17.9±2.1%, p<0.05 compared to the Cortisol negative control (-
CC) to a total of 35.4±0.6% while the percentage of activated Caspase-3 
positive cells was significantly decreased by -46.9±7.1%, p<0.01 to a total of 
8.2±1.1%. SOX2 and Nestin were unchanged. This suggests that the increase 
in dividing cells was due to a big increase in survival. In the O- -C the 
percentage of Ki67 positive cells was increased by 25.3±1.5%, p<0.05 to a total 
of 37.5±0.4%, while also the percentage of apoptotic cells was decreased by 
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42.1±2.5%, p<0.01 to a total of 10.4±0.2%. SOX2 and Nestin did not change, 
please see Section 3.3 for a possible explanation. 
Both treatment groups, the pre-treatment only and the continuous DHA 
treatment, could prevent and counter act the effects of the stress-mimicking 
Cortisol treatment. However, they did not reach the level of DHA only (OO) 
treatment (51.3±2.9%) and did not exceed the level of the vehicle control 
(EtOH, 39.5±0.1). On the other hand both decreased the percentage of 
apoptotic cells to the level of DHA only group (8.2±0.6%) and the EtOH control 
group (8.9±0.4%). This suggests that DHA pre-treatment prevents the negative 
effects Cortisol has on the proportion of dividing cells and apoptosis by 
increasing the percentage of dividing cells through an increase in survival. 
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Figure 3-17 Ki67 and activated Caspase-3 expression In HPC03A/07 cells 
treated with DHA under the Cortisol Stress Model 
a, c, e, g depict the percentage of positive cells relative to absolute cell numbers, b, d, 
f, h show the percentage change of the marker in Cortisol treated cultures compared to 
EtOH treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 
expressing cells; p-values were generated using One-Way ANOVA with Newman-
Keuls post hoc test, Error bars are the Standard Error of the Mean (SEM), *p<0.05, 
**p<0.01, ***p<0.001; See Table 3-2 for abbreviations  
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3.4.2.2 DHA pre-treatment prevents the Cortisol-induced decrease of the 
proportion of dividing and neuronal cells as well as the increase of 
apoptosis in differentiating HPC03A/07 
To investigate the preventative effects of DHA in the Cortisol stress model in 
differentiating HPC03A/07, cultures were treated with DHA and Cortisol as 
described in Section 3.4 / Table 3-2,2). In the OOO –CC group cultures were 
continuously supplemented with DHA before and during Cortisol treatment. The 
percentage of dividing cells was significantly increased by 42.0±1.6%, p<0.001 
compared to the Cortisol only treated group (-CC) to a total of 35.3±0.7% 
(Figure 3-18a,b,d), also the percentage of Dcx (47.0±2.7%, p<0.001, total 
21.8%, Figure 3-19a,b,d) and MAP2 positive cells were significantly increased 
(71.5±3.8%, p<0.001, total 20.2%, (Figure 3-20a,b,d). The percentage of 
activated Caspase-3 (Figure 3-21a,b,d), SOX2 or Nestin expressing cells was 
unchanged compared to the Cortisol group, please see Section 3.3. This 
suggests that this treatment prevents the effects of Cortisol by increasing the 
percentage of dividing cells, early and mature neuronal cells above the level of 
both DHA only (Ki67 35.2±0.9% Figure 3-18a; Dcx 18.5±0.1%, Figure 3-19a; 
MAP2 15.2±1.6%, Figure 3-20a) and EtOH control (Ki67 27.6±1.4, Figure 
3-18a; Dcx 16.3±0.3%, Figure 3-19a; MAP2 19.4±0.5%, Figure 3-20a). This is 
not based on increased survival as DHA failed to prevent the apoptotic effects 
of Cortisol, which suggests that the decreasing effects of DHA on apoptosis 
during proliferation (Section 3.4.2.1) disappears when cultures were treated 
during differentiation. 
The (OO- -CC) cultures were pretreated with DHA and treated together with 
Cortisol during proliferation but not during differentiation. The percentage of 
Ki67 cells in this assay was significantly increased to a total of 32.2±1.7%, 
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29.6±4.2%, p<0.001 higher compared to the Cortisol group (Figure 3-18a,b,e), 
as was the percentage of the neuronal marker Dcx (17.0±1.5%, p<0.05, to a 
total of 16.8±0.4%, Figure 3-19a,b,e) and MAP2 (26.1±3.5%, p<0.05 to a total 
16.8%, Figure 3-20a,b,e). The percentage of activated Caspase-3 positive cells 
was significantly decreased by -46.6±3.5%, p<0.001 to a total of 10.4±0.7% 
(Figure 3-21a,b,e). SOX2 and Nestin were unchanged. This suggests that 
treatment with DHA during proliferation only prevents the effect of Cortisol by 
increasing the percentage of dividing and early and mature neuronal cells 
above the EtOH control (Ki67 27.6±1.4%, Figure 3-18a; Dcx 16.3±0.3%, Figure 
3-19a; MAP2 19.4±0.5%, Figure 3-20a) and almost to the DHA only treatment 
(Ki67 35.2±0.9%, Figure 3-18a; Dcx 18.5±0.1%%, Figure 3-19a; MAP2 
15.2±1.6%, Figure 3-20a), while decreasing apoptosis lower than the EtOH 
(13.7±0.4%, Figure 3-21a) and DHA only treatment (9.9±0.5%, Figure 3-21a). 
This indicates that the increase in dividing and neuronal cells is partly based on 
increased survival. 
In the O-- -CC group cultures were only pretreated with EPA before Cortisol 
treatment was started. The percentage of Ki67 cells was significantly increased 
to a total of 30.6±0.7, 23.2±1.7%, p<0.001 higher compared to the Cortisol 
group (Figure 3-18a,b,f), so was the percentage of MAP2 positive cells 
(55.4±16.7%, p<0.01, to total of 12.3%, (Figure 3-20a,b,f). Dcx was not 
increased (Figure 3-19a,b,f). However the increase in MAP2 positive cells 
compared to the Cortisol group was still lower than the DHA only (15.2±1.6%, 
Figure 3-20a) and the EtOH group (19.4±0.5%, Figure 3-20a), indicating that to 
prevent the effect of Cortisol on neuronal differentiation with DHA, DHA is 
required during differentiation and not only during proliferation. The percentage 
of activated Caspase-3 positive cells was significantly decreased by -
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33.0±2.1%, p<0.001 to a total of 13.1±0.4% (Figure 3-21a,b,f) which is the level 
of the EtOH group (13.7±0.4%, Figure 3-21a) but higher than the DHA only 
treatment (9.9±0.5%, Figure 3-21a). Also the percentage of dividing cells was 
increased above the EtOH group (27.6±1.4%, Figure 3-18a) but was still below 
the DHA only group (35.2±0.9%, Figure 3-18a). SOX2 and Nestin were 
unchanged. 
All three treatment conditions, using DHA to prevent the effects of Cortisol on 
proliferation, differentiation and apoptosis, prevent the effect on dividing cells by 
increasing their proportion above the vehicle control. During neuronal 
development and apoptosis the treatment groups gave different results. The 
OOO –CC group prevents the effects of Cortisol by increasing the proportion of 
dividing cells, early and mature neuronal cells above the level of both DHA only 
and EtOH control. As under this condition DHA failed to prevent the apoptotic 
effects of Cortisol, this effect cannot be due to increased survival but is due to 
an increase in proliferation and differentiation. After treatment during 
differentiation the effects of DHA on apoptosis during decreasing proliferation 
(Section 3.4.2.1) disappears, while DHA still impacts on the proportion of 
dividing and neuronal cells. The OO- -CC group prevents the effects of Cortisol 
regarding dividing, neuronal and apoptotic cells even above the EtOH group. 
The pre-treatment only group (O-- -CC) decreases apoptosis below the EtOH 
group but fails to increase neuronal differentiation above the EtOH, suggesting 
that DHA is required during stress (Cortisol treatment) to counter act its effects. 
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Figure 3-18 Ki67 expression in differentiating HPC03A/07 cells treated with 
DHA in the Cortisol stress model 
a) Comparison of the absolute percentage of Ki67 positive cells. b) Percentage change 
of Ki67 expression c) Cortisol only; -CC d) continuous DHA treatment before and 
during Cortisol treatment; OOO –CC e) DHA pre-treatment and treated together with 
Cortisol during proliferation but not during differentiation, OO- -CC f) DHA pretreatment 
followed by Cortisol treament. (Scalebar: 20µm; p-values were generated using One-
Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of 
the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for abbreviations)  
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Figure 3-19 Dcx expression in differentiating HPC03A/07 cells treated with DHA 
in the Cortisol stress model 
a) Comparison of the absolute percentage of Dcx positive cells. b) Percentage change 
of Dcx expression c) Cortisol only; -CC d) continuous DHA treatment before and during 
Cortisol treatment; OOO –CC e) DHA pre-treatment and treated together with Cortisol 
during proliferation but not during differentiation, OO- -CC f) DHA pretreatment followed 
by Cortisol treament. (Scalebar: 20µm; p-values were generated using One-Way 
ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of the 
Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for abbreviations)  
 Page 165 of 318 
 
 
Figure 3-20 MAP2 expression in differentiating HPC03A/07 cells treated with 
DHA in the Cortisol stress model 
a) Comparison of the absolute percentage of MAP2 positive cells. b) Percentage 
change of MAP2 expression c) Cortisol only; -CC d) continuous DHA treatment before 
and during Cortisol treatment; OOO –CC e) DHA pre-treatment and treated together 
with Cortisol during proliferation but not during differentiation, OO- -CC f) DHA 
pretreatment followed by Cortisol treament. (Scalebar: 20µm; p-values were generated 
using One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for 
abbreviations)  
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Figure 3-21 Activated Caspase-3 expression in differentiating HPC03A/07 cells 
treated with DHA in the Cortisol stress model 
a) Comparison of the absolute percentage of activated Caspase-3 positive cells. b) 
Percentage change of activated Caspase-3 expression c) Cortisol only; -CC d) 
continuous DHA treatment before and during Cortisol treatment; OOO –CC e) DHA 
pre-treatment and treated together with Cortisol during proliferation but not during 
differentiation, OO- -CC f) DHA pretreatment followed by Cortisol treament. (Scalebar: 
20µm; p-values were generated using One-Way ANOVA with Newman-Keuls post hoc 
test, Error bars are the Standard Error of the Mean (SEM), *p<0.05, **p<0.01, 
***p<0.001; See Table 3-2 for abbreviations)  
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3.4.3 Preventative effects of Resveratrol on proliferating and 
differentiating HPC03A/07 cells in a Cortisol Stress Model 
In order to assess the effect of RSVL pre-treatment on Cortisol-stressed 
HPC03A/07 cells, cultures were treated with 1µM RSVL and 100µM Cortisol as 
described in Section 3.4 and immunocytochemically analyzed to investigate 
changes in proliferation, differentiation and apoptosis. As shown in Section 0, 
Cortisol decreases the proportion of dividing and differentiating cells while 
increasing apoptotic cells over control treatment. I have also shown that RSVL 
alone increases the proportion of dividing cells and neuroblasts. RSVL has no 
effect on apoptosis during proliferation and increases it during differentiation 
(Please see Section 3.2). In the following I am investigating whether RSVL has 
the potential to prevent the detrimental effects of Cortisol on cell proliferation 
and neuronal differentiation. 
3.4.3.1 RSVL pre-treatment prevents the Cortisol-induced decrease of 
dividing cells in proliferating HPC03A/07 
To investigate the preventative effects of RSVL in the Cortisol stress model in 
proliferating HPC03A/07, cultures were treated with 1µM RSVL and Cortisol as 
explained in Section 3.4 / Table 3-2,1. In the RR –C group cells were pretreated 
with RSVL for 3 days and then treated with RSVL and Cortisol together for 
further 3 days of proliferation. The percentage of Ki67 cells was significantly 
increased to a total of 38.4±1.1%, 23.9±3.4%, p<0.01 higher compared to the 
Cortisol group, Figure 3-22a,b. The percentage of activated Caspase positive 
cells was unchanged Figure 3-22c,d. SOX2 or Nestin did not change, please 
see Section 3.3. 
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In the R- -C group also the percentage of dividing cells was significantly 
increased compared to the Cortisol group by 16.2±1.4%, p<0.01 to a total of 
36.0±0.4%, Figure 3-22a,b. The percentage of apoptotic cells (Figure 3-22c,d), 
SOX2 or Nestin was unchanged.  
Both the continuous RSVL treatment and pre-treatment increase the 
percentage of dividing cells above the EtOH group (34.5±0.9%, Figure 3-22c) 
but below the RSVL only group (41.9±1.4%). The percentage of activated 
Caspase positive cells was unchanged and with 17.2±0.8% in the RR –C and in 
the R- -C group 18.8±0.8% higher than ETOH (10.2±0.2%) and RSVL only 
(13.9±1.2%) and as high as Cortisol (16.8±0.2%). This suggests that RSVL 
increases the proportion of dividing cells thereby preventing the decreasing 
effects of Cortisol, but as expected it has no effect on preventing apoptosis. 
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Figure 3-22 Ki67 and activated Caspase-3 in HPC03A/07 cells treated with 
RSVL under the Cortisol Stress Model 
a, c, e, g depict the percentage of positive cells relative to absolute cell numbers, b, d, 
f, h show the percentage change of the marker in treated cultures compared to Cortisol 
treated cells. a) and b) Ki67 expressing cells c) and d) activated Caspase-3 expressing 
cells; p-values were generated using One-Way ANOVA with Newman-Keuls post hoc 
test, Error bars are the Standard Error of the Mean (SEM), ***p<0.001; See Table 3-2 
for abbreviations  
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3.4.3.2 RSVL pre-treatment prevents the Cortisol-induced decrease of 
dividing and neuronal cells in differentiating HPC03A/07 
To investigate the preventative effects of RSVL in the Cortisol stress model in 
differentiating HPC03A/07, cultures were treated with RSVL and Cortisol as 
described in Section 3.4 / Table 3-2,2). In the RRR –CC group cultures were 
continuously supplemented with RSVL before and during Cortisol treatment the 
percentage of dividing cells was significantly increased to a total of 34.9±0.2%, 
41.3±1.0%, p<0.001 increase compared to the Cortisol control (Figure 
3-23a,b,d). Also the percentage of Dcx expressing cells (73.2±0.6%, p>0.001, 
total of 27.4±0.1%, Figure 3-24a,b,d) and MAP2 positive cells (MAP2: 
158.9±15.7%, p<0.001, total of 33.3±0.8%, Figure 3-25a,b,d) was increased. 
Activated Caspase-3 (Figure 3-26a,b,d), SOX2 and Nestin were unchanged, 
please see Section 3.3. This shows that under these conditions RSVL increases 
dividing and early and mature neuronal cells above the EtOH group (Ki67 
27.6±1.4%, Figure 3-23a; Dcx 24.4±2.9%, Figure 3-24a; MAP2 24.1±1.0%, 
Figure 3-25a) and above the RRR group (Ki67 35.2±0.7, Figure 3-23a; Dcx 
28.3±1.9%, Figure 3-24a; MAP2 36.7±0.1%, Figure 3-25). This effect appears 
solely due to an increase in proliferation and differentiation as RSVL treatment 
has no decreasing effect on apoptosis, indeed RSVL alone increases apoptosis 
at this concentration (Section 3.2.3) and the co treatment with RSVL does not 
increase apoptosis above the Cortisol group, Nevertheless the groups with less 
co treatment display less apoptosis, leading to a treatment response curve, 
which suggests that the positive effects of RSVL without apoptotic side effects 
fall in a narrow range. When titrating RSVL in Section 3.2.1 I only examined the 
effect it has on proliferation and not on apoptosis, however its effects on 
apoptosis need closer investigation. 
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RR- -CC cultures were pretreated with RSVL and treated together with Cortisol 
during proliferation but not during differentiation. The percentage of Ki67 cells in 
this group was significantly increased to a total of 31.3±0.8%, which is a 
27.7±3.4%, p<0.001 increase compared to the Cortisol treatment, (Figure 
3-23a,b,e). Also, the percentage of Dcx (100.0±3.1%, p<0.001, total of 
31.7±0.5%, Figure 3-24a,b,e) and MAP2 (MAP2: 68.6±4.7%, p<0.001, total of 
50.3±3.0, Figure 3-25a,b,e) positive cells was significantly increased. The 
percentage of Ki67 expressing cells was increased above the EtOH group 
(Ki67 27.6±1.4%) but below the RRR group Ki67 (35.2±0.7%, Figure 3-23a) and 
the percentage of neuroblasts and mature neuronal cells was a lot higher than 
the EtOH (Dcx 24.4±2.9%; MAP2 24.1±1.0%) and RRR group (Dcx 28.3±1.9%; 
MAP2 36.7±0.1%), See Figure 3-24a Figure 3-25a respectively. Again the 
percentage of apoptotic cells was not significantly changed and with 26.7±1.1% 
higher than the EtOH (17.7±1.3%) and the RSVL only group (23.5±1.8%), 
Figure 3-26a. SOX2 and Nestin are unchanged. This suggests that RSVL 
treatment during proliferation is sufficient to prevent a decrease in the 
proportion of neuronal cells. Interestingly, proliferation only treatment is actually 
more efficient than treating with RSVL throughout proliferation and 
differentiation. Moreover, the increase in the proportion of dividing cells and 
neuronal cells is not due to increased survival as RSVL has no decreasing 
effect on apoptosis but is due to increased proliferation and survival. 
In the R-- -CC group, cultures were only pre-treated with RSVL, the percentage 
of dividing cells was significantly increased to a total of 32.6±0.6%, increased by 
27.1±2.4%, p<0.001 compared to the Cortisol only treatment (Figure 3-23a,b,f). 
Further, the percentage of neuroblasts (30.4±2.2%, p<0.05, total of 20.6±0.4%, 
Figure 3-24a,b,f) and mature neurons (89.2±0.5%, p<0.001, 32.7±0.9%, Figure 
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3-25a,b,f) was also significantly increased. Activated Caspase-3 (Figure 
3-26a,b,f), SOX2 or Nestin were unchanged. This data suggests that pre-
treatment only is sufficient to increase the percentage of dividing cells and 
mature neuronal cells above the EtOH control group (Ki67 27.6±1.4%, Figure 
3-23a; MAP2 24.1±1.0%, Figure 3-25a), and the percentage of neuroblasts was 
higher than the Cortisol group (15.8±0.9%) but lower than the EtOH group (Dcx 
24.4±2.9%) (Figure 3-24a). As previously stated a co treatment with Cortisol 
and RSVL has no effect on apoptosis and RSVL treatment alone already 
increases apoptosis in differentiating cultures.  
Together these results indicate that RSVL treatment in all three groups 
increases the percentage of dividing and neuronal cells. None of the groups 
decreases apoptosis making the increase in dividing cells a genuine result that 
is not due to increased survival. However, RSVL apparently already increases 
apoptosis on its own and it is necessary to examine which cell types die. The 
treatment group with RSVL treatment during proliferation together with Cortisol 
(RR- -CC) shows the highest increase in neuronal proliferation, and pre-
treatment only increases mature neuronal cells and neuroblasts compared to 
the Cortisol group but below the EtOH group. This suggests that pre-treatment 
alone is sufficient to improve neuronal differentiation compared to the Cortisol 
treatment but not back to level of EtOH treated cultures. However to increase 
the percentage of neuronal cells above the level of the EtOH group, RSVL 
treatment appears to be necessary together with Cortisol during proliferation 
(RR- -CC) but not during differentiation (RRR –CC).  
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Figure 3-23 Ki67 expression in differentiating HPC03A/07 cells treated with 
RSVL in the Cortisol stress model 
a) Comparison of the absolute percentage of Ki67 positive cells. b) Percentage change 
of Ki67 expression c) Cortisol only; -CC d) continuous RSVL treatment before and 
during Cortisol treatment; RRR –CC e) RSVL pre-treatment and treated together with 
Cortisol during proliferation but not during differentiation, RR- -CC f) RSVL 
pretreatment followed by Cortisol treament. (Scalebar: 20µm; p-values were generated 
using One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for 
abbreviations) 
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Figure 3-24 Dcx expression in differentiating HPC03A/07 cells treated with 
RSVL in the Cortisol stress model 
a) Comparison of the absolute percentage of Dcx positive cells. b) Percentage change 
of Dcx expression c) Cortisol only; -CC d) continuous RSVL treatment before and 
during Cortisol treatment; RRR –CC e) RSVL pre-treatment and treated together with 
Cortisol during proliferation but not during differentiation, RR- -CC f) RSVL 
pretreatment followed by Cortisol treament. (Scalebar: 20µm; p-values were generated 
using One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for 
abbreviations)  
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Figure 3-25 MAP2 expression in differentiating HPC03A/07 cells treated with 
RSVL in the Cortisol stress model 
a) Comparison of the absolute percentage of MAP2 positive cells. b) Percentage 
change of MAP2 expression c) Cortisol only; -CC d) continuous RSVL treatment before 
and during Cortisol treatment; RRR –CC e) RSVL pre-treatment and treated together 
with Cortisol during proliferation but not during differentiation, RR- -CC f) RSVL 
pretreatment followed by Cortisol treament. (Scalebar: 20µm; p-values were generated 
using One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for 
abbreviations) 
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Figure 3-26 Activated Caspase-3 expression in differentiating HPC03A/07 cells 
treated with RSVL in the Cortisol stress model 
a) Comparison of the absolute percentage of activated Caspase-3 positive cells. b) 
Percentage change of activated Caspase-3 expression c) Cortisol only; -CC d) 
continuous RSVL treatment before and during Cortisol treatment; RRR –CC e) RSVL 
pre-treatment and treated together with Cortisol during proliferation but not during 
differentiation, RR- -CC f) RSVL only (Scalebar: 20µm; p-values were generated using 
One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error 
of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001; See Table 3-2 for abbreviations)  
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3.4.4 Summary 
Table 3-3 summarizes the results from the EPA, DHA and RSVL prevention 
experiments in the Cortisol stress model in proliferating HPC03A/07 cells, Table 
3-4 summarizes the results in differentiating HPC03A/07 cells.  
The Omega-3s EPA and DHA and the stilbenoid RSVL display differences in 
their ability to prevent the effects of Cortisol, namely decreasing dividing and 
neuronal cells while increasing apoptosis. All components can prevent those 
Cortisol induced effects although with differences in the subgroups. RSVL is 
different from EPA and DHA as it does not decrease apoptosis and even slightly 
increases it when used on its own. EPA and DHA during proliferation increases 
the proportion of dividing cells despite Cortisol treatment in both groups, pre-
treatment only and continuous treatment, above the level of the vehicle control 
and EPA even to the level of EPA only treatment, whereas DHA did not reach 
the level of the DHA only group. Both EPA and DHA were able to decrease the 
proportion of apoptotic cells below the vehicle control and this time DHA 
reached the level of the DHA only treatment but not EPA (Table 3-3). During 
differentiation (Table 3-4), EPA treatment in all three groups, continuous EPA 
treatment (OOO –CC), EPA treatment during proliferation together with Cortisol 
(OO- -CC) and pre-treatment only (O-- -CC) has a very similar effect on 
increasing the proportion of dividing and neuronal cells and in decreasing 
apoptotic cells. The exception is the proportion of neuroblasts in the continuous 
treatment group that was not increased. This suggests that EPA treatment 
during differentiation pushes neuronal differentiation and maturation and after 7 
days all Dcx positive cells have matured. DHA performs very differently in the 
three subgroups, it appears that pre-treatment only is sufficient for preventing a 
decline in dividing cells; however it is not sufficient for neuronal differentiation 
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and maturation. Not only is the increase greater when cells a treated with DHA 
during proliferation in the Cortisol stress model but it even appears to be 
required during differentiation to ensure an increase in neuroblasts and mature 
neurons above or to the level of the vehicle control respectively. Both EPA and 
DHA decrease apoptosis in all three subgroups similarly compared to the 
Cortisol group. It appears that in the Cortisol stress model EPA is rather 
required for cell division and survival as EPA pre-treatment is already sufficient 
to achieve neuronal differentiation and maturation, whereas DHA is required to 
be present during the stress mimicking Cortisol treatment during proliferation 
and differentiation to ensure neuronal differentiation. 
RSVL treatment during proliferation increases the proportion of dividing cells 
most efficiently when present continuously, however not the level of the RSVL 
only treatment (Table 3-3). RSVL has no preventing effect on stress-induced 
apoptosis, neither during proliferation nor during differentiation. During 
differentiation (Table 3-4) pre-treatment only appears to be enough to increase 
dividing and neuronal cells, both early and mature, to almost the vehicle level, 
however when cultures were treated also during proliferation once the Cortisol 
treatment was started the increase was even greater although not to the level of 
RSVL only but above the vehicle. Continuous RSVL treatment also during 
differentiation increased dividing and neuronal cells; however not as efficiently 
as when cultures were treated during proliferation only. 
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3 d pro  
EPA OO C O C OO EtOH 
Ki67 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑ 
Caspase ↓ ↓ ↓↓ ↓ 
SOX2 - - - - 
Nestin - - - - 
DHA OO C O C OO EtOH 
Ki67 ↑ ↑ ↑↑↑ ↑↑ 
Caspase ↓↓ ↓↓ ↓↓ ↓↓ 
SOX2 - - - - 
Nestin - - - - 
RSVL RR C R C RR EtOH 
Ki67 ↑↑ ↑↑ ↑↑↑ ↑ 
Caspase - - - ↓ 
SOX2 - - - - 
Nestin ↓ - - - 
Table 3-3 Summary of the effect of EPA, DHA, RSVL on HPC03A/07 during 
proliferation under the Cortisol stress model. 
↑ stands for significanlty increased expression; ↓ for significantly decreased expression; 
- for no significant changes. Changes are relative to Cortisol treated cultures. DHA: 
Docosahexaenoic acid, EPA: eicosapentaenoic acid; RSVL: Resveratrol; Pro: 
Proliferation; Diff: Differentiation  
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7d diff 
EPA OOO CC OO CC O CC OOO EtOH 
Ki67 ↑ ↑↑ ↑ ↑↑ ↑ 
Dcx - ↑ ↑ ↑ - 
MAP2 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ 
Caspase ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ 
SOX2 - - - - - 
Nestin - - - - - 
DHA OOO CC OO CC O CC OOO EtOH 
Ki67 ↑↑ ↑↑ ↑↑ ↑↑↑ ↑ 
Dcx ↑↑↑ ↑ - ↑↑ - 
MAP2 ↑↑↑ ↑↑↑ ↑ ↑↑ ↑↑↑ 
Caspase - ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ 
SOX2 - - - - - 
Nestin - - - - - 
RSVL RRR CC RR CC R CC RRR EtOH 
Ki67 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑ 
Dcx ↑↑↑ ↑↑↑ ↑ ↑↑↑ ↑↑ 
MAP2 ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑ 
Caspase - - - ↓ ↓↓↓ 
SOX2 - - - - - 
Nestin - - - - - 
Table 3-4 Summary of the effect of EPA, DHA, RSVL on HPC03A/07 during 
differentiation under the Cortisol stress model. 
↑ stands for significanlty increased expression; ↓ for significantly decreased expression; 
- for no significant changes. Changes are realative to Cortisol treated cultures. DHA: 
Docosahexaenoic acid, EPA: eicosapentaenoic acid; RSVL: Resveratrol; Pro: 
Proliferation; Diff: Differentiation 
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3.5 Discussion 
3.5.1 Omega-3 fatty EPA and DHA acids increase the percentage of 
dividing cells and neurogenesis while decreasing apoptosis 
My results show that the Omega-3 fatty acids EPA and DHA increase the 
proportion of dividing cells and neuronal cells and decreases apoptosis  in vitro 
in HPC03A/07 cells (3.1), suggesting that EPA and DHA promote neurogenesis 
and the percentage of dividing cells mainly by increased survival but also due to 
increased neurogenesis. DHA effectively promotes neurogenesis and 
suppresses apoptosis both in vitro and in vivo in rat, suggesting that it 
modulates hippocampal function via neurogenesis (Kawakita et al., 2006). In 
adult immune stressed mice a diet enriched with PUFA decreased hippocampal 
microglia activation and increased proliferation (BrdU) and neurogenesis (Dcx) 
in the hippocampus leading to normal long-term potentiation (Crupi et al., 2011). 
This increase in proliferation and neurogenesis as well as the alleviation in 
decreased hippocampal Dcx expression by EPA and DHA in old rats (Dyall et 
al., 2010) are in accordance with my data, suggesting a positive effect of EPA 
and DHA on neurogenesis partly due to an increase in survival but also due to 
increased neurogenesis. The decrease in apoptotic cells is smaller than the 
combined increase in dividing cells (Ki67), neuroblasts (Dcx) and mature 
neurons (MAP2). 
In the literature to date, it is well accepted that the Omega-3 fatty acids EPA 
and DHA are crucial for the development of a healthy brain and are necessary 
throughout adulthood to maintain the normal brain function required for learning 
and memory, such as neurogenesis, synaptic plasticity and neuronal protection 
(Makrides et al., 2010). Interestingly, populations with high fish consumption 
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show a lower prevalence of major depression (Hibbeln, 1998; van Gelder et al., 
2007). And a deficiency of hippocampal Omega-3s is associated with a 
decrease in learning and memory abilities in rodents and humans (Freemantle 
et al., 2006; Chung et al., 2008) and can be reversed with a supplemented diet. 
Omega-3 supplemented diet enhances working and reference memory in 
healthy control animals and improves in Omega-3 fatty acid deprived rats. 
Further DHA is accumulated especially in the hippocampus and the olfactory 
bulb compared to visual cortex and cerebellum (Chung et al., 2008), suggesting 
that a Omega-3 supplemented diet leads to an accumulation of DHA areas with 
ongoing neuronal differentiation and maturation in the rodent brain and 
enhances learning and memory also in healthy animals. This raised the 
question whether pre-treatment with Omega-3 fatty acids may be able to 
prevent the effects of stress-relevant high concentrations of Cortisol.  
My results in 0 showed that high concentrations of the endogenous 
glucocorticoid hormone Cortisol (100µM) decrease the proportion of dividing 
cells and neurogenesis but increase apoptosis in HPC03A/07. The decrease in 
proliferation and neurogenesis in my results are partly due to an increased 
apoptosis and partly due to a genuine decrease in cell division and 
neurogenesis. This is because the increase in the percentage of cell death is 
smaller than the combined decrease in the percentage of dividing cells and 
neuronal cells. Anacker et al., using the same cell line and Cortisol 
concentration, showed that Cortisol only decreases proliferation and 
neurogenesis when cells are treated during the mitotic phase (Anacker et al., 
2011), which is why I treated the cultures with Cortisol under proliferation 
conditions before starting differentiation. Anacker et al. showed as well that 
Cortisol treatment does not affect apoptosis, whereas my data showed an 
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increase in apoptosis. However he treated the cells for only 24h under 
proliferative conditions before starting 7 days of differentiation, whereas I 
treated them for 3 days of proliferation and 7 days of differentiation, treating 
them during differentiation as well. High levels of glucocorticoids have been 
shown to induce cell death in lymphoid cells and rat brain (Gould et al., 1991; 
Haynes et al., 2003; Miller et al., 2005). The increase in apoptosis in my 
experimental setting can be explained by the longer exposure to Cortisol.  
3.5.2 Pre-treatment with EPA and DHA can prevent the negative effect of 
stress relevant concentrations of Cortisol (100µM) on dividing cells, 
neurogenesis and apoptosis 
My results in 3.4 showed that pre-treatment with either EPA or DHA could 
prevent the detrimental effects high Cortisol concentrations have on 
HPC03A/07: decrease of proliferation and neurogenesis that are partly due to 
decreased survival but also partly a genuine decrease in proliferation and 
neurogenesis. This can be explained by the greater combined increase of the 
dividing and differentiating cells compared to the apoptotic cells. 
These results are in line with the results of a study in adult immune stressed 
mice. In these mice a diet enriched with PUFA decreased hippocampal 
microglia activation and increased neurogenesis in the hippocampus leading to 
normal long-term potentiation (Crupi et al., 2011). This demonstrates that 
Omega-3s prevent neuroinflammation and deficits of hippocampal plasticity in 
immune stressed mice. Increased immune stress occurs in neuropsychiatric 
diseases associated with autoimmune diseases and the preventative properties 
described above suggest that Omega-3 treatment could act as a potential 
therapeutic option. Moreover DHA reduces cytokine-induced expression of 
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proatherogenic and proinflammatory proteins in human endothelial cells. De 
Caterina et al. conducted a similar pre-treatment experiment in human 
endothelial cells: Cells were pretreated with 10µM DHA and EPA followed by 
stimulation with TNFα and Il-1. Endothelial cells pretreated with DHA but not 
EPA had decreased expression of the endothelial leukocyte adhesion 
molecules vascular cell adhesion molecule (VCAM-1), intracellular  adhesion 
molecule (ICAM-1) and e-selectin (De Caterina et al., 1994). These molecules 
are required for the adhesion of leukocytes to the endothelium and their 
migration in endothelial inflammation and atheroma formation. A decrease in 
inflammatory proteins and subsequent atherosclerosis prevention can prevent 
inflammation and secure and improve the blood supply to the brain. A 
decreased blood flow to the brain is associated with dementia, known to 
deteriorate with age and is vital for optimal brain function (Nagahama et al., 
2003; Ruitenberg et al., 2005). De Caterina’s, Crupis and my results show that 
EPA and DHA have preventative properties in endothelial cells, in mouse brain 
and in human hippocampal progenitor cells; however it becomes apparent that 
EPA and DHA have different functions in the brain and the cardiovascular 
system. I will further discuss the differences between EPA and DHA below. 
My results are further in line with the literature to date that support the 
neurogenesis hypothesis of depression and cognition, which postulates that 
increased neurogenesis in the dentate gyrus of the hippocampus in the adult 
brain, is required to improve depressive symptoms and learning and memory. I 
could show that Omega-3 FAs have a similar effect on neurogenesis 
HPC03A/07 cells as antidepressants (Anacker et al., 2011). Literature to date 
has demonstrated that the by elevated corticosterone levels in the dentate 
gyrus of adult mice induced behavioural deficits and the decrease in cell 
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proliferation are reversed by chronic monoaminergic antidepressant (for 
example, fluoxetine) treatment (Murray et al., 2008). And when hippocampal 
neurogenesis is abolished by X-irradiation, the efficacy of fluoxetine is blocked 
in some, but not all, behavioural paradigms, suggesting both neurogenesis 
dependent and independent mechanisms of antidepressant action (David et al., 
2009). Antidepressant treatments have been shown to increase proliferation of 
NPC, neurogenesis and survival of neurons in the adult brain, especially the 
hippocampus (Jacobs et al., 2000; Malberg et al., 2000; Duman, 2004; Wang et 
al., 2008; Boldrini et al., 2009). These effects are dependent on the mouse 
strain but are always most pronounced in previously stressed animals (David et 
al., 2010). Stressors such as high levels of corticosterone might enhance the 
potency of the treatment such as monoaminergic antidepressants or Omega-3 
fatty acids. These treatments might even only elicit their positive effect if a 
stress or disease induced deficit prevails (David et al., 2010). This might explain 
the results I observed in the DHA treatment group under differentiation 
conditions (3.4.2.2): cultures that have been pre-treated, then continuously 
treated with DHA together with Cortisol treatment (OOO –CC), showed 
significantly increase in early and mature neurons compared to the vehicle 
treated and even the DHA only treated group. On the other hand the proportion 
of apoptotic cells is not decreased compared to Cortisol only treatment and is 
still increased compared to the vehicle control. This could indicate that 
continuous DHA treatment pushes HPC03A/07 cells into fate commitment and 
differentiation without preventing the Cortisol induced effects on apoptosis. EPA 
treatment in turn increased the proportion of differentiating cells, however never 
beyond the level of the EPA only treated cultures. However, these results also 
suggest that DHA, not EPA, is required during proliferation and differentiation 
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for neuronal differentiation (Dcx) and maturation into MAP2 positive cells in the 
Cortisol stress model. Anacker et al. demonstrated that the effects of the 
antidepressant sertraline on proliferating progenitor cells was essential to 
induce NPC differentiation into Dcx-positive neuroblasts, but not sufficient to 
promote their maturation into MAP2-positive neurons, because the number of 
MAP2-positive neurons was only increased when cells were treated 
continuously during proliferation and differentiation. Treatment during 
differentiation only had no effect (Anacker et al., 2011). Similar to this 
experiment the different effects of Omega-3 treatment on NPC differentiation in 
HPC03A/07 cells treated only during proliferation and treatment during 
differentiation only needs to be investigatet. 
3.5.3 EPA pre-treatment enhances survival and differentiation of 
HPC03/A07 cells in the Cortisol stress model while DHA is required 
for neuronal maturation and enhances survival 
As stated above my results in this thesis (3.4) show that EPA and DHA prevent 
the effects of Cortisol, namely decreasing proliferation and differentiation partly 
due to decreased survival, in my in vitro stress model. DHA exerts its 
preventative effect during both the proliferation and differentiation phase to 
ensure neuronal differentiation, while EPA pre-treatment is sufficient to prevent 
the Cortisol-induced effects on dividing cells, neuroblasts and mature neurons. 
Interestingly, in this thesis for the first time human hippocampal stem cells were 
used to investigate the effects of EPA and DHA, not in a mix but separately, on 
cell division and differentiation. My results show distinct differences in the effect 
of EPA and DHA. To date, most studies have used a mix of both EPA and DHA 
and so could not study individual effects of EPA and DHA. Two meta-analyses 
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started to examine the differences in efficacy and mode of action of EPA and 
DHA on depression and cardiovascular risk factors. EPA may be more 
efficacious than DHA in treating depression (Martins, 2009) whereas DHA 
appears to be more efficient in decreasing blood pressure, heart rate and 
platelet aggregation compared to EPA (Cottin et al., 2011). However both came 
to the conclusion that further evidence is required to fully understand those 
differences. An example for how difficult it is to compare the results from 
different groups on the differences between EPA and DHA is shown here: Two 
groups assess the impact of EPA and DHA on leukocyte function in vivo, but 
use different concentrations and use different means to assess their outcome. 
One group reported that DHA but not EPA supplementation decreased 
T-lymphocyte activation, which was assessed by CD69 expression (Kew et al., 
2004) whereas another group (Gorjao et al., 2006) showed an increased 
lymphocyte proliferation under DHA treatment. This kind of discrepancy makes 
it very difficult to compare research from different groups. 
My results show that EPA and DHA treatment has some similar effects and also 
distinctly different effects on HPC03A/07 cells. EPA and DHA treatment under 
proliferative conditions increases the percentage of dividing cells despite 
Cortisol treatment in the pre-treatment only (O- -C) and the continuous 
treatment group (OO –C). Please see 3.4 for a detailed description of the 
treatment groups. Both increase the proportion of dividing cells above the level 
of the vehicle control and EPA even to the level of EPA only treatment, whereas 
DHA did not reach the level of the DHA only group. Both EPA and DHA were 
able to decrease the percentage of apoptotic cells below the vehicle control, 
DHA to the level of the DHA only treatment but not EPA. This suggests that 
under proliferative conditions in HPC03A/07 cells EPA is better in preventing 
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the effects Cortisol has on dividing cells, suggesting an effect on cell division; 
whereas DHA can better prevent the Cortisol induced effects on apoptosis in 
proliferating cells, increasing the survival of NPC (See 3.4.1 and 3.4.2). 
During differentiation in the Cortisol stress model, EPA treatment in all three 
groups: continuous EPA treatment (OOO –CC), EPA treatment during 
proliferation together with Cortisol (OO- -CC) and pre-treatment only (O-- -CC), 
(see 3.4.1.2) has a very similar effect on increasing the proportion of dividing 
cells, neuroblasts (Dcx) and mature neuronal cells (MAP2) and in decreasing 
apoptotic cells. The exception is the percentage of neuroblasts (Dcx) in the 
continuous treatment group was not increased; however MAP2 positive mature 
neurons were increased. This suggests that EPA treatment during 
differentiation pushes neuronal differentiation and maturation and after 7 days 
all Dcx positive cells have already matured. DHA, on the other hand, behaves 
very differently in the three subgroups; it appears that pre-treatment alone is 
sufficient to prevent a decline in dividing cells mainly due to increased survival. 
However this is not sufficient to overcome the effects of Cortisol on neuronal 
differentiation and maturation. Not only is this increase in dividing cells greater 
when cells are treated with DHA during proliferation in the Cortisol stress model 
(OO- -CC), but it even appears to be required during differentiation (OOO –CC) 
to overcome the effect of Cortisol and ensure an increase in neuroblasts and 
mature neurons above or to the level of the vehicle control, see 3.4.2.2. Both 
EPA and DHA decrease apoptosis in all three subgroups similarly compared to 
the Cortisol group and prevent the Cortisol induced increase in apoptosis. 
Except under DHA treatment in the continuous treatment group as discussed in 
Section 3.5.2. It appears that in the Cortisol stress model, EPA is increasing cell 
survival and EPA pre-treatment is already sufficient to achieve neuronal 
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differentiation and maturation. Conversely, DHA is required to be present 
throughout proliferation and differentiation to overcome the effects of Cortisol 
and ensure neuronal differentiation and maturation. This is not only due to 
increased survival as the proportion of apoptotic cells in not decreased. It might 
be possible that under EPA treatment at an earlier time point in differentiation (3 
days) a significant increase of Dcx positive neuroblasts could occur and that 
after 7 days these neuroblasts have already matured into MAP2 positive 
neurons. Whereas cell differentiation into mature neurons under DHA treatment 
might take longer and the proportion of MAP2 positive cells might only increase 
after e.g. 14 days under differentiation conditions. On the other hand the 
survival of the neuroblasts or the mature neurons might not be maintained 
during DHA treatment, and the cells might die on their way to becoming mature 
neurons. This holds also true for the EPA or DHA only treated group. Therefore 
it will be necessary to characterise the nature of the apoptotic cells to explore 
what cell types die. Assessing the effects of EPA and DHA at different time 
points, for example, 3 and 14 days of differentiation would be an interesting 
experiment to conduct to investigate how Dcx, MAP2 and activated Caspase 3 
expression change over time.  
Due to the differences in acyl chain length and degree of saturation EPA 
(20:5 n-3) and DHA (22:6 n-3) would not be expected to have the same effect 
on cell structure and signalling and therefore brain function. However, the 
heterogeneity of studies investigating the effects of EPA and DHA in terms of 
dosage, duration, population target, cell line, sample size, as well as the relative 
amount of EPA and DHA used in supplements leads to variability in results in in 
vivo and in vitro studies, making it difficult to pin point differences between the 
modes of action of these two main Omega-3s. In the following section I am 
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going to discuss the data to date that compares EPA and DHA regarding brain 
content, inter-conversion, impact on depression, cardiovascular system, 
inflammation, gene expression and signalling to find possible explanations for 
the differences between EPA and DHA in my results. 
DHA is predominately found in the phophatidylethanolamine (PE) and the 
phosphatidylserin (PS) fraction which together with phophatidylcholin (PC) 
constitute the major building blocks of neuronal membranes (Rapoport, 2001). 
Stable isotope tracer studies showed that increasing ALA intake for some 
weeks to months elevates EPA but not DHA in plasma lipids, erythrocytes, 
leukocytes, platelets and breast milk (Burdge and Calder, 2005). ALA, EPA and 
DHA can be inter-converted although only to a minimal extent all the way 
through to DHA (Burdge and Calder, 2006). This explains the importance of 
sufficient dietary DHA intake. DHA supplementation has been shown to 
increase neurogenesis in vivo in rats and in vitro (Kawakita et al., 2006). 
However, a meta-analysis by Martins showed that EPA or a combination with a 
higher EPA to DHA ratio is more efficacious in alleviating depressive symptoms 
in human trials (Martins, 2009). My data illustrate that DHA supplementation in 
the Cortisol stress model is required to improve neuronal differentiation and 
maturation, whereas EPA pre-treatment is sufficient to prevent the Cortisol 
induced effects on proliferation and differentiation mainly by increasing survival 
(shown in 3.4) Furthermore, EPA seams more important for the survival of 
dividing cells (3.4.1.1). It might be that EPA is more efficacious in human trials 
because it is more relevant for proliferation and later can be converted to DHA. 
Indeed, the enzymes necessary for this conversion have been shown in my lab 
to be present in the HPC03A/07 cell line on mRNA level. DHA also might get 
degraded more easily on the way to the brain due to its length and additional 
 Page 191 of 318 
 
double bond. Regarding perinatal depression, a meta-analysis did not show any 
significant differences between the effect of EPA and DHA on depression, 
although most of the trials were of poor quality due to small sample sizes and 
failure to adhere to Consolidated Standards of Reporting Trials guidelines (Jans 
et al., 2010). Contrary to these findings a recent meta-analysis by Cottin et al. 
analysed the differential effects of EPA and DHA on cardiovascular risk factors 
and showed that DHA and not EPA appears to be responsible for lowering 
blood pressure and heart rate as well as platelet function (Cottin et al., 2011). 
An improved cardiovascular system can be beneficial for brain functions as 
increased blood flow in the brain is known to facilitate AHN (Nagahama et al., 
2003; Ruitenberg et al., 2005). Additionally, fMRI studies have shown that 
cerebral blood flow is decreased in patients with dementia (Nagahama et al., 
2003; Ruitenberg et al., 2005). Fish oil consumption is also beneficial for arterial 
compliance and endothelial function (Cottin et al., 2011). However, any 
differences between EPA and DHA regarding their vascular effect are poorly 
understood. EPA and DHA also markedly affected the expression of genes 
clustered as cytokines and related receptors, signal transduction pathways, 
transcription factors, cell cycle, defence and repair, apoptosis, DNA synthesis, 
cell adhesion, cytoskeleton, and hormone receptors in T-Lymphocytes. 
Noticeable differences were observed between the effects of EPA and DHA, 
indicating that it is an over-simplification to generalize the effects of Omega-3s. 
For a detailed review on changes in gene expression please see (Verlengia et 
al., 2004). Although in vitro and in vivo studies indicated an effect on 
inflammation or insulin sensitivity, neither EPA nor DHA alone showed an effect 
in human subjects (Cottin et al., 2011). EPA and DHA also impact on the 
mitogen activated protein kinase (MAPK) pathway that modulates cellular 
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activities, such as proliferation, gene expression, differentiation, mitosis, cell 
survival, and apoptosis. Xue at al. observed differences in EPA and DHA on the 
MAPK pathway in human umbilical vein cells (HUVEC) that were activated with 
TNF-α (Xue et al., 2006). EPA or DHA alone significantly reduced the TNF-α-
induced activation of p38 and JNK kinases, but EPA is a more potent inhibitor 
than DHA. Further, DHA and not EPA reduced the TNF-α-induced JNK mRNA 
expression, suggesting that EPA and DHA can inhibit stress induced apoptosis 
and inflammation. These data could explain the differences between EPA and 
DHA in neurogenesis in the continuous treatment group (OOO –CC) of the 
Cortisol stress model where EPA increases neuroblasts and mature neurons 
while DHA increases mature neurons only when cells were treated during 
differentiation (see 3.4) and the differences between EPA and DHA only in 
neurogenesis and the degree of decrease in apoptosis observed where EPA 
alone increases mature neurons while DHA increases neuroblasts. EPA alone 
decreases apoptosis to a greater level than DHA. EPA as the more potent 
inhibitor of JNK kinases and p38 might facilitate the proper maturation of 
neuroblasts short-term, whereas DHA is a long-term inhibitor by reducing the 
JNK kinase mRNA (Xue et al., 2006) and might therefore be more important for 
differentiation and maturation. Further supporting the idea that DHA is more 
effective in easing inflammatory stress is provided by Weldon et al. who in an in 
vitro study indicated that DHA may be more effective than EPA in alleviating 
lipopolysaccharide induced pro-inflammatory cytokine production by 
macrophages (Weldon et al., 2007). The proinflammatory cytokines tumour 
necrosis factor α (TNFα) and interleukin (IL)-6 are found to be increased in 
patients with Major depressive disorder (MDD) (Dowlati et al., 2010; Liu et al., 
2011). One explanation for the decrease in cytokines under DHA treatment is 
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that EPA competes with the Omega-6 FA AA and acts as a substrate for 
cyclooxigenase and lipoxygenase, being converted to eicosanoids, whereas 
DHA does not (see 1.3.1). Further, a diet enriched with Omega-3 PUFA 
dampened the inflammatory response and the physiological re-equilibration of 
body fat deposition in obese Zucker rats by reducing substrates for 
inflammatory molecules and endocannabinoids in the visceral adipose tissue 
and in the liver and heart (Batetta et al., 2009).  
EPA and DHA have different effects on membrane structure (Mitchell and 
Litman, 1998). The length and the degree of unsaturation of fatty acid chains 
impacts on membrane fluidity as unsaturated lipids due to their double bonds 
create a kink, preventing the fatty acids from packing together as tightly. Fatty 
acids decrease membrane organisation with increasing unsaturation from one 
to six carbon-carbon double bonds (Mitchell and Litman, 1998), which results in 
increased aqueous defects and therefore increased proton permeability through 
proton passive pathways (Decoursey, 2003) and a decrease in melting 
temperature and therefore fluidity. DHA possesses a longer carbon chain and 
one more double bond than EPA, which is thought to be the reason for the 
greater influence of DHA on membrane fluidity and cholesterol content 
(Hashimoto et al., 1999), and thus on the activity of membrane protein or ion 
channels. Lipid raft content was altered in lymphocytes after DHA but not EPA 
treatment (Ma et al., 2004). Further, the fatty acid distribution in biological 
membranes can modulate those membranes and incorporate microdomains, 
such as lipid rafts and caveolae (Ma et al., 2004). This re-organisation of 
membrane structures influences cell signalling by moving signalling protein in 
and/or out of rafts (Wassall and Stillwell, 2008). The IL-2 receptor is located in 
lipid rafts (Li et al., 2005) and DHA and EPA decrease the stimulatory effect IL-2 
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has on human lymphocyte proliferation via different pathways: The effect of 
DHA on lymphocyte proliferation was associated with a reduction in the IL-2-
induced activation of the JAK/STAT, ERK, and Akt pathways and a decrease in 
CD25 expression whereas EPA decreased the phosphorylation of the IL-2R 
signalling proteins by a mechanism that did not involve CD25 (Gorjao et al., 
2007). In MDD patients, levels of IL-2 receptor, TNF-α and IL-6 were 
significantly higher than controls (Liu et al., 2011), suggesting EPA and DHA as 
a treatment as they can diminish the increase of inflammatory cytokines as 
described above.  
Two nuclear receptors important for neuroprotection are nuclear retinoid X 
receptor (RXR) and peroxisome proliferator-activated receptors (PPARs). EPA 
and DHA are endogenous ligands of RXR (Urquiza et al., 2000; Lengqvist et al., 
2004) and PPAR (Chambrier et al., 2002) and have neuroprotective effects on 
the aged brain (Gamoh et al., 2001; Dyall et al., 2007). Retinoic acid receptors 
(RARs), RXRs, and PPARs are transcription factors involved in many cellular 
processes, such as learning and memory and their mRNA levels decrease with 
age (Chiang et al., 1998; de Urquiza et al., 2000; Chambrier et al., 2002; 
Lengqvist et al., 2004). Dyall et al. showed that RARα, RXRα, RXRβ, and 
PPARγ protein expression significantly decreases in the forebrain with ageing, 
and this was reversed by EPA and DHA supplementation (1.5:1 ratio). EPA and 
DHA supplementation could further restore the significant age-related 
decreases in RARα and RXRβ expression in CA1 and the dentate gyrus. DHA 
only supplementation also appeared to increase receptor expression in the 
prefrontal cortex, striatum, and hippocampus. Decreases in hippocampal Dcx 
expression were also partially alleviated (Dyall et al., 2010). Also my data show 
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for the first time that EPA and DHA prevent the Cortisol-induced decrease in 
Dcx positive cells in the Cortisol stress model in the HPC03A/07 cell line.  
We are beginning to understand the different modes of action of EPA and DHA 
but we still don’t understand why EPA is more efficacious than DHA in 
improving depressive symptoms especially as the concentration in the brain of 
DHA is a lot higher than the concentration of EPA. A possible explanation could 
be that EPA acts on endothelial cells and the cardiovascular system thereby 
increasing the blood flow to the brain which is associated with an increase in 
cognition (Tiehuis et al., 2008). My results support the positive effects of EPA 
and DHA on the survival, dividing cells, differentiation and maturation in a 
hippocampal progenitor cell line. By increasing the survival more dividing cells 
are available to go on to differentiate and mature. My results also confirm that 
EPA and DHA have different effects, as they may exert their effects through 
different pathways, which are yet to be elucidated. These results further the 
understanding on the beneficial effects of the Omega-3s EPA and DHA on the 
hippocampus, an area important for learning and memory and mood. They 
further add to the body of evidence suggesting Omega-3s as a potential 
treatment for depression and cognitive decline. However, the exact cellular 
mechanisms behind the effects of EPA and DHA still remained to be elucidated. 
Figure 3-27 shows an overview of the possible mechanisms involved in the 
effects of EPA and DHA in depression and cognition. 
My results show for the first time the potential of dietary supplementation of 
Omega-3s in preventing a Cortisol induced decrease in survival and 
neurogenesis in human hippocampal progenitor cells. Although the cellular 
mechanisms behind their beneficial effects still remains to be elucidated, DHA 
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and EPA supplements have long been accepted to be beneficial in depressed 
patients. If Omega-3s were to be recommended as an additional or 
monothereapy for depression, or to improve learning and memory performance 
it will be important to bear in mind that not all individuals will respond to DHA 
and/or EPA in the same way which is also the case for antidepressants. 
Ongoing nutrigenetic research will be crucial in defining future advice regarding 
dietary and supplementary EPA and DHA. Further, supplementation is likely to 
be only effective in case of a prevailing deficit in EPA and DHA. 
The next step is now to investigate the potential rescue abilities of EPA and 
DHA in the human hippocampal progenitor cell line. Experiments investigating 
the potential rescue properties of EPA and DHA using the Cortisol stress model 
in the HPC03A/07 cell line are currently ongoing in the Thuret lab.  
 
Figure 3-27 Overview of possible ways EPA and DHA affect mood 
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3.5.4 The stilbenoid Resveratrol increases the proportion of dividing cells 
and neuronal cells 
My data show that RSVL increases the proportion of dividing cells and mature 
neuronal cells. The proportion of apoptotic cells is increased during 
differentiation. The effects of RSVL are dose dependent and the increasing 
effects on dividing cells and cell death are contained within a narrow range. 
When titrating the concentration for the highest rate of dividing cells, I did not 
investigate the percentage of dying cells. It might be that the concentration 
(1µM) I chose, lead to the greatest increase in proliferation but was still too high 
in respect to apoptosis. A lower concentration might still have given a significant 
increase in proliferation with lower (or absence of) apoptosis. Closer 
investigation of the effect of RSVL on cell death in the human embryonic 
progenitor cell line is required. It will further be necessary to examine which cell-
type dies. These results are also in accordance with the Klotho over-expression 
data in 4.2, which also increases cell fate commitment and apoptosis in 
differentiating HPC03A/07 cells. RSVL impacts on proliferation and 
differentiation partly through Klotho activation shown in 5.4. RSVL is produced 
by plants as a phytoalexin to protect them from fungal and bacterial invasion. 
Phytoalexins are broad spectrum inhibitors that act as toxins to attacking 
organisms. This toxic potential explains its effects on increasing apoptosis in 
higher concentrations in HPC03A/07 cells. In short lived organisms such as fruit 
flies and nematodes, RSVL increases life span (Wood et al., 2004). In yeast 
RSVL feeding increases life span and also the activity of the enzyme Sirtuin2 
(Sir2) that plays a key role in an organism's response to stresses, is associated 
with longevity and is also increased during caloric restriction (CR) (Lin et al., 
2000; Howitz et al., 2003). Long term administration of RSVL induces similar 
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gene expression patterns to CR in mice and delays aging related deterioration, 
but does not extend life span when started in mid life (Pearson et al., 2008). 
RSVL acts on various targets that are associated with protection against 
lifestyle-related diseases, such as depression, diabetes and high blood 
pressure. Amongst those targets that are activated by 5µM RSVL are Sirtuin1, 
the mammalian homologue to Sir2, which is involved in cellular regulation, the 
nuclear transcription factors PPARα, δ and γ, COX1 and 2 that are key 
enzymes in prostaglandin biosynthesis and eNOS, the endothelial nitric oxide 
synthase that generates NO in blood vessels and regulates vascular tone in 
vitro in human cells (Nakata et al., 2012). However SIRT1 over-expression does 
not extend life span in healthy mice (Herranz et al., 2010), compared to its 
equivalent Sir2 in yeast (Howitz et al., 2003). Although RSVL might not extend 
lifespan in mammals it ameliorates aging-related metabolic phenotypes by 
inhibiting cAMP phosphodiesterases in mice and consequently increases 
Nicotinamide adenine dinucleotide (NAD) and the activity of SIRT1 via AMPK 
(Park et al., 2012) See 1.3.2.1. Moreover, RSVL improves cognitive function in 
wild type mice by increasing production of insulin-like growth factor-I and 
enhancing angiogenesis and neurogenesis in the hippocampus (Harada et al., 
2011). Also my data show an increase of mature neurons in the HPC03A/07 cell 
line after RSVL supplementation but no attenuating effect on apoptosis.  
In human, a single dose of orally administered RSVL can modulate cerebral 
blood flow but has no effect on cognitive performance (Kennedy et al., 2010). A 
recently completed clinical trial by Haskell also found that RSVL 
supplementation increases cerebral blood flow in young healthy males but has 
no effect on cognition (http://clinicaltrials.gov/; Identifier: NCT01010009).  
 Page 199 of 318 
 
The pro-angiogenic effects of RSVL in brain endothelial cells are mediated via 
activation of PI3-K/MAPK/ERK signalling pathways and lead to improved blood 
pressure and blood flow (Simao et al., 2012). As stated previously, an improved 
cardiovascular system can be beneficial for brain functions, as increased blood 
flow in the brain is known to facilitate AHN (Nagahama et al., 2003; Ruitenberg 
et al., 2005). Based on its antioxidant, chemopreventive and anti-inflammatory 
action RSVL predominantly appears to be improving health in damaged 
systems, such as ischemic brain damage (Palmer et al., 2000), diabetes or 
cancer (Rivera et al., 2009). I therefore investigated the preventative effects of 
RSVL in the Cortisol stress model. 
3.5.5 RSVL pre-treatment can prevent the negative effects of Cortisol on 
proliferation and differentiation, but not on apoptosis.   
My data show that RSVL treatment of HPC03A/07 cells in the Cortisol stress 
model during proliferation increases the proportion of dividing cells most 
efficiently when present continuously, however not to the level of the RSVL only 
treatment. RSVL pre-treatment does not prevent apoptosis during both 
proliferation and differentiation. During differentiation pre-treatment only (R-- -
CC) appears to be enough to increase dividing cells, neuroblasts and mature 
neuronal cells, to almost the vehicle level, however when cultures were treated 
also during proliferation once the Cortisol treatment was started (RR- -CC) the 
increase was even greater although not to the level of RSVL only but above the 
vehicle. Continuous RSVL treatment (RRR –CC) also during differentiation 
increased dividing and neuronal cells; however not as efficient as when cultures 
were treated during proliferation only. The increase in dividing cells, neuronal 
cells and apoptosis might be because RSVL treatment pushes cells rapidly into 
fate commitment leading to increased cell death. To my knowledge RSVL has 
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never before been studied in a human hippocampal cell line and never for its 
ability to prevent Cortisol induced stress. Further, very little is known todate 
about the effect of RSVL on neurogenesis. A study conducted recently by 
Girbovan et al. investigated the effect of RSVL pre-treatment on global ischemia 
in rats. They concluded that repeated RSVL administration leads to lasting 
protection against neuronal damage in the hippocampus but induces dose 
related alterations of behavior and memory (Girbovan et al., 2012). These data 
are similar to my results that indicate that RSVL can prevent the Cortisol 
induced effects on dividing cells, neuroblasts and mature neurons by increasing 
the proportion of dividing and neuronal cells by increasing proliferation and 
neurogenesis and not due to survival as the percentage of apoptotic cells is not 
decreased. RSVL can further attenuate the deleterious effects of focal cerebral 
ischemia/reperfusion-induced brain injury and function as a potential 
neuroprotective agent by decreasing apoptosis (Li et al., 2012). Contrary to this, 
my data show an increase in apoptosis during differentiation. RSVL is cytotoxic 
at higher concentrations and the concentration of 1µM used in my experiments, 
despite increasing the proportion of dividing cells most, might still elicit apoptotic 
effect and increase on cell death. It is well known that RSVL has cytotoxic effect 
on cancer cells and can reduce cell viability at high concentrations (Takahashi 
et al., 2009). However in non cancer cells RSVL (40mg/kg) improves 
hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and 
inhibiting apoptosis of granular cells (Moriya et al., 2011), which is similar to the 
neurogenic effect I observe, however the concentration I choose for this 
experiment does not decrease apoptosis. RSVL supplementation also 
attenuates obesity-associated peripheral and central inflammation and improves 
memory deficit in mice fed a high-fat diet (Jeon et al., 2012). RSVL shifts the 
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physiology of middle-aged mice on a high-calorie diet towards that of mice on a 
healthy diet and significantly increases their survival by impacting on molecules 
associated with longer lifespan, including increased insulin sensitivity, reduced 
IGF-I levels, increased AMPK and PGC-1alpha activity, increased mitochondrial 
number and improved motor function (Barger et al., 2008a). Moreover RSVL 
exerts anti-inflammatory effects in murine microglia and astrocytes by inhibiting 
different proinflammatory cytokines and key signalling molecules such as TNF-
alpha, IL-6, iNOS/NO and NF-kappaB (Lu et al., 2010). RSVL exerts its 
protective effects against lifestyle-related diseases via various pathways 
involving: SIRT1, p53, NF-κB, PGC1α, eNOS, FOXO, PPARs, MAPK, AKT, 
PI3K, cAMP, AMPK (Pirola and Frojdo, 2008; Nakata et al., 2012; Park et al., 
2012). It appears that RSVL, as a pharmacological agent, has a wide target 
spectrum. The biological activities of RSVL may thus be dependent on its 
simultaneous activity on multiple molecular targets. 
However it is becoming increasingly clear that RSVL has two faces. On one 
hand, it protects cells by potentiating a survival signal; on the other hand, it 
selectively kills cancer cells (Dudley et al., 2009; Takahashi et al., 2009; 
Edwards et al., 2010; Moriya et al., 2011; Aluyen et al., 2012). RSVL behaves 
as an antioxidant, yet it can induce redox signalling (Dudley et al., 2009). RSVL, 
similar to Cortisol, has a differential dose dependent effect. At moderate 
concentrations they are beneficial for survival, proliferation and neuronal 
differentiation and if the concentrations reach a certain threshold their effects 
become detrimental and can lead to cell death (3.2.1). It might be possible that 
RSVL has greater effects on survival, cell division and differentiation under 
preceding stress, such as elevated Cortisol levels, Klotho knock down (as 
discussed in 4.3) or diabetes, obesity and ischemia. 
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Although in vitro and in vivo animal experiments conclude that RSVL acts on 
pathways involved in cell cycle metabolism and improves symptoms of aging 
related diseases and cognitive function, it will be difficult to extrapolate these 
effects to human, as the concentrations used are difficult to achieve in human 
by diet alone and also RSVL is highly processed and therefore only blood 
vessels might get in contact with RSVL whereas the organs are left with its 
metabolites (Walle et al., 2004). This suggests that further research is needed 
into the metabolic effects of the RSVL metabolites have on cellular 
mechanisms, especially regarding neurogenesis. 
 
  










Chapter 4 Expression of Klotho in mouse brain and its effect on 
proliferation and differentiation in vitro in HPC03A/07 
  
 Page 204 of 318 
 
In this chapter, I describe my findings related to Aim 2 the expression of Klotho 
in mouse brain and its impact on proliferation, differentiation and survival in 
HPC03A/07. Klotho is known as the ‘ageing suppressor gene’, due to the 
distinct symptoms of a recessive Klotho mutant mouse (kl/kl) resembling those 
in the course of the aging process in human (Kuro-o et al., 1997). The Klotho 
mutant phenotype includes a short lifespan, infertility, arteriosclerosis, skin 
atrophy, osteoporosis, emphysema, hypokinesis and gait disturbance. 
Histological analysis of the central nervous system in kl/kl mice revealed a 
decreased number of Purkinje cells, but there were no other age-related 
changes such as brain atrophy, senile plaques or amyloid deposits (Kuro-o et 
al., 1997). However, they did not look at neurogenesis in kl/kl mice. In turn, in a 
mouse model where Klotho is over expressed the lifespan of this mouse is 
extended by up to 30%. Further, Insulin and IGF1 resistance increases by 
suppression of tyrosine phosphorylation of the insulin and IGF1 receptors 
(Kurosu et al., 2005). The effect of Klotho over-expression on the brain has not 
been analysed. 
As described in 1.4. Klotho is a single pass transmembrane protein that 
consists of two external β-glucosidase-like domains (hKL1 and hKL2), a 
transmembrane domain and very short cytoplasmic domain. The membrane 
domain facilitates the high affinity binding of FGF23 to the FGF receptor and is 
therefore involved in the endocrine regulation of phosphate homeostasis as part 
of a bone-kidney-parathyroid axis (Hu et al., 2010). The external domain can be 
shed by alternative splicing of the mRNA and proteolytic cleavage of the protein 
in the area of Exon 3 leading to a secreted form of Klotho (Chen et al., 2007; 
Bloch et al., 2009; Wang and Sun, 2009). The secreted Klotho can be found in 
blood, urine and Cerebrospinal fluid (CSF) and explains the pleiotropic, cell 
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non-autonomous effects of this gene (Kuro-o et al., 1997). Klotho is primarily 
expressed in the Kidney. However, German et al. have just described the 
expression of transmenbrane Klotho in the mouse brain. They have found 
transmembrane Klotho to be mostly expressed in the choroid plexus off the SVZ 
and in cerebellar Purkinje cells. It is expressed in the plasma membrane as well 
as near the nuclear membrane (German et al., 2012). 
Recently we observed that Klotho expression is increased in rodents upon 
intermittent fasting specifically in the hippocampus. Moreover, this up regulation 
of Klotho expression was associated with increased AHN and improved 
retention memory in these animals (Data has not yet been published, but was 
described in this thesis 1.3.4. Altogether these data suggest a potential role for 
Klotho in regulating adult hippocampal neurogenesis.  
First I wanted to investigate what cell types in the mouse hippocampus express 
Klotho. Second, I will show that Klotho expression increases in the 
hippocampus of mice maintained on an intermittent fasting diet. Third, to be 
able to work under controlled conditions I went on to investigate the effects of 
Klotho over-expression and Klotho knock down in vitro on HPC03A/07 
proliferation and differentiation. 
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4.1 Klotho protein is expressed in the dentate gyrus of the mouse 
brain  
To assess the co-expression of Klotho in the hippocampus in the brain of 3 
months old mice, PFA fixed wild type mouse brain sections were 
immunohistochemically stained for Klotho and co-labelled for SOX2, NeuN or 
GFAP. Sections were further co-labelled for Nestin, Ki67 and Dcx. I have than 
qualitatively assed which cell types in the hippocampus express Klotho protein. 
In the hippocampus, Klotho is predominantly expressed in the CA 1,2 and 3 and 
the dentate gyrus. Figure 4-1 shows that Klotho is co-expressed in NEUN and 
SOX2 positive cells, but not in GFAP positive cells. Further data showed that 
Klotho is not expressed in Nestin, Ki67 or Dcx positive cells (data not shown). 
This indicates that Klotho is expressed in mature neurons and putative stem 
cells, but not in astrocyts.  
 
Figure 4-1 Klotho expression in wild type mouse brain 
In wild type mouse brain in the hippocampus Klotho co-localises with NEUN and SOX2 
but not with GFAP. Arrowheads point at Klotho co-expressing cells. (Scalebar: 20µm) 
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4.1.1 Klotho expression in the hippocampus of adult mice upon 
intermittent fasting 
As described in Section 1.3.4 Klotho mRNA expression was increased in the 
hippocampus of mice on an intermittent fasting diet. To investigate the changes 
in Klotho protein expression in the hippocampus of these mice, I then went on 
to immunohistochemically assess changes in Klotho protein expression in the 
hippocampus of the intermittent fasting (IF) mouse model as described in 
Section 2.5.2. It was assumed that the increased AHN was due solely to 
reduced calorie intake, however unpublished pilot work by Sandrine Thuret’s lab 
has shown that increased AHN in dietary restriction paradigms is not only 
dependent of calorie intake but also depends on meal frequency in the form of 
intermittent fasting (See 1.3.4). In this IF model, C56Bl/6 mice restrict their 
caloric intake automatically by 10% over two days. Under calorie restriction 
(CR) the daily measured calorie intake is restricted to 90% of AL calorie intake. 
Briefly, three groups of animals were kept for three months under either ad 
libitum (AL), calorie restriction (CR) or IF conditions. Stereological analysis was 
conducted as described in 2.6.1.2 and threshold analysis was conducted as 
described in Section 2.6.1.3. 
Klotho positive cells were found in the hippocampus (images in Figure 4-2) with 
some Klotho expressing cells with processes observed inside the DG and inside 
the blade of the DG (Figure 4-2 CR and IF, arrow). Stereological quantification 
of Klotho positive cells in the DG of the hippocampus did not show significant 
differences in the IF or the CR group compared to the AL fed mice, see Figure 
4-2. 
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Nonetheless the Q-PCR results for Klotho expression showed a twofold 
increase in Klotho mRNA expression in the IF group compared to the AL and 
CR groups. Moreover, while blinded to the code, I also noted a difference in 
intensity in Klotho expressing cells in some of the brains. Consequently I 
decided to conduct threshold analysis that showed a significant increase of 
Klotho protein in the IF group compared to the AL control group by 
335.5±72.64, p<0.01 (Figure 4-3) but not in the CR group, suggesting that the 
number of Klotho expressing cells does not increase, but that upon IF the 
existing Klotho positive cells produce more protein, see Figure 4-3 images.  
Altogether, the results described above showed that Klotho is co-expressed in 
neurons and dividing cells in the dentate gyrus in the mouse brain and that 
Klotho expression is increased upon IF diet which is associated with increased 
neurogenesis in the dentate gyrus and improved memory (see 1.3.4). Next, I 
decided to continue to work in vitro in the human hippocampal HPC03A/07 cell 
line to be able to study the effect of Klotho on human proliferation and 
neurogenesis and to investigate the molecular mechanisms behind it under 
controlled conditions. Therefore, I first analysed the effects of Klotho over-
expression in a conditionally Klotho over expressing subclone of the 
HPC03A/07 cells (KLover) to investigate the effect of the humoral active 
secreted form of Klotho on proliferation, differentiation and survival. Based on 
the results in the IF in vivo model, I hypothesised that an increase in Klotho 
expression in vitro should entail an increase in neurogenesis. Second I knocked 
down Klotho secreted and membrane expression in HPC03A/07 cells using 
siRNA to investigate whether Klotho is required for proliferation, differentiation 
and survival. 
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Figure 4-2 Stereological analysis of the number of Klotho expressing cells in the 
DG of ad libitum (AL), caloric restriction (CR), Intermittent fasting (IF) fed mice. 
Histogram of stereological quantification in the Dentate Gyrus (DG): There is no 
difference between the groups in the number of Klotho expressing cells. Top row 
images show the whole hippocampus, bottom row images show the DG at higher 
magnification of coronal sections. Arrow head: Klotho positive cells inside DG; Arrow: 
Klotho positive cells inside the blade of the DG (Scalebar: top: 100µm; bottom: 20µm; 
AL n=3, CR n=5, IF n=5, One-Way ANOVA with Newman-Keuls post hoc test, Error 
bars are the Standard Error of the Mean (SEM)). 
 
Figure 4-3 Klotho protein threshold analysis in the dentate gyrus for Klotho of ad 
libitum (AL), caloric restriction (CR), Intermittent fasting (IF) fed mice.  
Klotho protein threshold analysis showed a significant increase in the intensity of the 
Klotho staining in Klotho positve cells in the IF group compared to the AL and CR 
group. Arrows indicate Klotho positive cells with higher intensity in the IF group 
compared to AL and CR group. (Scalebar: 20µm, One-Way ANOVA with Newman-
Keuls post hoc test Error bars are the Standard Error of the Mean (SEM), *p<0.05)  
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4.2 Klotho over expression in Klover cells in vitro 
To assess the effect of the secreted form of the gene Klotho on the proliferation 
and differentiation of HPC0A07/03A cells, these cells were genetically 
engineered to conditionally over-express this form of Klotho using the Lenti-XTM 
Tet-On® Advanced Inducible Expression System (Clonetech). Cells were 
selected for successful transfection by antibiotic selection, see 2.1.8. Gene 
expression is activated in this system using the tetracycline Doxycycline, 
leading to a stable Klotho over-expression. After the over-expression of Klotho 
was started, cultures were maintained for either 3 days under proliferation 
conditions or for 7 days under differentiation conditions in order to assess the 
effect of Klotho on proliferation, differentiation and survival.  
4.2.1 Validation of Klotho over expression in Klover cells using Q-PCR 
and Western Blot 
To confirm the over-expression of Klotho in Klover cells at the mRNA level I 
used Q-PCR (SYBR green). These Q-PCR values were normalised against the 
geometric mean of the three normalisers UBC, HPRT1 and β-actin that were 
chosen as their expression remains unchanged when Klotho is over-expressed. 
Figure 4-4 shows a comparison of Klotho mRNA levels from Klover cells in 
which Klotho over-expression was not switched on (OFF) and the ON group in 
which Klotho was over-expressed in proliferating (Figure 4-4a) and 
differentiating (Figure 4-4b.) Klover cells. In ON proliferating Klover cells Klotho 
mRNA expression was non-significantly increased. In differentiating Klover 
cells, Klotho mRNA expression was significantly increased to 34.3±10.3%, 
p<0.05 in the ON group compared to the OFF control. Klotho over-expression is 
a lot higher during differentiation than during proliferation possibly because 7 
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days differentiation allows additional time for the expression of Klotho compared 
to only 3 days proliferation. However, Klotho over-expression during 
proliferation shows a significant increase in protein (Figure 4-5a.) despite the 
relatively low increase in mRNA levels indicating that even a minor increase in 
mRNA is sufficient for protein level to be significantly increased. 
 
Figure 4-4 Changes in mRNA levels upon Klotho over-expression in 
proliferating and differentiating HPC03A/07  
Klotho expression is significantly increased in Klover cells after Klotho over-expression 
was initiated in differentiating cells (b) but not proliferating cells (a). OFF: Klover cells 
where Klotho over-expression is not switched on; ON: Klotho overexpression is 
switched on. (Student’s t-test, Error bars are the Standard Error of the Mean 
(SEM);*p<0.05) 
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To confirm the successful over-expression of the secreted form of Klotho 
protein, western blot analysis was carried out on both whole cell lysates of 
Klover cells and on supernatant collected from these cells after 3 days 
proliferation and 7 days differentiation in culture. Proteins were visualised using 
the Odyssey detection system. The relative density of the Western blot bands 
was analysed using ImageJ software. The intensity of the band was plotted as 
relative percentage of Klotho protein against a blank. In proliferating ON Klover 
cultures (Figure 4-5a) the secreted form of Klotho was observed to be increased 
by 22.8±0.9%, p<0.0001 in the supernatant and by 27.2±0.002%, p<0.0001 in 
the whole cell lysate. In differentiating ON Klover cultures (Figure 4-5b) the 
secreted form of Klotho was increased by 25.9±2.9%, p<0.001 in the 
supernatant and by 21.5±3.5%, p<0.01 in the whole cell lysate. This indicates a 
successful over-expression of Klotho protein during proliferation and 
differentiation in whole cell lysate and supernatant.  
 
Figure 4-5 Klotho protein levels in whole cell lysates and supernatant from 
proliferating (a) and differentiating (b) Klover cells  
Klotho protein was increased in the supernatant and the whole cell lysate in Klover ON 
cells compared to Klover OFF cells. Abbreviations: Super: supernatant; OFF: Klotho 
over-expression is not switched on; ON: Klotho overexpression is switched on. 
(Student’s t-test, Error bars are the Standard Error of the Mean (SEM); **p<0.01, 
****p<0.00001) 
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4.2.2 Immuncytochemistry upon Klotho over expression in HPC03A/07 
After I confirmed the successful over-expression of the secreted form of Klotho 
in Klover cells in the presence of Doxycycline (Dox) on mRNA and protein level 
I now wanted to investigate the effect Klotho over-expression on proliferation, 
cell fate commitment and survival. Therefore, cultures were grown either under 
proliferative (3 days) or differentiative conditions (7 days) in the presence and 
absence of Dox before they were fixed with 4% PFA. Cultures were stained 
immunocytochemically with markers that identify proliferating (KI67) and 
apoptotic cells (activated Caspase-3) or progenitor cells (SOX2 and Nestin). 
Under differentiation conditions cells were also stained with markers identifying 
neuroblasts (Dcx), mature neurons (MAP2) and astrocytes (S100b). Numbers 
are presented as percentage change of Klover ON compared to Klover OFF 
cells. 
4.2.2.1 SOX2 is increasingly expressed in the cytoplasm of proliferating 
Klover cells 
As expected after 3 days of proliferation Klotho expression in Klover ON cells 
was significantly increased compared to Klover OFF cells (1245±27.6%, 
p<0.0001) (Figure 4-6b) with 45.2±0.9% of total cells expressing Klotho (Figure 
4-6a). Although the percentage of cells expressing nuclear SOX2 (total 
99.6±0.1%, Figure 4-6c) was significantly decreased (-0.4±0.1%, p<0.0001) 
compared to Klover OFF cells (Figure 4-6d), the percentage of cells expressing 
SOX2 in the cytoplasm was significantly increased by 146.8±7.8%, p<0.0001 
(Figure 4-6f) with a total of 6.8±0.8% positive cells, Figure 4-6f. SOX2, a nuclear 
transcription factor, is essential to maintain self-renewal of undifferentiated 
embryonic stem cells. SOX2 proteins are regulated in part by nuclear import 
and export (Li et al., 2007). Excluding a transcription factor such as SOX2 from 
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the nucleus blocks its ability to bind to target DNA sequences and control target 
gene expression, thereby prohibiting it to drive the transcription of its target 
genes and in the case of SOX2 eventually rendering the cells incapable of self-
renewal and pluripotency. The percentage of cells expressing Nestin was also 
decreased by -0.59±0.1%, p<0.0001 in Klover ON cells (Figure 4-6h) with a 
total of 99.4±0.1%, Figure 4-6g Nestin positive cells. Ki67 expression showed 
no significant changes with a total of 47.4±1.9% Ki67 positive cells in Klover ON 
cells (Figure 4-7b). Activated Caspase-3 showed a not significant increase 
compared to Klover OFF cells with a total of 4.3±0.2% positive cells in Klover 
ON cells (Figure 4-7f).  
These data suggest that after initial increased proliferation, Klover ON cells 
might cease self-renewal due to Klotho over-expression. 
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Figure 4-6 Klotho, SOX2, SOX2 cytoplasm and Nestin expression in 
proliferating Klover cells 
a, d, e show the percentage of positive cells relative to the total number of cells 
counted. b, d, f show the percentage change of the marker in Klover ON cells 
compared to Klover OFF cells. a) and b) Klotho expressing cells. c) and d) SOX2 
expressing cells. e) and f) SOX2 cytoplasm expressing cells. g) and h) Nestin 
expressing cells. Abbreviationss: OFF: Klotho over-expression is not switched on; ON: 
Klover cell line overexpressing the secreted form of Klotho. (Student’s t-test, Error bars 
are the Standard Error of the Mean (SEM); ****P<0.0001) 
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Figure 4-7 Ki67 and activated Caspase-3 expression in proliferating Klover cells 
a and c show the percentage of positive cells relative to the total number of cells 
counted. b and d show the percentage change of the marker in Klover ON cells 
compared to Klover OFF cells. a) and b) Ki67 expressing cells of total cells. c) and d) 
activated Caspase-3 expressing cellsof total cells. Abbreviationss: OFF: Klotho over-
expression is not switched on; ON: Klover cell line overexpressing Klotho secreted. 
(Student’s t-test, Error bars are the Standard Error of the Mean (SEM); *p<0.05, 
**p<0.01, ***p<0.001, ****P<0.0001) 
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4.2.2.2 Klotho over-expression increased cell fate commitment and 
apoptosis in differentiating Klover ON cells 
After investigating the effect of Klotho over-expression on proliferating 
HPC03A/07 cells I also wanted to examine its effects on differentiation. After 7 
days of differentiation cultures were treated as described in Section 4.2.2. As 
expected the percentage of cells expressing Klotho was significantly increased 
upon Klotho over-expression by 378.6±40.5%, p<0.001 in Klover ON cells 
compared to Klover OFF cells to a total of 37.9±2.7% Klotho positive cells 
(Figure 4-8). The percentage of Dcx expressing cells was significantly increased 
to a total of 12.7±1.2% in Klover ON cells (percentage change from Klover OFF: 
127.8±21.9%, p<0.01) (Figure 4-9a,b,c) and the proportion of MAP2 positive 
cells was significantly increased to 28.7±9.8% (percentage change from Klover 
OFF: 245.3±80.1%, p<0.05) (Figure 4-9d,e,f). S100b, an astrocyte marker, was 
significantly increased by 67.9±14.4%, p<0.05 to a total of 22.8±1.9% (Figure 
4-10a,b,c). Activated Caspase-3 also showed a significant increase by 
143.3±14.9%, p<0.01 upon Klotho over-expression to a total of 7.8±0.5% 
(Figure 4-12). A total of 31.2±4.4% cells expressed Ki67 in Klover ON cells 
leading to a non-significant change from Klover OFF cells (Figure 4-11). 
Nuclear SOX2 expression was not changed (total: 96.4±1.6%), whereas the 
percentage of cells that express SOX2 in the cytoplasm is significantly 
increased by 97.45±12.42%, p<0.05 to a total of 2.2±0.1%. Nestin expression is 
significantly decreased by -4.2±1.1%, p<0.05 (Figure 4-13) to a total of 
94.9±1.0%.  
The proportion of neuronal cells increases as do astrocytic cells, but there is no 
or very little change in dividing cells and cells labelled for SOX and Nestin. 
However, these data together with the increase in SOX2 cytoplasm positive 
 Page 218 of 318 
 
cells suggest that Klotho over-expression pushes the cultures into cell fate 
commitment. 
When analysing the S100b data I noticed that S100b is not expressed in Klotho 
positive cells in the Klover OFF group but is expressed in Klotho positive cells in 
the Klover ON group. Therefore I went on to examine the proportion of Klotho 
positive cells co labelling with S100b in the Klover ON group. I found that 
29.3±6.7% of Klotho positive cells co-express S100b in the Klover ON group 
compared to none in the OFF control (Figure 4-10d,e). I also analysed the 
proportion of Ki67, Dcx, MAP2 and activated Caspase-3 positive cells in the 
Klotho positive population; however there were no significant changes compare 
to their proportion in the Klotho population in the OFF group. See Figure 4-9-
Figure 4-12 for pictures, graphs are not shown as no change cna be detected. 
To sum up in the total cell population Klotho, Dcx, MAP2, S100b, activated 
Caspase-3 and SOX2 in cytoplasm are significantly increased, with S100b 
being only expressed in Klotho positive cells in the Klover ON group. This 
correlates with the staining in mouse brain where GFAP (another astrocytic 
marker) is not co-expressed in Klotho positive cells suggesting that the effect 
Klotho has on astrocytes is elicited by the secreted form as Klotho is not 
normally expressed in astrocytes. It would be interesting to examine the brains 
of Klotho mutant mice and of mice over-expressing Klotho to analyse which cell 
types co-express Klotho. Further investigation is also needed on which cell 
types are dying when Klotho is over-expressed by co-labelling cells for activated 
Caspase-3 and Dcx, MAP2, S100b and Ki67. A possible explanation for the 
increased cell death could be that over expressing the secreted form of Klotho 
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accelerates fate commitment to such an extent, which in turn could be leading 
to increased cell death.  
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Figure 4-8 Klotho expression in differentiating Klover cells 
a) Comparison of the absolute percentage of Klotho positive cells in Klover OFF and 
Klover ON cells. b) Percentage change of Klotho expression compared to the OFF 
control c) Images in the top row show Klover ON cultures, bottom row shows Klover 
OFF. OFF: Klotho over-expression is not switched on; ON: Klover cell line 
overexpressing Klotho secreted. (Scalebar: 20µm; Student’s t-test, Error bars are the 
Standard Error of the Mean (SEM); ***p<0.001) 
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Figure 4-9 Dcx and MAP2 expression in differentiating Klover cells 
a) Comparison of the absolute percentage of Dcx positive cells in Klover OFF and 
Klover ON cells. b) Percentage change of Dcx expression compared to the OFF control 
d) Comparison of the absolute percentage of MAP2 positive cells in Klover OFF and 
Klover ON cells. e) Percentage change of MAP2 expression compared to the control c) 
and f) Images in the top row show Klover ON cultures, bottom row shows Klover OFF. 
Arrows indicate double labelled cellsAbbreviations: OFF: Klotho over-expression is not 
switched on; ON: Klover cell line overexpressing Klotho secreted. (Scalebar: 20µm; 
Student’s t-test, Error bars are the Standard Error of the Mean (SEM); *p<0.05, 
**p<0.01)  
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Figure 4-10 S100b expression in differentiating Klover cells 
a) Comparison of the absolute percentage of S100b positive cells in Klover OFF and 
Klover ON cells. b) Percentage change of S100b expression compared to the OFF 
control . c) Images in the top row show Klover ON cultures, bottom row shows Klover 
OFF. d) Comparision of the percentage of S100b positive cells in the population of 
Klotho expressing cells e) Percentage of change of S100b and Klotho expressing cells 
compared to the Klotho positive cells. Abbreviations: OFF: Klotho over-expression is 
not switched on ;ON: Klover cell line overexpressing Klotho secreted. (Scalebar: 20µm; 
Student’s t-test, Error bars are the Standard Error of the Mean (SEM), *p<0.05) 
  
 Page 223 of 318 
 
 
Figure 4-11 Ki67 expression in differentiating Klover cells 
a) Comparison of the absolute percentage of Ki67 positive cells in Klover OFF and 
Klover ON cells b) Percentage change of Ki67 expression compared to the OFF control 
c) Images in the top row show Klover ON cultures, bottom row shows Klover OFF. 
Arrows indicate double labelled cells. Abbreviationss: OFF: Klotho over-expression is 
not switched on ; ON: Klover cell line overexpressing Klotho secreted. (Scalebar: 
20µm; Student’s t-test, Error bars are the Standard Error of the Mean (SEM)) 
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Figure 4-12 Activated Caspase-3 expression in differentiating Klover cells 
a) Comparison of the absolute percentage of activated Caspase-3 positive cells in 
Klover OFF and Klover ON cells b) Percentage change of activated Caspase-3 
expression compared to the OFF control c) Images in the top row show Klover ON 
cultures, bottom row shows Klover OFF. Arrows indicate double labelled cells. 
Abbreviationss: OFF: Klotho over-expression is not switched on; ON: Klover cell line 
overexpressing Klotho secreted. (Scalebar: 20µm; Student’s t-test, Error bars are the 
Standard Error of the Mean (SEM); **p<0.01) 
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Figure 4-13 SOX2 and Nestin expression in differentiating Klover cells 
a) and b) The percentage of SOX2 positive cells observed after Klotho over-expression 
shows no change. c) and d) SOX2 expression in the cytoplasm is significantly 
increased in ON cells compared to OFF cells e) and f) Nestin expression is significantly 
decreased in the On cells compared to the OFF cells. g.) Images show in the top row 
Klover ON cultures, the bottom row shows Klover OFF cultures The arrows indicate 
cells wher SOX2 is expressed in the cytoplasm. OFF: Klotho over-expression is not 
switched on; ON: Klover cell line overexpressing Klotho secreted. (Scalebar: 20µm; 
Student’s t-test, Error bars are the Standard Error of the Mean (SEM); *p<0.05)  
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4.3 Klotho knock down in vitro in HPC03A/07 cells 
To assess the effects of suppressing Klotho expression on HPC03A/07 cells, 
cultures were transfected using the N-TER nanoparticle system with three 
different siRNA and a mix of all three to evaluate the effect of diminishing Klotho 
expression on proliferation and differentiation. HPCOA07/03 cells were 
transfected as described in 2.1.7. 24h after seeding and for the proliferation 
assay maintained under proliferating conditions for 3 days. For the 
differentiation assay, differentiation was started 24h after siRNA transfection. 
Cultures were maintained under differentiation conditions for either 3 or 7 days 
as indicated in Figure 4-14 and were then fixed with 4%PFA for 
immunocytochemistry. Cultures were stained with markers that identify 
proliferating (KI67) and apoptotic cells (activated Caspase-3) or progenitor cells 
(SOX2 and Nestin). Under differentiation conditions cells were also stained with 
markers identifying neuroblasts (Dcx), mature neurons (MAP2) and astrocytes 
(S100b). Numbers are presented as percentage change of Klotho knock down 
compared to control siRNA transfected cells. 
 
Figure 4-14 Timeline for siRNA transfection of HPCA07/03A cells.  
For the proliferation assay (line 1) cells were transfected using the N-TER Nanoparticle 
siRNA Transfection System 24h after seeding and maintained for 3 days. For the 
differentiation assay (line 2 and 3) cells were kept for 24h under proliferation was 
started and maintained for 3 or 7 days.  
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4.3.1 Klotho mRNA levels are very low before Klotho knock down  
To confirm Klotho knock down on mRNA level I used several SYBR green 
primers as well as TaqMan probes. Both failed to deliver accurate results in 
biological triplicates in the knock down samples as Klotho already has a rather 
low expression in HPC03A/07 cells. The cycle threshold (CT) for Klotho after 
siRNA knock down is very high (~CT 35) meaning it is expressed at a very low 
level and the results are out of the dynamic range, therefore an accurate 
analysis of mRNA levels could not be carried out. Nonetheless, Figure 4-15 
shows three technical replicates of Klotho mRNA expression after Klotho knock 
down. In the siRNA III group mRNA levels have been decreased by a fold 
change of 0.9. These are not satisfying Q-PCR data, therefore it was decided to 
validate Klotho knock down by assessing Klotho protein expression by 
immunohistochemistry for each siRNA experiment as shown further in Figure 
4-16a,b; Figure 4-17a,b; Figure 4-19a,b. 
co















Figure 4-15 Klotho Q-PCR in differentiating HPC03A/07 upon Klotho knock 
down 
Klotho mRNA levels are reduced to a 0.9 fold change after Klotho knock down with 
siRNA III. Three technical replicates have been used 
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4.3.2 Attempt to Klotho knock down has no significant effects on 
proliferating HPC03A/07 
Cultures were fixed with 4% PFA and then stained immunocytochemically for 
Klotho, the proliferation markers BrdU and Ki67 and the NPC markers SOX2 
and Nestin. Expression of Klotho decreases slightly upon transfection with 
siRNA but this change is not significant (Figure 4-16a,b). Similarly, the reduction 
in percentage of Ki67 positive cells was not significant (Figure 4-16c,d). There 
was no change in SOX2 (Figure 4-16e,f) and Nestin expressing cells (Figure 
4-16g,h). Each siRNA separately showed variability in knockdown efficiency 
and the combination of all three siRNAs is most effective in Ki67, SOX2 and 
Nestin stained cultures. None of the results are significant which could be 
because three days is too short for the remaining Klotho protein that was 
produced in the first 24h to be degraded after the knock down inhibits its further 
production. 
Together these results suggest that during proliferation, Klotho RNAi is not 
sufficiently efficient to significantly decrease the percentage of Klotho protein 
expressing cells. This might explain only a minor influence of Klotho on 
proliferation as already indicated by the non significant increase in Ki67 positive 
cells in proliferating and differentiating Klover cells in Section 4.2. The 
experiment in Klover ON cells show that the effect of Klotho on cell 
development was more pronounced under differentiation conditions. Therefore I 
next investigated the impact Klotho knock down on HPC03A/07 cells after 7 
days of differentiation.  
 Page 229 of 318 
 
 
Figure 4-16 Klotho, Ki67, SOX2 and Nestin expression upon Klotho knock down 
in proliferating HPC03A/07 cells 
a, c, e, g depict the percentage of positive cells relative to absolute numbers, b, d, f, h 
show the percentage change of the marker relative to control transfected cells. a) and 
b) Percentage of Klotho expressing cells c) and d) Percentage of Ki67 expressing cells. 
e) and f) Percentage of SOX2 expressing cells g) and h) Percentage of Nestin 
expressing cells. Abbreviationss: Co siRNA: control siRNA not binding to mRNA; I: 
siRNA binding Klotho mRNA at Exon 2; II: siRNA binding Klotho mRNA at Exon 3; III: 
siRNA binding Klotho mRNA at Exon 5; I-III: mixture of the three siRNAs. (One-Way 
ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of the 
Mean (SEM).  
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4.3.3 Klotho knock down reduces neuronal commitment in HPC03A/07 
after 3 days differentiation 
For the 3 days of differentiation experiments, cultures were treated and stained 
as described in Section 4.3. The proportion of Klotho expressing cells was 
significantly decreased upon Klotho knockdown with siRNAI -54.5±1.8% 
p<0.001, siRNAII -32.66±4.2% p<0.01, siRNAIII -21.2±11% p<0.05, siRNAI-III 
-61.2±2.4% p<0.001 (Figure 4-17a,b). The percentage of cells expressing Ki67 
showed a non-significant decrease upon transfection (Figure 4-17c,d). The 
proportion of Dcx expressing cells was significantly decreased with siRNAII by 
-16.9±3.9% p<0.05, but not significantly decreased with the other siRNAs 
(Figure 4-17e,f). The percentage of MAP2 expressing cells was significantly 
decreased with siRNAI-III by -20.0±3.0% p<0.05 but not significantly decreased 
with the other siRNAs (Figure 4-17g,h). S100b was not significantly decreased 
(Figure 4-18a,b). Activated Caspase-3 in turn shows not significant increase 
upon Klotho knock down (Figure 4-18c,d). There was no change in the 
percentage of cells expressing the NPC markers SOX2 and Nestin expressing 
cells (See Figure 4-18e,f,g,h). 
The percentage of expression of the marker for neuronal differentiation Dcx and 
MAP2 was significantly decreased with siRNAII and siRNAI-III respectively. 
These data suggest that Klotho plays a role in neuronal fate determination in 
HPC03A/07 cells. To investigate further the role of Klotho during differentiation 
cultures were next maintained under differentiation conditions for a longer 
period (7 days).  
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Figure 4-17 Klotho, Ki67, Dcx and MAP2 expression upon Klotho knock down 
after 3 days differentiation in HPC03A/07 cells 
a, d, e show the percentage of positive cells relative to absolute cells numbers. b, d, f 
show the percentage change of the marker in Klotho knock down cells. a) and b) 
Klotho expressing cells. c) and d) Ki67 expressing cells. e) and f) Dcx expressing cells. 
g) and h) MAP2 expressing cells. Abbreviations: Co siRNA: control siRNA not binding 
to mRNA; I: siRNA binding Klotho mRNA at Exon 2; II: siRNA binding Klotho mRNA at 
Exon 3; III: siRNA binding Klotho mRNA at Exon 5; I-III: mixture of the three siRNAs. 
(One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error 
of the Mean (SEM); *p<0.05, **p<0.01) 
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Figure 4-18 S100b, activated Caspase-3, SOX2 and Nestin expression upon 
Klotho knock down after 3 days differentiation in HPC03A/07 
a, d, e show the percentage of positive cells relative to absolute cells numbers. b, d, f 
show the percentage change of the marker in Klotho knock down cells. a) and b) 
S100b expressing cells. c) and d) activated Caspase-3 expressing cells. e) and f) 
SOX2 expressing cells. g) and h) Nestin expressing cells. Abbreviations: Co siRNA: 
control siRNA not binding to mRNA; I: siRNA binding Klotho mRNA at Exon 2; II: 
siRNA binding Klotho mRNA at Exon 3; III: siRNA binding Klotho mRNA at Exon 5; I-III: 
mixture of the three siRNAs. (One-Way ANOVA with Newman-Keuls post hoc test, 
Error bars are the Standard Error of the Mean (SEM).  
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4.3.4  Klotho knock down increases apoptosis and decreases neuronal 
commitment in HPC03A/07 after 7 days differentiation 
For the 7-day differentiation experiments, cultures were treated and stained as 
described in Section 4.3. After 7 days of differentiation Klotho expression was 
significantly decreased upon Klotho knockdown (siRNAI -51.2±0.4%; siRNAII 
-39.5±6.1%; siRNAIII by -44.7±4.4%; siRNA I-III by -67.4±1.4; all p<0.001) 
(Figure 4-19). Ki67 expression was not significantly decreased upon 
transfection (Figure 4-20). Dcx expression was significantly decreased with 
siRNAII -16.5±2.9% p<0.01 and siRNAI-III by 18.11±5.8%, p<0.01, but not 
significantly with siRNAI and siRNA III (Figure 4-21a-c) and MAP2 was 
significantly decreased when transfected with siRNAIII by -15.2±5.9%, p<0.05 
but not significantly with siRNAI, siRNAII, siRNAI-III (Figure 4-21d-f). S100b, a 
glial marker, was not significantly decreased (Figure 4-22). Activated Caspase-3 
in turn showed a significant increase upon Klotho knock down (siRNAI by 
95.6±12.8%, p<0.05; siRNAII by 117.1±12.0%, p<0.05; siRNAIII by 
108.0±21.3%, p<0.05; siRNAI-III by 163.6±34.9%, p<0.01) (Figure 4-23). The 
proportion of SOX2 and Nestin expressing cells is not significantly changed. 
The markers for neuronal differentiation Dcx and MAP2 significantly decreased 
with siRNAII and siRNAIII respectively and the proportion of apoptotic cells was 
significantly increased. This suggests that Klotho is necessary for the survival of 
differentiating cells. It appears that the neuronal cells develop but then die as 
the percentage of neuronal cells is the only population that is significantly 
decreased (apart from the Klotho population). However to confirm what cell 
types die it will be necessary to co-label cultures for activated Caspase-3 and 
marker for proliferation, differentiation and astrocytosis. Together with the data 
from 3 days proliferation (Section 4.3.1) and 3 days differentiation after knock 
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down (Section 4.3.4) these data indicate that Klotho is important during early (3 
days) and more advanced (7 days) differentiation and survival in HPC03A/07 
cells. However, it seems as if Klotho has no effect on dividing cells. As shown 
earlier (4.3.1) Klotho expression is very low and therefore a knockdown of 
Klotho might not have as big as an impact as over expressing it. 
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Figure 4-19 Klotho expression in differentiating HPC03A/07 upon Klotho knock 
down 
a) Comparison of the absolute percentage of Klotho positive cells in knock knock down 
and control cells. b) Percentage change of Klotho expression compared to the control 
c) Images show in the top row cultures transfected with control siRNA, bottom row 
shows cultures transfected with a mix of the three siRNAs. Abbreviations: siRNA: 
control siRNA not binding to mRNA; I: siRNA binding Klotho mRNA at Exon 2; II: 
siRNA binding Klotho mRNA at Exon 3; III: siRNA binding Klotho mRNA at Exon 5; I-III: 
mixture of the three siRNAs. (Scalebar: 20µm, One-Way ANOVA with Newman-Keuls 
post hoc test, Error bars are the Standard Error of the Mean (SEM); ***p<0.001) 
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Figure 4-20 Ki67 expression in HPC03A/07 upon Klotho knock down 
a) Comparison of the absolute percentage of Ki67 positive cells in knock knock down 
and control cells. b) Percentage change of Ki67 expression compared to the controlc) 
Images show in the top row cultures transfected with control siRNA, bottom row shows 
cultures transfected with a mix of the three siRNAs. Avreviations: Co siRNA: control 
siRNA not binding to mRNA; I: siRNA binding Klotho mRNA at Exon 2; II: siRNA 
binding Klotho mRNA at Exon 3; III: siRNA binding Klotho mRNA at Exon 5; I-III: 
mixture of the three siRNAs. (Scalebar: 20µm, One-Way ANOVA with Newman-Keuls 
post hoc test, Error bars are the Standard Error of the Mean (SEM)) 
 Page 237 of 318 
 
 
Figure 4-21 Dcx and MAP2 expression in differentiating HPC03A/07 cells 
a, e show the percentage of positive cells relative to absolute cells numbers. d, e show 
the percentage change of the marker in Klotho knock down cells a) Comparison of the 
absolute percentage of Dcx positive cells in knock down and control cultures. b) 
Percentage change of Dcx expression compared to control d) Comparison of the 
absolute percentage of MAP2 positive cells in knock down and control cultures. e) 
Percentage change of MAP2 expression compared to the control c) and f) Images in 
the top row show control transfected cultures, bottom row shows Klotho knock down. 
Abbreviations: co siRNA: control siRNA not binding to mRNA; I: siRNA binding Klotho 
mRNA at Exon 2; II: siRNA binding Klotho mRNA at Exon 3; III: siRNA binding Klotho 
mRNA at Exon 5; I-III: mixture of the three siRNAs. (Scalebar: 20µm; Student’s t-test, 
Error bars are the Standard Error of the Mean (SEM); *p<0.05, **p<0.01, ***p<0.001)   
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Figure 4-22 S100b expression in differentiating HPC03A/07 upon Klotho knock 
down 
a) Comparison of the absolute percentage of S100b positive cells in knock down and 
control cells. b) Percentage change of S100b expression compared to the control c.) 
Images show in the top row cultures transfected with control siRNA, bottom row shows 
cultures transfected with a mix of the three siRNAs. Abbreviationss: Co siRNA: control 
siRNA not binding to mRNA; I: siRNA binding Klotho mRNA at Exon 2; II: siRNA 
binding Klotho mRNA at Exon 3; III: siRNA binding Klotho mRNA at Exon 5; I-III: 
mixture of the three siRNAs. (Scalebar: 20µm, One-Way ANOVA with Newman-Keuls 
post hoc test, Error bars are the Standard Error of the Mean (SEM)) 
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Figure 4-23 Activated Caspase-3 expression in differentiating HPC03A/07 upon 
Klotho knock down 
a) Comparison of the absolute percentage of activated Caspase-3 positive cells in 
knock knock down and control cells. b) Percentage change of activated Caspase-3 
expression compared to the control c) Images show in the top row cultures transfected 
with control siRNA, bottom row shows cultures transfected with a mix of the three 
siRNAs. Abbreviations: Co siRNA: control siRNA not binding to mRNA; I: siRNA 
binding Klotho mRNA at Exon 2; II: siRNA binding Klotho mRNA at Exon 3; III: siRNA 
binding Klotho mRNA at Exon 5; I-III: mixture of the three siRNAs. (Scalebar: 20µm, 
One-Way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error 
of the Mean (SEM); *p<0.05, **p<0.01,) 
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4.3.5 Summary 
Over-expression of Klotho in proliferating Klover cells increases translocation of 
SOX2 in the cytoplasm but has no notable effect on apoptosis or proliferation. 
During differentiation Klotho over-expression increases apoptosis as well as the 
proportion of neuronal cells and astrocytic cells. These data together with the 
increase in SOX2 cytoplasm positive cells suggest that Klotho over-expression 
pushes the cultures into cell fate commitment. It is possible that over expressing 
the secreted form of Klotho accelerates fate commitment to the point of inducing 
more rapid cell death. It would be interesting to investigate which cell types are 
dying by co-labelling cells for activated Caspase-3 together with neuronal, 
astrocytic or NPC marker. Klotho over-expression appears to affect neuronal 
and astrocytic development as well as cell survival but has no effect on the 
proportion of dividing cells. 
A Klotho knock down on the other hand was expected to have the opposite 
effect. However, mRNA levels of Klotho are already very low before Klotho 
knock down. It was therefore difficult to further decrease Klotho expression and 
reliably quantify the extent of the knock down especially for the proliferation 
experiments. Indeed, during proliferation, Klotho knock down does not lead to 
any significant decrease in the percentage of Klotho, Ki67, SOX2 or Nestin 
positive cells, suggesting that the diminishing Klotho does not have a major 
influence on HPC03A/07 cells during proliferation. The not significant decrease 
in the percentage of Klotho expressing cells might be due to the fact that after 3 
days of proliferation after the knock down, previously generated Klotho protein 
has not been degraded yet. However, after 3 days of differentiation the 
proportion of Klotho expressing cells was significantly decreased suggesting 
that Klotho turnover is higher in differentiating cells and that its expression 
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affects cell development during differentiation rather than proliferation. 
Moreover, after 3 days of differentiation the proportion of neuronal cells was 
decreased when transfected with siRNAII or I-III, further suggesting a role for 
Klotho during neuronal development. This is confirmed during more advanced 
(7 days) differentiation where Klotho knock down leads to a significant decrease 
in Klotho and early and mature neurons, whereas apoptosis was significantly 
increased, suggesting that Klotho is required for cell survival upon 
differentation. To quantify what cell type dies, double labelling with activated 
Caspase-3 and marker for proliferation, neurons and astrocytes will be 
necessary. 
Together, Klotho over-expression and Klotho knock down indicate that Klotho is 
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4.4 Discussion 
4.4.1 Klotho is expressed in mouse hippocampus in neurons and stem 
cells 
My results in 4.1 show that in wild type mouse brain, Klotho protein is 
expressed in some neurons (NEUN+) and stem cells (SOX2+), but not in glial 
cells (GFAP+), NPC (Nestin+), dividing cells (Ki67+) and neuroblasts (Dcx+), 
suggesting that Klotho is only expressed in mature neurons and SOX2 positive 
stem cells. To date the majority of research regarding Klotho has been 
conducted in kidney, liver or the cardiovascular system (Kuro-o, 2011; Maltese, 
2012) and sofar my study is the first to specify which cell types in the brain 
express Klotho. 
The present study in this thesis shows for the first time that Klotho protein is 
expressed in the DG of the hippocampus, which correlates with the presence of 
Klotho mRNA in the same region. Klotho protein is not expressed in GFAP 
positive cells in the mouse hippocampus nor in S100b positive cells in the 
human hippocampal cell line. Interestingly, Klotho was detected in ependymal 
cells off the SVZ (German et al., 2012). Ependymal cells are a type of glial cells 
typically expressing GFAP and/or S100b, illustrating that the Klotho population 
in the DG is likely made of different cell types than the Klotho positive 
population near the SVZ. Further, my data show that in the DG, Klotho is 
expressed in SOX2 but not in GFAP positive cells. Interestingly, self-renewing 
nonradial progenitors in the SGZ, the type 2 cells, are SOX2+ but GFAP- and 
give rise to Dcx+ neuroblasts that differentiate into dentate granule cells (Mu et 
al., 2010). This might be an indication that Klotho is expressed in type 2 cells in 
the DG, suggesting a putative role of Klotho for cell differentiation. 
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4.4.2 Intermittent fasting increased the amount of Klotho protein in the 
dentate gyrus but not the number of Klotho positive cells.  
My results in 4.1.1 show that intermittent fasting (IF) increases the amount of 
protein that the existing Klotho positive cells produce in the dentate gyrus of 
mice but that the total proportion of Klotho expressing cells did not increase. A 
difference in Klotho intensity was also shown by German et al in the choroid 
plexus of wild type, Klotho mutant and Klotho over-expressing mice. Klotho 
expression in the organs of Klotho over-expressing mice is very intense 
compared to wild type and Klotho mutant mice (German et al., 2012). The 
difference in the intensity of Klotho expression was also seen in unpublished 
data by the Thuret lab described in the introduction (1.3.4) demonstrating that 
Klotho mRNA was increased twofold in the hippocampus of mice maintained on 
an IF diet. These animals displayed increased neurogenesis and proliferation in 
the DG and improved associated behaviour. IF, Klotho and RSVL show similar 
effects on lifespan and age related diseases, namely increasing lifespan and 
ameliorating the symptoms of age related diseases (Kurosu et al., 2005; 
Pearson et al., 2008; Dolinsky and Dyck, 2011; Mercken et al., 2011). The 
increase in mRNA and Klotho protein expression in the brain without increasing 
the number of Klotho positive cells underpins the endocrine, humoral activity of 
the secreted form of Klotho explaining the general phenotype in Klotho mutant 
mice despite the organ-restricted expression (Kuro-o et al., 1997; Nagai et al., 
2003). Using heterochronic parabiosis Villeda et al. show that blood-borne 
factors present in the systemic milieu can inhibit or promote adult neurogenesis 
in an age-dependent fashion in mice. Accordingly, exposing a young mouse to 
an old systemic environment or to plasma from old mice decreased synaptic 
plasticity, and impaired contextual fear conditioning and spatial learning and 
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memory. This confirms that the decline in neurogenesis and cognitive 
impairments observed during ageing can be in part attributed to changes in 
blood-borne factors (Villeda et al., 2011). 
4.4.3 Klotho over expression increases neurogenesis but has no effect on 
dividing cells  
My data show in (4.2) that over-expression of Klotho in HPC03A/07 increases 
neurogenesis and apoptosis during differentiation but has no effect on 
proliferating cells. Klotho appears to be involved in neurogenesis and survival; 
however it seems to have no effect on dividing cells and proliferation. It appears 
Klotho did not show any effects on proliferation in HEK-293 cells (Chen et al., 
2010), which is in accordance with my data that neither Klotho over-expression 
nor Klotho knock down affect dividing cells.  
Klotho has marked effects on insulin physiology by inhibiting insulin/IGF1R 
signalling (Kurosu et al., 2005). Negative regulation of insulin/IGF1R signalling 
is an evolutionarily conserved mechanism to suppress aging and extends life 
span in yeast, nematodes, fruit fly and rodents (Barbieri et al., 2003; Tatar et al., 
2003). Endogenous IGF1 plays an important role for neurogenesis in the adult 
rat brain development (Anderson et al., 2002; Koltai et al., 2011) and during 
brain development in human (Netchine et al., 2011). Klotho inhibits IGF1 
signalling and thereby it appears to be increasing lifespan but decreasing 
neurogenesis and thereby ensuring the availability of stem cells in the brain into 
ripe old age, similar to Wnt which is discussed below. This mechanism could 
explain why Klotho over-expression in my in vitro model has no effect on the 
percentage of dividing cells. However, data from the Vischer lab suggested that 
decreased Klotho expression is not a general feature of rodent models of insulin 
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resistance and that the soluble Klotho protein does not inhibit IGF-1 and/or 
insulin signalling in HEK293, L6 and HepG2 cultured cells, arguing against a 
direct role of Klotho in insulin signalling (Lorenzi et al., 2010).  
Additionally apoptosis is increased in the Klover ON cells in this thesis. Strong 
mitogen stimulation such as Klotho over-expression can cause growth arrest 
and senescence by over-activating mitogen-activated pathways. In primary 
cells, the Ras/Raf/MEK/MAPK pathway is initially mitogenic but eventually 
induces premature senescence. (Lin et al., 1998). This over-stimulation could 
be a potential explanation for the increase in cell death in the Klotho over-
expressing cultures in my results. 
4.4.4 Klotho is required for differentiation and survival but not dividing 
cells 
My results in 4.3 show that Klotho is required for neuronal differentiation and 
survival during differentiation but is not important during proliferation and for 
dividing cells. It is plausible that Klotho is involved in the regulation of brain 
aging: Klotho mutant mice have a reduced number of Purkinje cells in the 
cerebellum but no other age-related changes such as senile plaques or amyloid 
deposits (Nagai et al., 2003). Further, in Klotho mutant brain, reduction of 
synapses was evident in the hippocampus (Li et al., 2004). However, a role 
during development seems unlikely, because Klotho mutant mice develop 
normally up to at least 2 weeks of age in both macroscopic and histological 
appearance, therefore the phenotypes seen in Klotho mutant mice cannot 
simply be a result of incomplete development (Kuro-o et al., 1997). This 
supports the diminishing effect on neuronal differentiation in the in vitro knock 
down model in this thesis in 4.3.3. To further corroborate the importance of 
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Klotho during differentiation Klotho promoted differentiation in adipocytes during 
the period of transient proliferation by elevating mRNA levels of adipocyte 
differentiation marker, such as PPARγ (Chihara et al., 2006). In 5.6.1 I will 
further discuss the link between Klotho and PPARγ in HPC03A/07 cells.  
My results also show an increase in apoptosis following Klotho knock down 
which is in line with the findings in Klotho mutant mice (Nagai et al., 2003). 
Interestingly, the increase in apoptosis in the hippocampus of Klotho mutant 
mice is caused by an increase in lipid peroxide and oxidative damage to DNA 
(Nagai et al., 2003). In turn Klotho in Klotho over-expressing mice increases the 
resistance to oxidative stress involving the ASK1-signalosome via the p38 
MAPK pathway (Hsieh et al., 2010). It would be worth investigating what cell 
type dies in the HPC03A/07 cell line. 
The changes in cellular composition following reduced expression of Klotho in 
Klotho mutant or old mice lead to behavioural changes in rodents that mirror the 
phenotype of human aging. Klotho mutant mice display impaired long-term, but 
not short-term retention of novel object recognition and fear conditioning at 7 
weeks but not at 6 weeks (Nagai et al., 2003). The findings from the Thuret lab 
described in the introduction 1.3.4 show a similar effect although the other way 
around: IF mice with increased Klotho level in the hippocampus display 
improved long-term but not short-term retention memory. These data are in 
accordance with the decreased neurogenesis described in depressed patients 
(Stanley Medical Research Institute ID6322) and my data demonstrating that a 
decrease of Klotho leads to decreased neurogenesis. Further, a polymorphism 
in the Klotho gene in young and aged human is associated with lower cognitive 
ability (Deary et al., 2005). 
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To understand better how Klotho elicits its effect on neurogenesis and survival 
in HPC03A/07 it would be necessary to investigate which cell types are dying by 
co-staining cells for activated Caspase-3 with marker for proliferation (BrdU), 
neuroblasts (Dcx) and neurons (MAP2). Further, to elucidate the cellular 
mechanism behind the effects of Klotho on differentiation, it would be interesting 
to investigate changes in Wnt expression upon Klotho over-expression and 
knock down. Wnt can be bound by the secreted form of Klotho (Kirstetter et al., 
2006; Scheller et al., 2006; Liu et al., 2007), which leads to suppression of Wnt 
activity when Klotho is over-expressed and an increase in Wnt signalling in 
Klotho mutant mice. Continuous Wnt exposure triggered accelerated cellular 
senescence (Liu et al., 2007). Wnt over-expression triggers neurogenesis in the 
adult brain (Lie et al., 2005). The suppression of Wnt by Klotho might protect 
the stem cell pool from depletion and ensure the availability of self-renewing 
cells to a ripe age. 
Further, the Insulin/IGF1 pathway would be worth a closer examination to 
elucidate the conundrum between its effect on aging and neurogenesis as 
described above. This should preferably be investigated in an animal model to 
be able to assess the effects of aging properly. Obviously it would be very 
interesting to thoroughly examine proliferation and differentiation in Klotho 
mutant and Klotho over-expressing mice and further behavioural tests to 
investigate the role of Klotho in learning/memory and depression as so far only 
one group looked at and confirmed cognitive impairment in Klotho mutant mice 
(Nagai et al., 2003). 
  










Chapter 5 The proliferative and neurogenic effects of 
Resveratrol on neural stem cells are partly dependant on 
Klotho and PPARγ  
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In Section 3.2 I have shown that RSVL increases the number of dividing and 
neuronal cells. I now wish to determine whether this effect is mediated by 
Klotho via PPARγ.  
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear 
receptor proteins that function as transcription factors regulating the expression 
of genes (Greene et al., 1995). PPARs play essential roles during cellular 
differentiation, development, cell metabolism and tumorigenesis (Fajas et al., 
1997). Activation of PPARγ regulates, amongst a variety of other genes and 
pathways, neural stem cell proliferation and differentiation in vivo and in vitro 
(Morales-Garcia et al., 2011). PPARγ activates transcription of Klotho in 
HEK293 cells (Zhang et al., 2008). Moreover, PPARγ can be activated by RSVL 
in murine primary cortical cultures, bovine brain microvessel vascular 
endothelial cells (BBMEC), human umbilical venous endothelial cells (HUVEC) 
and bovine arterial endothelial cells (BAEC) (Inoue et al., 2003). PPARγ and 
Klotho therefore potentially provide another link between diet (RSVL) and AHN, 
where I hypothesise that RSVL exerts its neurogenic effect via PPARγ and 
Klotho. The experiments within this chapter aim to test this hypothesis by 
determining whether RSVL (1) increases the percentage of Klotho expressing 
cells, (2) acts via PPARγ to increase the percentage of HPC03A/07 cells that 
express Klotho and (3) acts via PPARγ and Klotho to influence the division and 
neurogenesis of HPC03A/07 cells.  
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5.1 RSVL increases the number of Klotho expressing cells in 
proliferating and differentiating HPC03A/07 
To assess the effect of RSVL on the proportion of Klotho expressing cells, cells 
were cultured as described in Section 2.1.1. 24h after seeding, cultures were 
treated with 1µM RSVL and maintained for under proliferative conditions for the 
proliferation assay. For the differentiation assay differentiation was started 24h 
after seeding and RSVL was added at the same time. Cultures were maintained 
for 7 days under differentiation conditions. At the end of each experiment, 
cultures were fixed with 4% PFA for immunocytochemical staining. Cells were 
stained for Klotho protein, the proliferative activity marker Ki67, the neuroblasts 
marker Dcx and the mature neurons marker MAP2. 
Treatment with 1µM RSVL for 3 days under proliferation conditions significantly 
increased the percentage of Klotho positive cells in the cultures by 119.9±2.7%, 
p<0.001. Also after 7 days of differentiation RSVL significantly increases the 
percentage of Klotho positive cells by 47.9±2.0%, p<0.001 (See Figure 5-3a). 
This set of data confirms my first hypothesis that RSVL increases the proportion 
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5.2 RSVL partly requires PPARγ to act on Klotho positive cells and 
neurogenesis but not to act on dividing HPC03A/07 cells  
To assess whether RSVL exerts its effect on AHN exclusively via PPARγ, 
HPC03A/07 were cultured as described in Section 2.1.1, and 24 hours later 
treated as shown in Figure 2-10 with GW9662, an irreversible PPARγ 
antagonist. After a further 24h, cultures were treated with RSVL. Cells were 
then maintained either for 3 days under proliferative conditions or 7 days under 
differentiation conditions before being fixed with 4% PFA and 
immunocytochemically stained for Klotho protein, the proliferation marker Ki67 
as well as Dcx, a marker for neuroblasts, and MAP2, a neuronal marker.  
 
Figure 5-1 Timeline for PPARγ experiment on HPC0A07/03A cells  
1.) Proliferation assay, 2) Differentiation assay. Cells were cultured for 24h after 
seeding before GW9662 was added. After 24h proliferation RSVL was added. For the 
proliferation assay cells were then maintained under proliferation conditions for 3 days. 
For the differentiation assay, differentiation was started simultaneously with RSVL 
treatment and maintained for 7 days. 
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5.2.1.1 RSVL partly requires PPARγ to activate Klotho  
PPARγ was observed to be necessary during proliferative conditions for the 
activation of Klotho expression by RSVL (Figure 5-3b). The percentage of 
Klotho expressing cells was significantly decreased by -42.4±0.7%, (p<0.001) to 
a total of 18.3±0.2% compared to RSVL (total of 31.7±0.4%) only treated 
cultures when PPARγ was blocked by GW9662 prior to RSVL treatment. 
However it was significantly increased compared to the DMSO control with a 
total of 14.4±0.1%. Also during differentiation PPARγ is required for the 
activation of Klotho expression by RSVL as shown Figure 5-3f. The percentage 
of Klotho positive cells is significantly decreased when PPARγ is blocked with 
GW9662 by -21.9±0.2%, p<0.001 to a total of 28.8±0.1% compared to RSVL 
(36.9±0.5%) only treated cultures. However the percentage of Klotho 
expressing cells was significantly increased compared to the DMSO control 
(24.9±0.1%) 
5.2.1.2 RSVL does not require PPARγ to increase the number of Ki67 
expressing cells in proliferating and differentiating HPC03A/07  
Here I confirm what I have already demonstrated in 3.2: RSVL treatment 
significantly increases (31±0.7%, p<0.01) the percentage of Ki67 positive cells 
compared to DMSO treated control cultures during proliferation (Figure 5-4a). 
Also under differentiation conditions RSVL treatment significantly increases the 
percentage of Ki67 positive cells by 100.9±2.9%, p<0.001, see Figure 5-4a. 
This confirms that RSVL is able to increase division even under differentiation 
conditions as demonstrated before. 
Figure 5-4b shows that during proliferation PPARγ is not necessary for the 
activation of Ki67 expression by RSVL. The percentage of Ki67 positive cells 
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shows no significant change compared to the RSVL treated cultures when 
PPARγ is blocked with GW9662. Also during differentiation PPARγ is not 
required by RSVL to increase the percentage of Ki67 positive cells (Figure 5-4f). 
The percentage of Ki67 positive cells shows no significant changes in either 
proliferation or differentiation, suggesting that PPARγ is not involved it the 
activation of dividing cells by RSVL. 
5.2.1.3 RSVL partly requires PPARγ to increase neurogenesis in 
differentiating HPC03A/07 
First I confirmed the increase in the percentage of Dcx and MAP2 expressing 
cells in cultures treated with RSVL. In these experiments, cultures express 
significantly more Dcx positive cells when compared to control cultures 
(percentage change of 86.8±3.8%, p<0.001, Figure 5-5a) . The changes in the 
percentage of MAP2 expression was similar to Dcx. Cultures treated with RSVL 
are composed of significantly more MAP2 positive cells by 91.02±1.2%, 
p<0.001 (Figure 5-5e) compared to the DMSO control. The increase in 
neurogenesis induced by RSVL that is observed is genuinely due to an 
increased production of neuronal differentiation and not due to increased 
survival as RSVL also increases the proportion of apoptotic cells under the 
same conditions, see Figure 5-6a.  
PPARγ is required for RSVL to increase the percentage of Dcx (Figure 5-5b) or 
MAP2 (Figure 5-5f) expressing cells. Indeed, the proportion of neuroblasts is 
significantly decreased after RSVL treatment when PPARγ is blocked with 
GW9662 by -26.6±1.1%, p<0.001 to a total of 17.5±0.3% compared to RSVL 
only treated cultures. This however was significantly increased compared to the 
DMSO control with 12.7±0.6% (p<0.001). Also the proportion of mature neurons 
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is significantly decreased when PPARγ is blocked with GW9662 by -38.3±2.0%, 
p<0.001 to a total of 23.7±0.8. Compared to the DMSO control (total of 
20.1±0.6%) this value was significantly (p<0.001) increased. 
5.2.1.4 Absence of PPARγ prevents RSVL induced apoptosis in the 
differentiating HPC03A/07 
I first confirmed in this independent set of experiments what I discovered in 3.2: 
RSVL treatment significantly increases the percentage of activated Caspase-3 
expressing cells by 24.2±0.9%. When PPARγ is blocked before RSVL treatment 
apoptosis is significantly decreased by -15.6±0.3%, p<0.001 to a total of 
17.5±0.1% compared to RSVL only treated cultures (total of 16.7±0.4%) (Figure 
5-6b). This suggests that PPARγ is involved in the apoptotic effect RSVL exerts 
on HPC03A/07 cells.  
5.3 Summary 
PPARγ is partly required by RSVL to exert its increasing effect on Klotho 
expression and neurogenesis. PPARγ is not necessary for RSVL induced 
effects on dividing cells. RSVL induced apoptosis is diminished by the lack of 
PPARγ. 
These results are similar to my results in 4.3, where a Klotho knock down 
affects neurogenesis and apoptosis but not dividing cells in HPC03A/07 cells. 
Further in my results PPARγ was observed to be necessary for the activation of 
Klotho expression by RSVL during proliferation and differentiation (Figure 
5-3b,f).  
I therefore went on to investigate the role of Klotho downstream of RSVL 
induced changes to dividing and neuronal cells and apoptosis.  
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5.4 RSVL partly requires Klotho to increase the number of Ki67 
positive cells and neurogenesis  
To assess whether Klotho was a necessary downstream target of PPARγ for 
proliferation and neurogenesis, Klotho expression was knocked down by 
transfection with a mixture of three different Klotho targeting siRNAs using the 
N-TER transfection system as explained in 2.1.7. 24h after the siRNA 
transfection, cultures were treated with either the PPARγ agonist Rosiglitazone 
or RSVL. Rosiglitazone was used to compare the effects of RSVL to specific 
PPARγ activation. If RSVL and Rosiglitazone show the same 
immunocytochemical profile it suggests that RSVL acts exclusively via PPARγ, 
conversely if significant differences are observed this suggests that RSVL acts 
independently or only partly via PPARγ. If Klotho is uniquely necessary for the 
action of PPARγ (activated by RSVL or Rosiglitazone) then I would not expect 
to see an effect in the Klotho knock down group. As described above, after 
completion of the treatments cultures were maintained for either 3 days under 
proliferative conditions or 7 days under differentiation conditions before being 
fixed with 4% PFA followed by immunochytochemical staining for the markers 
stated above (see Figure 5-2 for a cartoon of these experimental procedures). 
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Figure 5-2 Timeline for Klotho and PPARγ experiment on HPC0A07/03A cells  
1) Proliferation assay, 2) Differentiation assay. Cells were cultured for 24h after 
seeding before Klotho knock-down using siRNA. After 24h proliferation either RSVL or 
Rosiglitazone (ROSI) were added. For the proliferation assay cells were then 
maintained under proliferation conditions for 3 days. For the differentiation assay, 
differentiation was started simultaneously with RSVL or ROSI treatment and 
maintained for 7 days. 
 
For the Klotho knock down Klotho expression was knocked down by 
transfection with a mixture of three different Klotho targeting siRNAs using the 
N-TER transfection system as explained in Section 2.1.7. 24h after seeding. For 
the proliferation assay cells were maintained for 3 days under proliferation 
conditions, for the differentiation assay differentiation was started 24h after the 
transfection and cultures were maintained for 7 days under differentiation 
conditions. To demonstrate a valid Klotho knock down for this set of 
experiments, cells were also stained for Klotho protein upon siRNA treatment as 
described in 2.2. As shown previously, Klotho knock down leads to significant 
decrease of the percentage of cells expressing Klotho by -17.2±1.4%, p<0.001 
(Figure 5-3a) at 3-day proliferation and significantly decreases the percentage 
of Klotho expressing cells -67.3±0.5%, p<0.001(Figure 5-3e) at 7-day 
differentiation, confirming that the Klotho knock down successfully decreases 
the proportion of Klotho expressing cells in proliferating and differentiating 
HPC03A/07. 
 Page 257 of 318 
 
5.4.1.1 RSVL impacts on Klotho expression despite a Klotho knock down 
Figure 5-3c shows that during proliferation RSVL treatment following Klotho 
knock down significantly increases the percentage of Klotho positive cells 
compared to Klotho knock down alone (73.6±0.2%, p<0.001); however the 
percentage is significantly lower by -34.6±0.0%, p<0.01 compared to RSVL only 
treated cultures (Figure 5-3b). This suggests that RSVL might increase Klotho 
mRNA to such an extent that the amount of siRNA is not sufficient to bind to all 
Klotho mRNA leading to Klotho protein being produced even in cells transfected 
with Klotho targeting siRNA. Under these circumstances it would be interesting 
to conduct a dosage experiment and titrate the siRNA concentration needed to 
fully block the RSVL induced Klotho mRNA activation. The specific PPARγ 
agonist rosiglitazone has no impact on the number of Klotho positive cells 
(Figure 5-3c) after Klotho knock down. This indicates that PPARγ activation has 
no impact on Klotho mRNA during Klotho knock down during proliferation 
On the other hand, data presented in Figure 5-3g shows that during 
differentiation conditions specific PPARγ activation (94.5±8.1%, p<0.001) and 
RSVL treatment (145.5±11.3, p<0.001) both significantly increase the 
percentage of Klotho positive cells following Klotho knock down compared to 
the Klotho knock down without following treatment; however the proportions are 
significantly decreased compared to the RSVL only group by -45.7±2.5%, 
p<0.001 (Figure 5-3f). This suggests that in differentiating HPC03A/07 cultures 
PPARγ activation and RSVL treatment impact on Klotho expression despite a 
>80% knock down. 
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5.4.1.2 RSVL partly requires Klotho to increase the number of Ki67 
expressing cells in proliferating but not differentiating HPC03A/07  
Klotho knock down significantly decreases (-14.9±6.8%, p<0.05) the proportion 
of Ki67 positive cells compared to DMSO treated control cultures during 
proliferation (Figure 5-4a). In differentiating cultures RSVL has no effect on the 
proportion of dividing cells. 
Klotho appears to be partly required under RSVL treatment to increase the 
number of dividing cells to the level of RSVL only treatment. Indeed, upon 
RSVL treatment on Klotho knock down cells, the percentage of Ki67 expressing 
cells is significantly decreased by -11.4±1.5%, p<0.01 compared to RSVL only, 
see Figure 5-4b. On the other hand, data presented in Figure 5-4c shows that 
PPARγ activation, but not RSVL, significantly increases the percentage of Ki67 
positive cells following Klotho knock down when compared to the Klotho knock 
down only group (Rosiglitazone: 25.9±4.5%, p<0.05). This suggests that PPARγ 
activation does not require Klotho to increase the proportion of dividing cells to 
the level of the vehicle control, but it is necessary under RSVL treatment to 
further increase the proportion of dividing cells to the RSVL only level under 
proliferative conditions.  
Under differentiation conditions Figure 5-4g shows that PPARγ activation 
(96.6±14.9%, p<0.001) and RSVL treatment (115.3±1.2, p<0.001) both 
significantly increase the percentage of Ki67 positive cells following Klotho 
knock down compared to the Klotho knock down alone; even to the level of the 
RSVL only group, (Figure 5-4f). This indicates that neither RSVL nor 
Rosiglitazone, the specific PPARγ agonist require Klotho to impact on the 
proportion of dividing cells under differentiation conditions.  
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5.4.1.3 RSVL requires both Klotho and PPARγ to increase neurogenesis in 
differentiating HPC03A/07 
Klotho knock down decreases the percentage of Dcx (by -22.8±0.3%) and 
MAP2 (-8.9±0.4%, p<0.05) expression significantly compared to DMSO treated 
cultures (Figure 5-5a,e).  
The percentage of Dcx and MAP2 positive cells is significantly decreased after 
RSVL treatment following Klotho knock down by -47.5±0.8%, p<0.001 and 
-40.9±1.1%, p<0.001 respectively compared to the RSVL only treated cells, 
suggesting that Klotho is needed for RSVL to elicit its effect on neurogenesis 
(Figure 5-5b,f) 
In turn PPARγ activation (17.8±7.4%, p<0.05) and RSVL treatment (27.0±1.9%, 
p<0.05) following Klotho knock down both significantly increase the percentage 
of Dcx positive cells compared to the Klotho knock down alone, see Figure 
5-5c; suggesting that Klotho is required to increase the percentage of 
neuroblasts to the level of RSVL but not to increase it above the Klotho knock 
down only. 
On the other hand, Rosiglitazone, the specific PPARγ agonist does not have the 
ability to increase MAP2 expression without Klotho and even decreases the 
percentage of MAP2 positive cells by -25.8±1.1%, p<0.001, Figure 5-5g. RSVL 
treatment however significantly increases the percentage of MAP2 positive cells 
following Klotho knock down compared to the Klotho knock down alone by 
27.8±2.3%, p<0.001). This indicates that RSVL does not require Klotho and 
PPARγ to increase the proportion of mature neurons above vehicle level, 
however they are necessary to reach the level of RSVL only treated cells. 
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Further, PPARγ cannot impact on MAP2 without Klotho; this is in contrast to the 
effect of PPARγ on Dcx which does not depend on Klotho.  
5.4.1.4 RSVL decreases the Klotho knock down induced apoptosis in 
differentiating HPC03A/07 
I first confirmed in this independent set of experiments what I discovered in 
3.2.3 RSVL treatment significantly increases the percentage of activated 
Caspase-3 expressing cells by 24.2±0.9%. Klotho knock down alone increases 
the percentage of apoptotic cells by 96.1±0.7%, indicating that both RSVL and 
Klotho knock down increase apoptosis in differentiating HPC03A/07 cells. 
Klotho knock down in differentiating HPC03A/07 followed by RSVL treatment 
increases the percentage of apoptotic cells compared to RSVL only treatment 
by 22.5±1.4%, whereas when PPARγ is blocked before RSVL treatment 
apoptosis is decreased by -15.6±0.3% (Figure 5-6b). However, when Klotho is 
knocked down prior to RSVL treatment the percentage of apoptotic cells is 
decreased compared to the Klotho knock down only cultures by -44.8±3.4% and 
also when Klotho knock down is followed by PPARγ activation apoptosis is 
decreased by -61.5±0.8% (Figure 5-6a). This suggests that RSVL treatment, 
although increasing apoptosis on its own has the ability to decrease apoptosis 
following Klotho knock down.  
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Figure 5-3 Role of PPARγ and Klotho for Klotho activation through RSVL in 
proliferating and differentiating HPC03A/07  
a, b, c, d depict proliferating e, f, g, h differentiating cultures. Percentage change of 
Klotho positive cells in treated cultures compared to (a and e) DMSO treated cultures, 
b) and f) RSVL treated cultures, c) and g) Klotho knock down cultures. A Summary of 
the quantification of Klotho positive cells (absolute numbers) is shown in (d and 
h).DMSO: vehicle; RSVL: Resveratrol; ROSI: PPARγ agonist Rosiglitazone; GW9662: 
PPARγ antagonist; Klotho k.d.: Klotho knock down (p-values were generated using 
One-way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error 
of the Mean (SEM), ***p<0.001) 
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Figure 5-4 Impact of PPARγ and Klotho the percentage of Ki67 cells through 
RSVL in proliferating and differentiating HPC03A/07  
a, b, c, d depict proliferating e, f, g, h differentiating cultures. Percentage change of 
Ki67 positive cells in treated cultures compared to (a and e) DMSO treated cultures, (b 
and f) RSVL treated cultures, (c and g) Klotho knock down cultures. A Summary of the 
quantification of Ki67 cells (absolute numbers) is shown in (d and h).DMSO: vehicle; 
RSVL: Resveratrol; Klotho k.d.: Klotho knock down; ROSI: PPARγ agonist 
Rosiglitazone; GW9662: PPARγ antagonist; (p-values were generated using One-way 
ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error of the 
Mean (SEM), ***p<0.001) 
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Figure 5-5 Role of PPARγ and Klotho for Dcx and MAP2 expression through 
RSVL in differentiating HPC03A/07  
a, b, c, d depict a quantification of Dcx; e, f, g, h of MAP2. Percentage change of 
Dcx/MAP2 positive cells in treated cultures compared to (a and e) DMSO treated 
cultures, (b and f) RSVL treated cultures, (c and g) Klotho knock down cultures. A 
Summary of the quantification of Dcx/MPA2 positive cells (absolute numbers) is shown 
in (d and h). DMSO: vehicle; RSVL: Resveratrol; Klotho k.d.: Klotho knock down; ROSI: 
PPARγ agonist Rosiglitazone; GW9662: PPARγ antagonist; (p-values were generated 
using One-way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard 
Error of the Mean (SEM), *p<0.05, **p<0.01, ***p<0.001)  
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Figure 5-6 Role of PPARγ and Klotho for activated Caspase-3 activation 
through RSVL in differentiating HPC03A/07  
Percentage change of activated Caspse-3 positive cells in treated cultures compared to 
a) DMSO treated cultures, b) RSVL treated cultures, c) Klotho knock down cultures. A 
Summary of the quantification of Klotho positive cells (absolute numbers) is shown in 
(d). DMSO: vehicle; RSVL: Resveratrol; Klotho k.d.: Klotho knock down; ROSI: PPARγ 
agonist Rosiglitazone; GW9662: PPARγ antagonist; (p-values were generated using 
One-way ANOVA with Newman-Keuls post hoc test, Error bars are the Standard Error 
of the Mean (SEM), *p<0.05, ***p<0.001, )  
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5.5 Summary 
To summarize, an overview of the quantification of Klotho positive cells during 
proliferation and differentiation after being treated as described in Figure 2-10 
and Figure 5-2 is shown in Table 5-1. It confirms the successful Klotho knock 
down and demonstrates that RSVL partly requires PPARγ for Klotho activation 
during proliferation and neurogenesis in HPC03A/07 cells and acts on Klotho 
despite a >80% Klotho knock down. RSVL might increase Klotho mRNA to such 
an extent that the amount of siRNA is not sufficient to bind to all Klotho mRNA 
leading to Klotho protein being produced in cells after Klotho knock down.  
Proliferation: 
RSVL treatment increases the percentage of Klotho expressing cells compared 
to the Klotho knock down cultures after PPARγ block and Klotho knock down 
during proliferation. However never to the level of RSVL only treated cultures, 
suggesting that PPARγ is only partly involved in the effect RSVL has on Klotho. 
Klotho expression appears to be higher during differentiation than proliferation 
in all treatment groups and during proliferation PPARγ activation has no effect 
on Klotho compared to the Klotho knock down cultures. Altogether, this data 
indicates that RSVL is very potently activating Klotho expression and is also 
independent of a PPARγ dependent pathway. 
Figure 5-4d shows a summary of the quantification of Ki67 positive cells after 
being treated as described in Figure 2-10 and Figure 5-2. RSVL partly requires 
Klotho but does not depend on PPARγ to increase the proportion of Ki67 
expressing cells in proliferating and PPARγ does not require Klotho to increase 
the proportion of dividing cells. Altogether, this set of data shows that PPARγ is 
not required for RSVL to act on dividing cells and neither RSVL nor PPARγ 
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activation do require Klotho to increase the proportion of dividing cells 
compared to control conditions, however I also demonstrate here that RSVL 
partly requires Klotho to fully increase the proportion of Ki67 positive cells to the 
level observed under RSVL treatment. 
Differentiation: 
RSVL treatment increases the percentage of Klotho expressing cells compared 
to the Klotho knock down cultures after PPARγ block and Klotho knock down 
during differentiation. However never to the level of RSVL only treated cultures, 
suggesting that PPARγ is only partly involved in the effect RSVL has on Klotho. 
Klotho expression appears to be higher during differentiation than proliferation 
in all treatment groups and during differentiation PPARγ activation increases 
Klotho despite the knock down. Altogether, this data indicates that RSVL is very 
potently activating Klotho expression and is also independent of a PPARγ 
dependent pathway. 
Figure 5-4h shows a summary of the quantification of Ki67 positive cells during 
differntiation. RSVL does not require Klotho or PPARγ to increase the 
proportion of Ki67 expressing cells and Klotho is not required for PPARγ to 
increase the proportion of dividing cells in differentiating HPC03A/07. 
Altogether, this set of data shows that RSVL does not require PPARγ and 
neither RSVL nor PPARγ activation do require Klotho to increase the proportion 
of dividing cells compared to control conditions, however I also demonstrate 
that RSVL partly requires Klotho to fully increase the proportion of Ki67 positive 
cells to the level observed under RSVL treatment. 
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RSVL partly requires both Klotho and PPARγ to increase neurogenesis in 
differentiating HPC03A/07. Figure 5-5d shows a summary of the quantification 
of Dcx positive cells. RSVL does not require Klotho and PPARγ to increase the 
proportion of Dcx positive cells compared to the control; however both are 
necessary to increase Dcx to the full level of RSVL only. Further, PPARγ 
activation partly requires Klotho to impact on Dcx expression. On the other hand 
the summary of the quantification of MAP2 (Figure 5-5h) illustrate my findings 
on the ability of RSVL but not of the specific PPARγ agonist Rosiglitazone to 
activate differentiation independently of Klotho. Furthermore, it shows that 
PPARγ and Klotho are required for RSVL to increase MAP2 expression to its 
full potential.  
Figure 5-6d shows a summary of the quantification of activated Caspase-3 
expressing cells in differentiating HPC03A/07. Absence of PPARγ prevents 
RSVL induced apoptosis, while on the other hand RSVL and PPARγ activation 
decrease the Klotho knock down induced apoptosis in differentiating 
HPC03A/07. This indicates that RSVL treatment increases survival following 
Klotho knock down suggesting that RSVL during stress prevents cell death 
although RSVL on its own increases apoptosis, PPARγ and Klotho both appear 
to be involved in apoptosis in HPC03/A07 cells. 
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Figure 5-7 Effect of Resveratrol on AHN, Klotho and PPARγ 
The graph shows what was known in the literatur before his thesis and after. RSVL 
impacts on AHN via PPARγ and Klotho, but also directly via an independent pathway. 
PPARγ and Klotho are both partly required for RSVL to exert its effect on AHN to its full 
potential. 
Abbreviations:AHN: adult hippocampal neurogensis; RSVL: Resveratrol; ROSI: the 
PPARγ activator Rosiglitazone; GW9662: PPARγ blocker; black arrows indicate the 
effet shown in the literature; green arrows indicate the effect shown in the thesis in 
HPC03A/07  
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 RSVL w/o Klotho ROSI w/o Klotho  RSVL w/o PPARγ 
Compared to: KL k.d. RSVL KL k.d. RSVL DMSO RSVL 
Proliferation  
Klotho ↑ ↓ - ↓ - ↓ 
Ki67 ↑ ↓ ↑ - ↑ - 
Differentiation  
Klotho ↑ ↓ ↑ ↓ ↑ ↓ 
Ki67 ↑ - ↑ - ↑ - 
Dcx ↑ ↓ ↑ ↓ ↑ ↓ 
MAP2 ↑ ↓ ↓ ↓ ↑ ↓ 
Activated Caspase-3 ↓ ↑ ↓ ↓ - ↓ 
Table 5-1 Summary of the effect of RSVL after Klotho knock down and PPARγ 
block. 
↑ significant increase; ↓ significant decrease; - no significant changes 
RSVL: Resveratrol; Kl k.d.: Klotho knock down; ROSI: Rosiglitazone 
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5.6 Discussion 
5.6.1 PPARγ is partly required for RSVL stimulated Klotho expression and 
neurogenesis, but not for proliferation 
Firstly my results proved that RSVL increases the number of Klotho expressing 
cells in proliferating and differentiating HPC03A/07 cultures. My results further 
show that RSVL partly requires PPARγ to increase the number of Klotho 
expressing cells during proliferation as well as during differentiation. RSVL 
impacts on the proportion of Klotho positive cells despite a >80% Klotho knock 
down. This suggests that RSVL might increase Klotho mRNA to such an extent 
that the amount of siRNA is not sufficient to bind to Klotho mRNA leading to 
Klotho protein being produced even in cells transfected with Klotho targeting 
siRNA. Under these circumstances it would be interesting to titrate the siRNA 
concentration needed to fully block the RSVL induced Klotho mRNA activation. 
These results are in line with Zhang et al. that demonstrated that a PPARγ 
agonist increases Klotho expression in mouse kidneys whereas PPARγ 
antagonists reduce its expression. However, I am the first to demonstrate 
PPARγ is partly required for RSVL to elicit its Klotho increasing action. In my 
results RSVL was still able to increase the proportion of Klotho expressing cells 
despite PPARγ being blocked and even despite a previous Klotho knock down, 
indicating that RSVL acts on Klotho expression not only via PPARγ but also via 
an alternative, maybe direct pathway. RSVL acts on various targets that are 
associated with the protection against aging related diseases, such as diabetes 
and cardiovascular diseases. RSVL acts on SIRT1 that has been associated 
with aging and the nuclear transcription factors PPARα, δ and γ that are 
involved in cell cycle mechanisms. Also COX1 and 2, enzymes involved in 
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inflammatory processes and eNOS that regulates vascular tone by generating 
nitric oxide (NO) synthase that generates NO in blood vessels (Nakata et al., 
2012). This demonstrates that RSVL most likely acts on organisms via many 
pathways. 
My results also show that RSVL partly requires Klotho but not PPARγ to act on 
dividing cells; moreover RSVL increases the proportion of dividing cells in 
differentiating cultures; however this action partly requires Klotho, only during 
proliferation, but not PPARγ. RSVL increases the proportion of Ki67 positive 
cells almost to the level of RSVL only treated cultures despite a Klotho knock 
down during proliferation. During differentiation neither Klotho nor PPARγ are 
required for RSVL to act on dividing cells. This suggests that RSVL actually 
requires Klotho and/or PPARγ to impact on proliferation not at all or to a 
minimal extent. This is in accordance with my data on Klotho (Section 0 and 
4.4.4), where neither Klotho over-expression nor a Klotho knock down 
significantly affected cell division, suggesting that RSVL and Klotho target 
different pathways. 
Although RSVL has dose and duration dependent chemopreventive, 
proapoptotic, antiproliferation and anti-inflammation effects in cancer cells 
(Aluyen et al., 2012), its positive effects on healthy organisms are widely 
accepted (Nakata et al., 2012). However, it is not understood how one molecule 
can have such dramatically differently effects. RSVL not only reduces brain 
injury but also promotes recovery after stroke by promoting proliferation and 
migration. It also activates phosphoinositide 3 kinase (PI3-K)/Akt and Mitogen-
Activated Protein Kinase (MAPK)/ERK signalling pathways that are involved in 
cellular activities such as differentiation and apoptosis in a human cerebral 
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endothelial cell line (Simao et al., 2012) which could explain how RSVL in my 
results increases differentiation and apoptosis. Interestingly, in one study 
conducted in rats with and without diabetes, RSVL could not increase 
proliferation in the hippocampus of nondiabetic rats whereas in diabetic animals 
it could (Venturini et al., 2010). This indicates that RSVL might only unfolds its 
potential in influencing cell cycle mechanism under systemic stress, as I have 
also established in the Cortisol stress model, where RSVL, despite increasing 
apoptosis on its own, can prevent the stress mimicking Cortisol induced effects 
on dividing cells, differentiation and apoptosis. Further supporting this idea are 
my data that show that RSVL treatment decreases the apoptosis induced by 
Klotho knock down. 
RSVL does not require Klotho and PPARγ activation to increase the proportion 
of Dcx positive cells. However both are necessary to increase Dcx to the full 
level seen in differentiating cultures treated with RSVL alone. On the other 
hand, PPARγ requires Klotho to increase Dcx expression supporting the 
conclusion that RSVL can impact on neurogenesis independently of PPARγ 
and directly via Klotho or even independently of Klotho. However, PPARγ and 
Klotho are required for RSVL to increase the proportion of mature neurons to 
the level of RSVL only treated cultures. Morales-Garcia recently demonstrated 
that the PPARγ activator Rosiglitazone regulates neural stem cell proliferation 
and differentiation both in vivo and in primary cultures in form of an increase in 
Dcx positive cells (Morales-Garcia et al., 2011). My data shows that 
Rosiglitazone however requires Klotho to increase neurogenesis in HPC03A/07 
cells as it was not able to increase the percentage of Dcx and MAP2 positive 
cells after Klotho knock down. 
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Interestingly, in a recent study by Bruedigam et al. Rosiglitazone and RSVL 
were shown to have opposing effects in vascular smooth muscle cells (VSMC) 
on vascular mineralisation (Bruedigam et al., 2011). Rosiglitazone stimulates 
mineralisation partly via caspase-dependent apoptosis and induces oxidative 
stress, which leads to an osteoblast-like differentiation phenotype. RSVL in turn 
reduces the osteoblast-like differentiation as well as the pro-apoptotic and pro-
calcifying effects of rosiglitazone. It has been reported repeatedly that 
rosiglitazone, used as an insulin sensitizer to treat type-II diabetes mellitus , is 
also associated with an increased risk of heart attacks (Nissen and Wolski, 
2007). This also suggests that RSVL acts not only as a PPARγ. However, I 
have analysed the percentage of activated Caspase-3 expressing cells as part 
of my study to see the effect of apoptosis after rosiglitazone treatment and 
could see no significant differences to the vehicle when cultures were treated 
with rosiglitazone after Klotho knock down, moreover rosiglitazone significantly 
decreased the percentage of apoptotic cells compared to the Klotho knock 
down only treatment suggesting PPARγ activation, similar to RSVL, rescues the 
increasing effect Klotho knock down has on apoptosis. My data showed that 
RSVL treatment, although increasing apoptosis on its own, has the ability to 
decrease apoptosis following Klotho knock down. PPARγ activation by 
Rosiglitazone and RSVL treatment decrease the percentage of apoptotic cells 
to the level of the vehicle control. This indicates that RSVL treatment increases 
survival in HPC03A/07 cells following Klotho knock down and PPARγ block. 
These differences in cell death might be explained by the different cell culture 
system. Bruedigam et al used VSMC and rosiglitazone at a concentration of 
10µM whereas I have used HPC03A/07 and rosiglitazone at 3µM. Next it would 
be interesting to analyse the effect of rosiglitazone alone on proliferation, 
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differentiation and apoptosis in HPC03A/07. PPARγ activation following a 
Klotho knock down did not increase the proportion of Klotho, Dcx and MAP2 
positive cells, however it increased the proportion of dividing cells and 
decreased apoptosis following Klotho knock down. Compared to this, in 
HPC03A/07 cells RSVL has the ability to increase Klotho expression, 
proliferation and neurogenesis even after a Klotho or PPARγ knock down or 
block respectively. Another reason for a RSVL effect beyond PPARγ is that it 
also impacts not only on PPARγ but also on PPARα and δ in BAECs (Inoue et 
al., 2003; Tsukamoto et al., 2010).  
In short lived organisms such as fruit flies and nematodes, RSVL increases life 
span (Wood et al., 2004) and in yeast RSVL feeding increases life span and 
also the activity of the enzyme Sir2. Sir2, in mammals SIRT1, plays a key role in 
an organism's response to stresses, is associated with longevity and is also 
increased during caloric restriction (CR) (Lin et al., 2000; Howitz et al., 2003).  
Also Klotho has been shown to increase lifespan in mice, however most likely 
by inhibiting insulin/IGF1R signalling (Kurosu et al., 2005). Negative regulation 
of insulin/IGF1R signalling is an evolutionarily conserved mechanism to 
suppress aging and extends life span in yeast, nematodes, fruit fly and rodents 
(Barbieri et al., 2003; Tatar et al., 2003). On the other hand endogenous IGF1 
plays an important role for and neurogenesis in the adult rat brain development 
(Anderson et al., 2002; Koltai et al., 2011) and during brain development in 
human (Netchine et al., 2011). 
Barger et al compared the effects on gene expression of caloric restriction (CR) 
(approximately 10% reduction compared to ad libitum fed mice) with RSVL 
supplementation (50mg/kg diet, 4.9mg/g body weight) from middle to old age in 
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mice. RSVL mimics CR at the gene expression level, but did not mimic the 
effects of CR on the few proteins examined (amongst those were IGF1 and 
SIRT1). These differences might be due to differences at the translational 
regulation (Barger et al., 2008b). On gene expression level RSVL, unlike CR did 
not reduce circulating IGF1 levels. Also both CR and RSVL do not alter SIRT1 
levels and CR but not RSVL induces PGC-1α transcriptional targets (Barger et 
al., 2008b). Based on these results it is unlikely that low doses RSVL 
supplementation exerts its beneficial effects on lifespan and health via a SIRT1 
or IGF1 involving pathway. Also Chang et al. showed that a RSVL 
supplemented diet did not significantly improve radial arm water maze function, 
did not increase sirtuin 1 (SIRT1) expression or downstream marker p53 of 
sirtuin 1 activation. Further markers of cellular stress, inflammation, and AD 
pathology were not modulated by RSVL. Chang et al used SAMP8 mice, a 
model of accelerated aging that is increasingly being validated as a model of 
sporadic and age-related AD, and RSVL at by diet achievable concentrations 
(explained below). The RSVL concentration (120 mg/kg diet) was equivalent to 
the content of RSVL in two glasses of wine. (Chang et al., 2011).  
Recently cAMP signalling as an alternative pathway has been shown to be a 
target of RSVL by suppressing the enzyme phosphodiesterase (PDE) (Park et 
al., 2012). cAMP signalling is highly complex and is a key mediator of metabolic 
regulation. The identification of PDEs as RSVL targets might explain how RSVL 
mimics some aspects of CR. CR increases cAMP levels by increasing glucagon 
and catecholamine signalling and decreasing insulin/IGF-1 signalling 
(Rondinone et al., 2000). PDE4 inhibitors have been shown to improve memory 
(Burgin et al., 2010) and protection against aging-related diseases such as 
Alzheimer’s (Smith et al., 2009) animal models. It is therefore possible that 
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RSVL acting as a PDE4 inhibitor may be useful for treating systemic and age 
related diseases humans. 
  










Chapter 6 Final Discussion and Conclusion 
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6.1 Summary of findings 
Using a model in vitro system based on human foetal hippocampal progenitor 
cells (HPC03A/07 cells) I investigated the cellular and molecular mechanisms 
that underlie the effects of certain dietary components on the proliferation and 
neuronal differentiation of human hippocampal progenitor cells. Specifically, I 
investigated the direct effects of the Omega-3 fatty acids EPA and DHA and the 
stilbenoid Resveratrol on human hippocampal NPC proliferation and 
neurogenesis, as well as their potential in preventing the negative effects of 
high Cortisol concentrations (100µM) on proliferation, differentiation and 
apoptosis (0). I further investigated the role of Klotho and the nuclear 
transcription factor PPARγ on human hippocampal NPC proliferation and 
neurogenesis. The main findings of my research are summarised below: 
1. The Omega-3 fatty acids EPA and DHA primarily promote survival resulting 
in an increased proportion of dividing progenitor cells and hence an increase 
in the proportion of neurons being generated and also increases 
neurogenesis. 
2. The effects of the stilbenoid Resveratrol are concentration dependent: It 
leads to cell death at very high concentrations (10µM), decreases the 
proportion of dividing cells at high concentrations (5µM) due to increased 
apoptosis. Lower concentrations (1µM) increase the proportion of dividing 
cells which seems based on an increase in proliferation as apoptosis was 
not decreased. 
3. In an in vitro model of stress, pre-treatment with EPA and DHA prevents the 
negative effect of high concentrations of Cortisol (100µM) on proliferation, 
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neurogenesis and apoptosis by promoting survival and enhancing 
neurogenesis. 
4. RSVL pre-treatment in an in vitro model of stress prevents the negative 
effects of high, stress-relevant concentrations of Cortisol (100µM) on 
proliferation and neurogenesis, but not on apoptosis by promoting 
neurogenesis and cell division. 
5. In wild type mouse brain, Klotho protein is expressed in neurons (NEUN) 
and stem cells (SOX2), but not in glial cells (GFAP). 
6. Intermittent fasting does not increase the total proportion of Klotho 
expressing cells in the dentate gyrus of mice, but the existing Klotho positive 
cells produce more Klotho protein. 
7. Over-expression of Klotho increases neurogenesis and apoptosis in 
HPC03A/07 during differentiation. This effect appears to be due to enhanced 
neurogenesis as Klotho seems to be involved in fate commitment, 
neurogenesis and neuronal survival. 
8. Klotho knock-down shows that Klotho is required for neurogenesis and 
survival during differentiation, but is not important for dividing cells. 
9. Klotho is not strictly required for RSVL to exert its positive effect on 
proliferation and differentiation. RSVL modulates the proportion of dividing 
cells and neurogenesis via a Klotho dependent pathway as well as via a 
Klotho independent pathway. 
10. RSVL increases proliferation and neurogenesis even after PPARγ 
inactivation and increases Klotho expression only during differentiation. This 
suggests that RSVL acts on proliferation and neurogenesis via a PPARγ 
dependent as well as a PPARγ independent pathway. It further indicates 
that the impact on differentiation of RSVL via Klotho is more prominent. 
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6.2 Methodological considerations  
There are a few methodological limitations that need to be considered when 
interpreting the findings obtained in this PhD thesis.   
6.2.1  The use of in vitro systems to study human hippocampal 
neurogenesis  
In this thesis I have used a conditionally immortalised human foetal 
hippocampal progenitor cell line (HPC03A/07) to examine the effects of dietary 
components on hippocampal neurogenesis.  
The major disadvantage of in vitro experimental studies is that they fail to 
replicate the precise cellular environmental conditions of an organism. In vivo, 
progenitor cells are never alone. Their relationship to a neurogenic 
microenvironment might be inseparable from their inherent properties. In 
principle the conditions in vitro are artificial and are approximate reconstitutions 
of biological processes by mixing the necessary components and reagents 
under controlled conditions, stressing the utmost importance of understanding 
the in vivo microenvironment in which neural precursors reside. Therefore it can 
be very difficult to extrapolate from the results of in vitro work back to the 
biology of the intact organism. Care must be taken not to over-interpretation in 
vitro results, which can sometimes lead to incorrect conclusions about the 
biology of the organism and the system. However, there are currently no other 
tools available to investigate the molecular mechanisms that underlie 
hippocampal neurogenesis in humans, and all studies aiming to elucidate the 
signalling mechanisms of dietary components on neurogenesis have so far only 
been conducted in animals or animal tissue culture. Although animal models do 
indeed allow for an investigation of a whole organism, apparent differences 
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between rodents and humans exist in physiology and behaviour. And translating 
human depressive pathophysiology into rodent behavioural paradigms of 
depression is especially a great challenge.  
On the other hand the simplicity of in vitro systems is a great advantage as it 
allows to examining the contribution of specific factors, such as dietary 
components or drugs, without confounding influences, which cannot be 
eliminated in in vivo models, but simply added or omitted in a cell culture 
system. Moreover investigating the effects of these factors on specific cell types 
enables the researcher to disentangle cell-type specific properties of certain 
treatments from their effects on more complex brain systems. 
The changes observed in this human hippocampal progenitor cell line in vitro 
regarding the effects of Omega-3 fatty acids, RSVL and Klotho are consistent 
with in vivo findings in the literature to date, which further validates the use of 
the cell line as a research tool to investigate molecular mechanisms in human 
hippocampal neurogenesis. 
6.2.2  The relevance of foetal progenitor cells 
The cell line used in this thesis was a foetal human hippocampal progenitor cell 
line. Although these cells have the advantage of being human, their properties 
could potentially differ from the ones of hippocampal progenitor cells in the adult 
brain. Nevertheless, these cells express the same markers as adult 
hippocampal progenitor cells and they also have the same properties to 
proliferate and to differentiate into neurons and glia (as described in 2.1.1). 
Although working with adult human brain cells would be the technically 
preferred system, however for obvious ethical reasons this is impossible. While 
hippocampal progenitor cells can be isolated from adult rodent brains, apparent 
 Page 282 of 318 
 
species-specific differences in physiology and behaviour also appear in the 
genetics, despite being very similar to the human genome. Therefore for this 
thesis the human hippocampal progenitor cell line was chosen to investigate the 
molecular mechanism of dietary components. 
6.2.3 The use of dietary components in vitro 
When testing the effect of dietary components on the brain in an in vitro system 
in order to be later used in vivo primary considerations are, whether they can 
reach the brain, cross the blood brain barrier as well as their metabolism on 
their way through the digestive system and the circulation. Firstly, EPA, DHA 
and RSVL can cross the blood barrier and thereby reach the brain. Dietary DHA 
is well absorb and is readily incorporated into the plasma, blood cell lipids 
(Innis, 1991). Several animal studies have also shown that dietary DHA is 
readily incorporated into lipids of the developing brain, both before and after 
birth (Innis, 2005). in vitro, glia and cerebral endothelial cells, but not neurons, 
can form DHA from ALA and other precursor Omega-3 FAs (Moore, 2001). A 
conversion of EPA to DHA in the HPC03A/07 cell line is possible as we have 
checked that the cells express the genes for the required enzymes in vivo. 
However it is not clear what exactly mediates the effect; It is most likely that the 
effect is mediated by EPA and DHA directly, however oxidised metabolites and 
eicosanoids also have to be considered. 
RSVL however is rapidly metabolised after oral uptake into conjugated forms 
such as glucuronate and sulfonate, which makes its oral bioavailability very low 
(Walle et al., 2004). After an oral dose of 25mg only trace amounts of RSVL can 
be detected in the blood; however plasma concentrations of RSVL and 
metabolites peaked at concentrations around 2 µM 1h later (Walle et al., 2004). 
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The concentration used in this study was with 1µM even lower and still had an 
effect on cell division and differentiation, which confirms that in this thesis 
physiological achievable concentration of RSVL were used. Investigating the 
effects of RSVL in a tissue culture system on cell cycle mechanism is therefore 
a valid system; however bioavailability and its metabolites should be examined 
in vivo.  
There are further issues with recommending concentrations for RSVL as a 
supplement as most of the beneficial studies highlighted earlier actually used 
concentrations higher than achievable by a normal diet. So what are by diet 
achievable concentrations in vivo? In a human study that addressed absorption 
and bioavailability of RSVL, serum concentrations only reach 20-50nM after oral 
administration of 25mg in healthy humans (Goldberg et al., 2003; Walle et al., 
2004). 25mg of RSVL are approximately contained in 2.3l of red wine (Pinot 
noir), 16.6kg of raw peanuts or 20.2kg of dark chocolate. Compared to this two 
glasses (150ml) of Pinot noir contain 3.14mg of RSVL (Chachay et al., 2011): 
All together the literature on RSVL is contradictory and confusing, due to the 
great variability of concentrations and doses used to achieve various effects in 
different in vitro and in vivo models and systems. Furthermore, RSVL is highly 
rapidly and extensively metabolised in the body, resulting in little unchanged 
RSVL in the systemic circulation, even at fairly high concentration of RSVL 
RSVL after the 25-mg oral dose (Walle et al., 2004). This suggests that further 
research is needed into the metabolic effects of the RSVL metabolites have on 
cellular mechanisms. 
Nonetheless, beneficial effects of plants rich in RSVL such as grapes have 
been reported for centuries. To be able to recommend RSVL as a mimetic for IF 
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it will be important to elucidate the long-term effects of RSVL and especially the 
molecular pathways behind it. Further, not only the molecular mechanism but 
also the effects of RSVL on learning memory and mood and depression would 
be very interesting to investigate especially as the Thuret lab could show that 
intermittent fasting (IF) improves memory and increases neurogenesis. Also CR 
has been shown on multiple occasions to improve cognitive function (Bondolfi et 
al., 2004; Cohen et al., 2004; Fontan-Lozano et al., 2007; Halagappa et al., 
2007; Adams et al., 2008). As described earlier RSVL acts on multiple targets 
and pathways and therefore: if RSVL was to be recommended as dietary 
intervention that has similar benefits to CR or IF further investigation is needed 
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6.3 Conclusion 
In conclusion this thesis provides insight into the impact of dietary modulation of 
human hippocampal neurogenesis via direct effects on human hippocampal 
progenitor cells. The Omega-3s EPA and DHA increase survival and 
neurogenesis and even prevent Cortisol induced changes on cell division, 
neurogenesis and survival. Differences in EPA and DHA are known, however 
the exact mechanism remains to be uncovered. In this thesis I have shown for 
the first time in on a human hippocampal cell line that DHA appears to be 
required for neuronal maturation while EPA pre-treatment is sufficient to induce 
differentiation. 
Figure 6-1 gives an overview based on my research on how RSVL, PPARγ, 
Klotho and intermittent fasting act on hippocampal neurogenesis. The stilbenoid 
RSVL increases cell division and neurogenesis but also increases apoptosis, 
however in the Cortisol stress model RSVL also increases cell division and 
neurogenesis, but does not affect apoptosis or survival. The longevity gene 
Klotho, which is increased in the hippocampus of mice maintained on an 
intermittent fasting diet is involved in cell fate commitment, cell division and 
apoptosis. Furthermore, Klotho expression can be increased by RSVL and 
RSVL partly requires PPARγ to act on Hippocampal neurogenesis. Thus within 
this thesis I have shown for the first time using a human hippocampal cell line 
that diet -here Omega-3 fatty acids and RSVL- impacts on human hippocampal 
neurogenesis and that the longevity gene Klotho plays an important role in 
regulating neurogenesis. Before to be able to make dietary recommendations 
on Omega-3 fatty acids, RSVL or fasting for prevention or treatment of cognitive 
decline or mood disorders, it will be necessary to conduct further investigations 
in animal models to be followed by human intervention studies. To uncover new 
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drug targets mimicking diet, more comprehensive data are needed on their 
molecular mode of action. Immediately, further studies should be aimed at 
elucidating (1) the molecular mechanisms of EPA, DHA and RSVL mediating 
their effect on neurogenesis as well as their differential effects on cognition; and 
(2) the effects of Klotho on AHN and behaviour in knock down and over-
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Figure 6-1 Overview of Resveratrol, PPARγ, Klotho and AHN: Before and After 
this thesis.  
Green arrows: increased expression/activation, dotted line: in short lived organisms 
only 
  










Chapter 7 Appendix 
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FORMULA   
Material names and concentrations: Final conc. 
Volume for 
500 ml 
DMEM F12        (Sigma D6421)  500.00 ml 
Discard volume  10.00 ml 
Human Albumin Solution 200g/l 
(Baxter VNA1F034/ Octapharma) 
20 % 0.03% 0.75 ml 
Apo-Transferrin, human 
(Scipac T100-5) 
50mg/ml 100µg/ml 1.00 ml 
Putrescine DiHCl   
(Sigma P5780) 
8.1mg/ml 16.2µg/ml 1.00 ml 
Insulin, human recombinant 
(Sigma I9278) 
10mg/ml 5µg/ml 0.25 ml 
Progesterone                                                                                                                                                                  
(Sigma P8783) 
20µg/ml 60ng/ml 1.00 ml 
L-glutamine            
(Invitrogen 25030024) 
200mM 2mM 5.00 ml 
Sodium Selenite    
(Sigma S9133) 
20µg/ml 40ng/ml 1.00 ml 
w GFs    
FGF2            
(Peprotech 100-18B) 
10µg/ml 10ng/ml 0.50 ml 
hEGF              
(Peprotech 100-15) 
10µg/ml 20ng/ml 1.00 ml 
4-hydroxy-tamoxifen (4OHT) 
(Sigma H7904) 
1µM 100nM 50 μl 
Table 7-1 Ingredients for full growths media for HPC03A/07 cell line 
  








(18:3 n-3) (ALA) 
 Sigma 100% Ethanol 
Eicosapentaenoic 
Acid (20:5 n-3) 
(EPA) 
10uM Sigma 100% Ethanol 
Docosahexaenoic 
Acid (22:6 n-3) 
(DHA) 
10uM Sigma 100% Ethanol 
Stearidonic Acid 
(18:4 n-3) (SDA) 
2uM Sigma 100% Ethanol 
Arachidonic Acid 
(20:4 n-6) (SDA) 




80nM/ 1uM Sigma DMSO 
Rosiglitazone 
PPARγ activator 






Table 7-2 List of all tissue culture drugs used for treatment in this thesis 
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Table 7-3 Primary antibodies used for the human embryonic HPC03A/07 cell line, sections and WB.
















Rabbit abcam ab15580 1:500 1:250 
 
Nestin 
Type VI intermediate 
filament protein 
Mouse Chemicon mab5326 1:1000  
 
SOX2 
TF essential for self 
renewal 
Rabbit Chemicon ab5603 1:1000 1:1000 
 
Neuronal marker   
Dcx  Early neurons Rabbit abcam ab18723 1:1000 1:10000  
MAP2ab Neurons Mouse abcam ab11267 1:500   
NeuN Mature neurons Mouse Chemicon IHCR1001-6 1:10 1:10  
Glial marker   
GFAP Astrocytes Rabbit Dako Z033401 1:1000 1:500  
S100beta glial cells of NS rabbit Dako Z0311 1:500   

















KM2076 1:500  1:5000 
Klotho membrane form (hKl) Rat 0.99mg/ml 
Kyowa 
Hakko Kirin 
KM2119 1:500   
Klotho  
membrane + secreted 
form (hKL1+2) 
mouse R&D MAB1819  1:500  




length Company No 
Dilution 
cells tissue WB 
anti rat donkey 488 Invitrogen A21208 1:500 1:250  
anti goat donkey 488 Invitrogen A11055 1:500 1:250  
anti mouse donkey 594 Invitrogen A21203 1:500 1:250  
anti rabbit donkey 488 Invitrogen A21206 1:500 1:250  
anti rabbit donkey 594 Invitrogen A21207 1:500 1:250  
anti rat goat 680 Invitrogen A21098   1:3000 
Table 7-4 Alexa fluor secondary antibodies used in this study 
 
Primary antibodies Secondary antibodies 
BrdU (rat) 
Ki67 (rabbit) 
Anti rat 488 
Anti rabbit 594 
Dcx (rabbit) 
MAP2 (mouse) 
Anti rabbit 488 
Anti mouse 594 
KM2119 (rat) 
Caspase (rabbit) 
Anti rat 488 
Anti rabbit 594 
SOX2 (rabbit) 
Nestin (mouse) 
Anti rabbit 488 
Anti mouse 594 
Table 7-5 Combinations of primary and secondary antibodies used for PPARγ 
and Klover experiment   
 
Primary antibodies Secondary antibodies 
BrdU (rat) 
Ki67 (rabbit) 
Anti rat 488 
Anti rabbit 594 
Dcx (rabbit) 
MAP2 (mouse) 
Anti rabbit 488 
Anti mouse 594 
KM2119 (rat) 
S100b (rabbit) 
Anti rat 488 
Anti rabbit 594 
SOX2 (rabbit) 
Nestin (mouse) 
Anti rabbit 488 
Anti mouse 594 
Table 7-6 Combinations of primary and secondary Antibodies used for the 
siRNA Klotho experiment 
 
Primary antibodies Secondary antibodies 
BrdU (rat) 
Ki67 (rabbit) 
Anti rat 488 
Anti rabbit 594 
Dcx (rabbit) 
MAP2 (mouse) 
Anti rabbit 488 
Anti mouse 594 
Caspase (rabbit) Anti rabbit 594 
SOX2 (rabbit) 
Nestin (mouse)  
Anti rabbit 488 
Anti mouse 594 
Table 7-7 Cominations of primary and secondary Antibodies used for the O3 
prevention experiment 
  




Table 7-8 Lysis Buffer for Western Blot 
 
 
SDS-Page Gel 10% gel 
ProtoGel30%  (national diagnostics) 3.33 ml 
4x Resolving buffer (national diagnostics) 2.50 ml 
Deionised water 4.15 ml 
10% APS (Sigma) 100 ul 
TEMED (Sigma) 10 ul 
Stacking buffer 4% gel 
ProtoGel30% (national diagnostics) 750 ul 
4x Stacking buffer (national diagnostics 1.25 ml 
Deionised water 3 ml 
10% APS (Sigma) 50 ul 
TEMED (Sigma) 3 ul 
Table 7-9 Reagents used for SDS-Page gel 
 





Na-Hepes pH 7.5 1000 mM 200 ul 20 mM 
NaCl 5000 mM 200 ul 100 mM 
Triton X100 10% 1500 ul 1% 
NaF 500 mM 300 ul 15 mM 
Phosphatase 
inhibitor 
100X 100 ul 1X 
Na4P2O7 100 mM 50 ul 10 mM 
Na-EDTA 500 mM 20 ul 1 mM 
Protease inh. 
Cocktail 
Roche complete mini 
tablets 
1 tablet 1X 
H2O  7530 ul  
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